

STN SEARCH TRANSCRIPT → 10/771,725

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sesptal623zct

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR 7):2

***** Welcome to STN International *****

NEWS 1 Web Page URL for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 4 OCT 28 KOREAPAT now available on STN
NEWS 5 NOV 30 PHAR reloaded with additional data
NEWS 6 DEC 01 LISA now available on STN
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004
NEWS 8 DEC 15 MEDLINE update schedule for December 2004
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 12 DEC 17 CSRAB reloaded; updating to resume; current-awareness
alerts (SDIs) affected
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDS/IFICDB
NEWS 14 DEC 30 EPPFULL: New patent full text database to be available on STN
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED
NEWS 16 JAN 03 No connect-hour charges in EPPFULL during January and
February 2005

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.


All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 13:04:14 ON 06 JAN 2005

=> file reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY TOTAL
SESSION
0.21 0.21



Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 13:04:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 59 TO ITERATE

100.0% PROCESSED 59 ITERATIONS 14 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 720 TO 1640
PROJECTED ANSWERS: 56 TO 504

L2 14 SEA SSS SAM L1

=> file caplus
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE ENTRY TOTAL
SESSION
0.43 0.64

FILE 'CAPLUS' ENTERED AT 13:05:04 ON 06 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jan 2005 VOL 142 ISS 2
FILE LAST UPDATED: 5 Jan 2005 (20050105/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2
L3 2 L2

=> d 1-2

FILE 'REGISTRY' ENTERED AT 13:04:34 ON 06 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4
DICTIONARY FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4


TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> Uploading C:\Program Files\Stnexp\Queries\HONG'S DIV IMIDAZOLE.str



chain nodes :
12 13 14 15 16
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
1-11 7-12 8-13 9-14 14-15 14-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11
exact/norm bonds :
7-8 7-11 8-9 9-10 10-11 14-16
exact bonds :
1-11 7-12 8-13 9-14 14-15
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 2002:107321 CAPLUS

DN 136:167373

TI Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors

IN Thirieau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry A.; Moinet, Christophe Philippe; Bigg, Dennis

PA Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.

SO PCT Int. Appl., 369 pp.
CODEN: PIXXD2DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002010140	A2	20020207	WO 2001-US23959	20010731
	WO 2002010140	A3	20020808		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA	2417204	AA	20020207	CA 2001-2417204	20010731
EP	1305294	A2	20030502	EP 2001-957342	20010731
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP	2004518613	T2	20040624	JP 2002-516272	20010731
NZ	523774	A	20040924	NZ 2001-523774	20010731
NO	2003000473	A	20030130	NO 2003-473	20030130
PRAI	US 2000-222584P	P	20000801		
WO	2001-US23959	W	20010731		
OS	MARPAT 136:167373				

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1999:795794 CAPLUS

DN 132:35701

TI Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors

IN Thirieau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry; Moinet, Christophe Philippe

PA Societe de Conseils de Recherches et d'Applications Scientifiques, S.A., Fr.

SO PCT Int. Appl., 342 pp.
CODEN: PIXXD2DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9964401	A2	19991216	WO 1999-US12760	19990608
	WO 9964401	A3	20030417		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT,				

LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2334945	AA	19991216	CA 1999-2334945	19990608
AU 9944257	A1	19991230	AU 1999-44257	19990608
AU 746963	B2	20020509		
EP 1086086	A1	20010328	EP 1999-927323	19990608
EP 1086086	B1	20041013		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2003523921	T2	20030812	JP 2000-553410	19990608
AT 279396	E	20041015	AT 1999-927323	19990608
NO 2000006267	A	20010207	NO 2000-6267	20001211
US 2004176379	P	20040909	US 2004-771725	20040204
PRAI US 1998-89087P	P	19980612		
US 1998-96431	A1	19980612		
WO 1999-US12760	W	19990608		
US 2001-719457	A3	20010613		
OS MARPAT 132:35701				

=> file reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:05:55 ON 06 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4
DICTIONARY FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s 11 sss full
FULL SEARCH INITIATED 13:06:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1175 TO ITERATE

100.0% PROCESSED 1175 ITERATIONS 344 ANSWERS
SEARCH TIME: 00.00.01

L4 344 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS


FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:06:11 ON 06 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

IE, SI, LT, LV, FI, RO, MK, CY, AL
PRIORITY APPLN. INFO.:

FR 1999-12643	A	19991011
FR 2000-10151	A	20000801
FR 2000-11169	A	20000901
WO 2000-FR2805	W	20001010
JP 1989-4943	A	20010410
JP 1990-1811	A	20020214
US 2002-89993	A2	20020404
EP 2000-967988	A3	20001010

OTHER SOURCE(S): MARPAT 141:106475
GI



AB The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivs. of general formula (I) (wherein Het = thiazole, oxazole, imidazole, isoxazole or isoxazoline; n = an integer from 0 to 6; A = optionally substituted aromatic radical; B = H, alkyl, Ph; R1, R2 = H, alkyl, cycloalkyl; n = NR46R47 or OR48; R46, R47 = H, alkyl, cycloalkyl, (CH2)k-CO2R51; R51 = alkyl, haloalkyl; R48 = H, alkyl). These compds. have advantageous pharmacol. properties which allow their use in a medicament intended to inhibit monoamine oxidases (MAO) and/or lipidic peroxidn. and/or to act as modulators of the sodium channels and notably their use in therapeutics for treating (1) central or peripheral nervous system, (2) neurodegenerative disorders selected from Parkinson's disease, Alzheimer's disease, Huntington's chorea and amyotrophic lateral sclerosis or (3) pain selected from the group consisting of postoperative pain, migraine, neuropathic pain, central pain, chronic inflammatory pain and pain linked to a cancer. Thus, 2-[[[(1,1-dimethylethoxy)carbonyl]methyl]a mino]ethanethioamide (4.3 g, 2.11 mmol) and 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (6.9 g, 2.11 mmol) were dissolved in 75 mL benzene under argon atmosphere and stirred at ambient temperature for 12 h to give, after

workup and silica gel chromatog., 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[[[(1,1-dimethylethoxy)carbonyl]-N-methyl-2-thiazolemethanamine which was treated with CP3CO2H and triethylsilane in 50 mL CH2Cl2 to give, after workup, 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-2-thiazolemethanamine (II). II showed IC50 of lower than 10 µM for inhibiting lipid peroxidn. of the cerebral cortex of rats.

IT 252314-87-7P, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenylurea
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 5-membered heterocycle derivs. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)

RN 252314-87-7 CAPLUS

CN Urea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jan 2005 VOL 142 ISS 2
FILE LAST UPDATED: 5 Jan 2005 (20050105/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 14
L5 5 L4

=> s 15 not 13
L6 3 L5 NOT L3

=> d 1-3 ibib abs hitstr

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:550745 CAPLUS
DOCUMENT NUMBER: 141:106475

TITLE: Preparation of 5-membered heterocycle derivatives for treating neurodegenerative disorders or pain
Chabrier De Lasseunier, Pierre-Stienne; Harnett, Jeremiah; Bigg, Dennis; Liberator, Anne-Marie; Pommier, Jacques; Lannoy, Jacques; Thureau, Christophe


PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 150 pp., Cont.-in-part of U.S. Ser. No. 89,993.
CODEN: USXXCO

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004132788	A1	20040708	US 2003-681002	20031008
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				



L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:283789 CAPLUS
DOCUMENT NUMBER: 134:311210

TITLE: 5-Membered heterocycle derivatives useful as monoamine oxidase inhibitors, lipid peroxidation inhibitors, and sodium channel modulators, and the production thereof, and use thereof as medicaments

INVENTOR(S): Chabrier de Lasseunier, Pierre-Stienne; Harnett, Jeremiah; Bigg, Dennis; Pommier, Jacques; Lannoy, Jacques; Liberator, Anne-Marie; Thureau, Christophe
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S., Fr.

PATENT ASSIGNEE(S): PCT Int. Appl., 261 pp.
CODEN: PIXXD2

SOURCE: Patent
DOCUMENT TYPE: French



LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
CA 2388505	AA	20010419	CA 2000-2388505	20001010
BR 2000014649	A	20020618	BR 2000-14649	20001010
EP 1223933	A2	20020724	EP 2000-967988	20001010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511416	T2	20030325	JP 2001-529718	20001010
NZ 518304	A	20040730	NZ 2000-518304	20001010
NO 2002001689	A	20020530	NO 2002-1689	20020410
US 2004132788	A1	20040708	US 2003-681002	20031008
PRIORITY APPLN. INFO.:				
FR 1999-12643	A	19991011		
FR 2000-10151	A	20000801		
FR 2000-11169	A	20000901		
EP 2000-967988	A3	20001010		


EP 2002-76763 A3 20001010
 WO 2000-FR2805 W 20001010
 JP 1989-4943 A 20010410
 JP 1990-1811 A 20020214
 US 2002-89993 A2 20020404

OTHER SOURCE(S): MARPAT 134:311210
 GI




AB The invention relates to pharmaceutical use of heterocyclic compds. of general formula Het(A)(B)-(CH₂)_n-CR₁R₂-Q [I; wherein the substituted heterocyclic ring Het(A)(B) = Q1-Q4; A = various aryl or heteroaryl systems, especially a substituted Ph or biphenyl radical, or also alkyl, cycloalkyl, or cycloalkylalkyl; B = especially H or alkyl, or also aryl or substituted alkyl; X = especially NH or S, or also substituted NH; Y = O or S;

n = 0-6; R₁, R₂ = especially H, alkyl, or cycloalkyl; Q = NR₃R₄ or OR₅; R₃ and R₄ = especially H, alkyl, cycloalkyl, alkynyl, cyanoalkyl, alkoxyalkyl, aralkoxyalkyl or (cycloalkyl)oxyalkyl; R₅ = H, alkyl, alkynyl, or cyanoalkyl]. I and their racemates, enantiomers, and/or salts can be used for producing medicaments for inhibiting monoamine oxidases (MAO), inhibiting lipid peroxidn., and/or for acting as modulators of sodium channels. The resulting medicaments are particularly for use in treating Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression, psychosis, pain and epilepsy. Approx. 350 synthetic examples of I and their salts are given, and numerous free bases of I are claimed. For instance, protection of sarcosinamide-HCl with BOC anhydride gave 72% BOC-N(Me)CH₂CONH₂, which was converted to the thioamide with (P255)2 in 65% yield. Cyclocondensation of the thioamide with 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (28%), followed by deprotection (73%) and selenylation (92%), gave thiazole derivative II as the HCl salt. II inhibited binding of the MAO-B specific ligand [3H]-Ro-19-6327 to rat mitochondrial prepns. with IC₅₀ < 10 μM. Selected I also inhibited formation of malondialdehyde by lipid peroxidn. in rat cerebral cortex prepns., and inhibited specific binding of [3H]-batrachotoxin to voltage-dependent



RN 252311-56-1 CAPLUS
 CN Urea, N-(1,1-dimethylethyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE REG	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	17.52	182.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-2.19	-2.19

FILE 'REGISTRY' ENTERED AT 13:09:42 ON 06 JAN 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE 'HELP USAGETERMS' FOR DETAILS.
 COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4
 DICTIONARY FILE UPDATES: 5 JAN 2005 HIGHEST RN 808732-83-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004


Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more

sodium channels in rat cerebral cortex homogenates.
 IT 252314-87-7, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenylurea
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
 RN 252314-87-7 CAPLUS
 CN Urea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2001:279029 CAPLUS
 DOCUMENT NUMBER: 135:107278
 TITLE: Novel non-peptide ligands for the somatostatin set3 receptor
 AUTHOR(S): Moinet, C.; Contour-Galceran, M.-O.; Poitout, L.; Morgan, B.; Gordon, T.; Roubert, P.; Thuriereau, C.
 CORPORATE SOURCE: ZA de Courtaboeuf, Institut Henri Beaufour, Les Ulis, F-91966, Fr.
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(8), 991-995
 CODEN: BMCL68; ISSN: 0960-894X
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A series of imidazole derivs. has been prepared using high throughput parallel synthesis. Several compds. showed high affinity (K_i in 10⁻⁶-10⁻⁸ M range) and selectivity at recombinant human somatostatin receptor subtype 3 (hst3).
 IT 252292-71-0P 252311-56-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of phenylimidazolyl(indolyl)ethylamines as somatostatin receptor antagonists)
 RN 252292-71-0 CAPLUS
 CN Urea, N-(2,4-difluorophenyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> Uploading C:\Program Files\Stnexp\Queries\HONG'S DIV IMIDAZOLE.str




chain nodes :
 12 13 14 15 16
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11
 chain bonds :
 1-11 7-12 8-13 9-14 14-15 14-16
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11
 exact/norm bonds :
 7-8 7-11 8-9 9-10 10-11 14-16
 exact bonds :
 1-11 7-12 8-13 9-14 14-15
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
 11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS

L7 STRUCTURE UPLOADED

=> d 17
 L7 HAS NO ANSWERS
 L7 STR



Structure attributes must be viewed using STN Express query preparation.

=> s k7
 L8 252 K7

=> s 17
 SAMPLE SEARCH INITIATED 13:10:01 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 606 TO ITERATE

100.0% PROCESSED 606 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 10644 TO 13596
PROJECTED ANSWERS: 1114 TO 2206

L9 50 SEA SSS SAM L7

=> s 17 sss full
FULL SEARCH INITIATED 13:10:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 11875 TO ITERATE

100.0% PROCESSED 11875 ITERATIONS 1671 ANSWERS
SEARCH TIME: 00.00.01

L10 1671 SEA SSS FUL L7

=> d his

(FILE 'HOME' ENTERED AT 13:04:14 ON 06 JAN 2005)

FILE 'REGISTRY' ENTERED AT 13:04:34 ON 06 JAN 2005

L1 STRUCTURE UPLOADED

L2 14 S L1

FILE 'CAPLUS' ENTERED AT 13:05:04 ON 06 JAN 2005

L3 2 S L2

FILE 'REGISTRY' ENTERED AT 13:05:55 ON 06 JAN 2005

L4 344 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 13:06:11 ON 06 JAN 2005

L5 5 S L4

L6 3 S L5 NOT L3

FILE 'REGISTRY' ENTERED AT 13:09:42 ON 06 JAN 2005

L7 STRUCTURE UPLOADED

L8 252 S K7

L9 50 S L7

L10 1671 S L7 SSS FULL

=> s 110 not 14

L11 1327 L10 NOT L4

=> file caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE ENTRY TOTAL
166.36 348.50

SINCE FILE ENTRY TOTAL
0.00 -2.19

FILE 'CAPLUS' ENTERED AT 13:11:11 ON 06 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Jan 2005 VOL 142 ISS 2
FILE LAST UPDATED: 5 Jan 2005 (20050105/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 111
L12 36 L11

=> d 1-36 ibib abs hitatr

L12 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:701970 CAPLUS

DOCUMENT NUMBER: 141:225511

TITLE: Preparation of substituted azoles as protein tyrosine phosphatase inhibitors for treatment of diabetes and other PTPase mediated conditions
INVENTOR(S): Mjalli, Adnan M. M.; Andrews, Robert C.; Yarragunta, Ravindra R.; Xie, Rongyuan; Ren, Tan; Subramanian, Govindan; Quada, James C., Jr.

PATENT ASSIGNEE(S): Transtech Pharma Inc., USA

SOURCE: PCT Int. Appl., 224 pp.

COOSN: PIXXD2



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071448	A2	20040826	WO 2004-US4076	20040212
WO 2004071448	A3	20041014		
W:	AB, AB, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NS, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NS, SN, TD, TG			
US 2004186151	A1	20040923	US 2004-777471	20040212
PRIORITY APPLN. INFO.:			US 2003-446924P	P 20030212
OTHER SOURCE(S):	MARPAT 141:225511			
GI				




AB Title imidazoles and analogs I [wherein m, n = independently 0, 1; A = H, alkyl, alkenyl, alkynyl; L1 = a bond, O, alkylene, CO, NHCO, NH, NHSO2, etc.; T = H, (un)substituted (cyclo)alkyl, heterocyclyl, (hetero)aryl, etc.; W = O, S, NR4; X = a bond, CO, CH2, SO2; R1 = H, halo, CN, alkyl, (hetero)aryl, heterocyclyl, etc.; R2 = H, perfluoroalkyl, alkylene optionally interrupted by one or more heteroatoms, (hetero)aryl, heterocyclyl, etc.; R3 = H, alkyl, (cyclo)alkylalkylene, (hetero)aryl(alkylene); R4 = H, alkyl, (hetero)aryl(alkyl), heterocyclyl(alkyl), etc.; Ar1 = (un)substituted optionally fused (hetero)aryl; Ar2 = (un)substituted optionally fused (hetero)arylene; and pharmaceutically acceptable salts, solvates, and prodrugs thereof] were prepared as inhibitors of protein tyrosine phosphatases (PTPases). For example, 3-[(tert-butoxycarbonyl)amino]-2-(4-butoxy-3-butoxycarbonylphenyl)-2-ethyl-4-(4-nitrophenyl)imidazole was coupled with 4-nitrophenacyl bromide to give the keto ester, which was treated with ammonium acetate in glacial acetic acid/anhydrous DMF to afford the imidazole II (40%). Comps. of the invention inhibited PTP 1B activity with IC50 values ranging from about 0.01 μ M to about 20 μ M. Thus, I and pharmaceutical compns. comprising them may be useful for the management, treatment, control, and adjunct treatment of diseases mediated by PTPase activity, such as Type I diabetes, Type II diabetes, immune dysfunction, AIDS, autoimmune diseases, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis and/or production of growth hormone or cytokines, of Alzheimer's disease (no data).

IT 746657-71-6P 746657-73-8P 746657-81-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(PTPase inhibitor; preparation of substituted imidazoles as PTPase inhibitors for treatment of diabetes and other PTPase mediated conditions)


RN 746657-71-6 CAPLUS
CN Cyclohexanecarboxamide, N-[(1S)-2-(4-butoxyphenyl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 746657-73-8 CAPLUS
CN Cyclohexanecarboxamide, N-[(1S)-2-(4-butoxyphenyl)-1-[4-(2,4-dichlorophenyl)-1H-imidazol-2-yl]ethyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 746657-81-8 CAPLUS
CN Cyclohexanecarboxamide, N-[(1S)-2-(4-butoxyphenyl)-1-[4-(pentafluorophenyl)-1H-imidazol-2-yl]ethyl]-4-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 746658-03-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PTPase inhibitor; preparation of substituted imidazoles as PTPase inhibitors for treatment of diabetes and other PTPase mediated conditions)

RN 746658-03-7 CAPLUS


Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.




Absolute stereochemistry.



Absolute stereochemistry.




Absolute stereochemistry



L12 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN
ACCESSION NUMBER: 2004:550745 CAPLUS
DOCUMENT NUMBER: 141:106475
TITLE: Preparation of 5-membered heterocycle derivatives for
treating neurodegenerative disorders or pain
INVENTOR(S): Chabrier De Lessauniers, Pierre-Stienne; Harnett,
Jeremiah; Bigg, Dennis; Liberatore, Anne-Marie;
Pommier, Jacques; Lannoy, Jacques; Thuriiau,
Christophe
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 150 pp., Cont.-in-part of U.S.
Ser. No. 89,993.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004132788	A1	20040708	US 2003-681002	20031008
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W:	AE, AO, AL,	AM, AT, AU, AZ,	BA, BB, BG, BR, BY, BZ,	CA, CH, CN,
	CR, CU, CZ,	DE, DK, DM, DZ,	ES, FI, GB, GD, GE, GH,	GM, HR,
	HU, ID, IL, IN,	IS, JP, KE, KG, KP,	KR, KZ, LC, LK, LR,	LS, LT,
	LU, LV, MA, MD,	MG, MK, MN, MW,	MX, MZ, NO, NZ, PL,	PT, RO, RU,
	SD, SE, SG, SI, SK,	SL, TJ, TM, TR,	TT, TZ, UA, UG,	US, UZ, VN,
	YU, ZA, ZW, AM,	AZ, BY, KG, KZ,	MD, RU, TJ, TH,	
RW:	GH, GM, KE,	LS, MW, MZ, SD,	SI, SZ, TZ, UG, ZW,	AT, BE, CH, CY,
	DE, DK, ES, FI,	FR, GB, GR, IE,	IT, LU, MC, NL, PT,	SE, SF, BJ,
	CF, CG, CI, CM,	GA, GN, GW, ML,	MR, NE, SN, TD, TG	
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R:	AT, BE, CH, DE, DK,	ES, FR, GB, GR,	IT, LI, LU, NL, SE,	MC, PT,
	IE, SI, LT, LV, FI,	RO, MK, CY, AL		
PRIORITY APPLN. INFO. :			FR 1999-12643	A 19991011
			FR 2000-10151	A 20000801
			FR 2000-11169	A 20000901
			WO 2000-FR2805	W 20001010
			JF 1989-4943	A 20010410
			JP 1990-1811	A 20020214
			US 2002-89993	A2 20020404




AB The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivs. of general formula (I) [wherein Het = thiazole, oxazole, imidazole, isoxazole or isoxazoline; n = an integer from 0 to 6; A = optionally substituted aromatic radical; B = H, alkyl, Ph; R1, R2 = H, alkyl, cycloalkyl; Q = NR46R47 or OR48; R46, R47 = H, alkyl, cycloalkyl, (CH2)k-CO2R51; R51 = alkyl, haloalkyl; R48 = H, alkyl]. These compds. have advantageous pharmacol. properties which allow their use in a medicament intended to inhibit monoamine oxidases (MAO) and/or lipidic peroxidn. and/or to act as modulators of the sodium channels and notably their use in therapeutics for treating (1) central or peripheral nervous system, (2) neurodegenerative disorders selected from Parkinson's disease, Alzheimer's disease, Huntington's chorea and amyotrophic lateral sclerosis or (3) pain selected from the group consisting of postoperative pain, migraine, neuropathic pain, central pain, chronic inflammatory pain and pain linked to a cancer. Thus, 2-[[[(1,1-dimethylethoxy)carbonyl]methyl]amino]ethanethioamide (4.3 g, 2.11 mmol) and 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (6.9 g, 2.11 mmol) were dissolved in 75 mL benzene under argon atmospheric and stirred at ambient temperature for 12 h to give,

after workup and silica gel chromatog., 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[[[(1,1-dimethylethoxy)carbonyl]methyl]-2-thiazolemethanamine which was treated with CF3CO2H and triethylsilane in 50 mL CH2Cl2 to give, after workup, 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-2-thiazolemethanamine (II). II showed IC50 of lower than 10 µM for inhibiting lipid peroxidn. of the cerebral cortex of rats.

IT 252279-09-7P, (1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 252302-96-8P, (1R)-N-Benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335244-94-5P 335246-59-8P 335246-68-9P, N-Benzyl[4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl]methanamine 335246-82-7P 335247-34-2P, 1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of 5-membered heterocycle derivs. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)


RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-96-8 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-94-5 CAPLUS
CN Carbamic acid, [1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methylhexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335246-59-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-68-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-82-7 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




RN 335247-34-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)- (9CI) (CA INDEX NAME)



IT 335247-29-5P, tert-Butyl [(S)-cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]carbamate 335247-30-8P, (S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine 335247-35-3P, tert-Butyl [1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl]carbamate 473541-90-1P 473541-95-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 5-membered heterocycle derivs. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)


RN 335247-29-5 CAPLUS
CN Carbamic acid, [(S)-cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-30-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(4-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335247-35-3 CAPLUS
CN Carbamic acid, [1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473541-90-1 CAPLUS
CN Carbamic acid, methyl[[4-(10H-phenothiazin-2-yl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 473541-95-6 CAPLUS
CN Carbamic acid, [[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



IT 167983-80-4P 175531-38-1P, (4-Phenyl-1H-imidazol-2-yl)methanamine 218944-40-2P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-nitrobenzoyl)-1H-imidazole-2-methanamine 218944-41-3P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-aminobenzoyl)-1H-imidazole-2-methanamine 218944-66-2P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-nitrophenyl)-1H-imidazole-2-methanamine 218944-68-4P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-aminophenyl)-1H-imidazole-2-methanamine 252279-15-5P, (1R)-2-(1H-Indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine 252302-55-9P, N-[(1S)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-hexanamine 252303-16-5P, (1R)-N-(Cyclohexylmethyl)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 252306-13-1P


252309-65-2P, (1S)-N-Benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 280775-44-2P, N-Benzyl[4-phenyl-1H-imidazol-2-yl]methanamine 335242-80-3P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-1H-imidazole-2-methanamine 335242-92-7P, N-[(S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335242-94-9P, N-[1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-5-methylhexyl]-N-cyclohexylamine 335242-95-0P, N-[1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]heptyl]cyclohexanamine 335242-98-3P, N-Benzyl-N-[(4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl)methyl]-1-hexanamine 335242-99-4P, N-Benzyl[4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl]-N-methylmethanamine 335243-00-0P 335243-01-1P 335243-03-3P 335243-04-4P 335243-05-5P 335243-07-7P, (4-Phenyl-1H-imidazol-2-yl)methanamine hydrochloride 335243-10-2P 335243-14-6P 335243-15-7P 335243-16-8P 335243-19-1P 335243-20-4P 335243-23-7P 335243-24-8P 335243-26-0P 335243-27-1P 335243-28-2P 335243-29-3P 335243-30-6P 335243-31-7P 335243-32-8P 335243-33-9P 335243-34-0P, Butyl [(4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl)methyl]carbamate 335243-35-1P 335243-36-2P, (S)-Cyclohexyl[4-phenyl-1H-imidazol-2-yl]methylamine hydrochloride 335243-41-9P, N-[(S)-Cyclohexyl[4-(3-fluoro-4-methoxyphenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335243-42-0P, N-[(S)-Cyclohexyl[4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335243-43-1P, N-[(S)-Cyclohexyl[4-(3-fluorophenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335243-50-0P, tert-Butyl [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 335243-51-1P, (1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-52-2P, N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]benzamide 335243-53-3P, Benzyl [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 335243-56-6P, tert-Butyl [(1R)-2-(1H-indol-3-yl)-1-(4-(4-nitrophenyl)-1H-imidazol-2-yl)ethyl]carbamate 335243-57-7P, tert-Butyl [(4-phenyl-1H-imidazol-2-yl)methyl]carbamate 335243-59-9P 335243-60-2P, (1R)-2-(1H-Indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine hydrochloride 335243-62-4P, (1R)-2-(1H-Indol-3-yl)-N-(2-phenoxyethyl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-65-7P 335243-68-0P 335243-70-4P, N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]benzenecarboximidamide 335243-71-5P, N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxybenzenecarboximidamide 335243-74-8P, tert-Butyl [(1R)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]carbamate 335243-75-9P 335243-79-3P, tert-Butyl [(1R)-3-phenyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]carbamate 335243-80-6P, tert-Butyl [(1R)-2-cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 335243-83-9P 335243-84-0P 335243-85-1P 335243-86-2P 335243-87-3P, 4-[2-[(tert-Butoxycarbonyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335243-88-4P, N-[(S)-Cyclohexyl[4-(4-methylsulfonylphenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine 335243-91-9P, [4-(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl]methanamine hydrochloride 335243-94-2P, N,N-Dibenzyl[4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl]methanamine 335243-95-3P 335244-02-5P, 4-[2-[(tert-Butoxycarbonyl)(methyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-04-7P, 4-[2-[(1R)-1-[(tert-Butoxycarbonyl)amino]-2-cyclohexylethyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-11-6P, (1R)-1-[4-(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl]-2-cyclohexylethanamine hydrochloride 335244-12-7P, [4-(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl]-N-methylmethanamine hydrochloride 335244-26-3P, 4-[2-[(Benzyl(tert-butoxycarbonyl)amino)methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-28-5P 335244-29-6P, N-Benzyl[4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl]methanamine hydrochloride 335244-30-9P 335244-31-0P 335244-35-4P

(S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-[3-(trifluoromethyl)phenyl]-1H-imidazol-2-yl]methanamine hydrochloride 335245-73-3P 335245-74-4P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335245-75-5P, (S)-1-Cyclohexyl-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-76-6P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-78-8P, N-[(S)-Cyclohexyl[4-(3-fluorophenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine hydrochloride 335245-80-2P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-2,6-di-tert-butylphenol hydrochloride 335245-82-4P, (R)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335246-23-6P 335246-24-7P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-2,6-di-tert-butylphenol 335246-41-8P 335246-42-9P 335246-43-0P, (S)-Cyclohexyl[4-phenyl-1H-imidazol-2-yl]methylamine 335246-44-1P 335246-46-3P, N-[(S)-Cyclohexyl[4-phenyl-1H-imidazol-2-yl]methyl]cyclobutanamine 335246-47-4P 335246-50-9P 335246-51-0P 335246-54-3P 335246-56-5P 335246-57-6P 335246-58-7P, [4-(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl]methanamine 335246-67-8P 335246-69-0P 335246-70-3P 335246-71-4P 335246-72-5P 335246-73-6P 335246-74-7P 335246-76-9P 335246-77-0P 335246-78-1P 335246-79-2P 335246-80-5P 335246-81-6P 335246-83-8P 335246-84-9P 335246-85-0P 335246-86-1P 335246-87-2P 335246-89-4P 335246-90-7P 335246-91-8P 335246-92-9P 335246-93-0P 335246-94-1P, (S)-Cyclohexyl[4-(3,4-difluorophenyl)-1H-imidazol-2-yl]methanamine 335246-95-2P, (S)-Cyclohexyl[4-(3-fluoro-4-methoxyphenyl)-1H-imidazol-2-yl]methanamine 335246-96-3P 335246-97-4P 335246-98-5P, (S)-Cyclohexyl-N-(cyclohexylmethyl)[4-phenyl-1H-imidazol-2-yl]methanamine 335246-99-6P 335247-00-2P, (S)-Cyclohexyl-N-(cyclopropylmethyl)[4-phenyl-1H-imidazol-2-yl]methanamine 335247-01-3P, (S)-Cyclohexyl-N-(cyclopropylmethyl)[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine 335247-02-4P, N-[(S)-Cyclohexyl[4-(4-cyclohexylphenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335247-04-6P, 4-[2-[(S)-Cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]-N,N-diethylaniline 335247-05-7P, 2,6-Di-tert-butyl-4-[2-[(S)-cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]phenol 335247-06-8P, 4-[2-[(S)-Cyclohexyl[(cyclohexylamino)methyl]-1H-imidazol-4-yl]-N,N-diethylaniline 335247-07-9P, N-[(S)-[4-(3-Bromophenyl)-1H-imidazol-2-yl](cyclohexyl)methyl]cyclohexanamine 335247-08-0P, (1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethanamine 335247-09-1P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-N,N-diethylaniline 335247-10-4P, (S)-1-Cyclohexyl-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl]methanamine 335247-11-5P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl]methanamine 335247-12-6P, N-[(S)-Cyclohexyl[4-(3-fluorophenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine 335247-13-7P, (R)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine 335247-14-8P, (1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine 335247-16-0P, N-[(1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethyl]cyclohexanamine 335247-17-1P, (1R)-N-(Cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine 335247-20-6P, (1R)-1-[4-(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl]-2-cyclohexylethanamine 335247-37-5P, [4-(1,1'-Biphenyl-4-yl)-1H-imidazol-2-yl]-N-methylmethanamine 396135-27-6P 396135-28-7P 473540-88-4P 473541-06-9P 473541-81-0P 473541-84-3P 717914-12-0P 717914-13-1P 717914-14-2P 717914-15-3P 717914-16-4P 717914-17-5P


335244-43-4P 335244-44-5P 335244-47-8P 335244-48-9P 335244-50-3P 335244-53-6P 335244-54-7P 335244-56-9P, 4-[2-[(1S)-1-[(tert-Butoxycarbonyl)amino]propyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-57-0P 335244-60-5P 335244-63-8P 335244-64-9P 335244-68-3P 335244-69-4P 335244-70-7P 335244-74-1P 335244-75-2P 335244-76-3P 335244-77-4P 335244-78-5P 335244-79-6P 335244-84-3P 335244-85-4P 335244-86-5P 335244-89-8P 335244-96-7P 335244-98-9P 335244-99-0P 335245-03-9P 335245-04-0P, 4-[2-[(1S)-1-[(Butoxycarbonyl)amino]ethyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335245-05-1P, 4-[2-[(1R)-1-[(Butoxycarbonyl)amino]ethyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335245-06-2P, N-[(S)-Cyclohexyl[4-phenyl-1H-imidazol-2-yl]methyl]cyclohexanamine 335245-11-9P 335245-18-6P, N-[(4-(3-Bromophenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335245-22-2P, (S)-Cyclohexyl[4-(3,4-difluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-23-3P, (S)-Cyclohexyl[4-(3-fluoro-4-methoxyphenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-25-5P, N-[(S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-2-propanamine 335245-26-6P, N-[(S)-Cyclohexyl[4-(3,4-difluorophenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335245-28-8P, N-[(S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine hydrochloride 335245-29-9P, (S)-Cyclohexyl-N-(cyclohexylmethyl)[4-phenyl-1H-imidazol-2-yl]methanamine hydrochloride 335245-31-3P, (S)-Cyclohexyl-N-(cyclopropylmethyl)[4-phenyl-1H-imidazol-2-yl]methanamine hydrochloride 335245-34-6P, N-[(S)-Cyclohexyl[4-(4-(trifluoromethoxy)phenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335245-37-9P, (S)-Cyclohexyl-N-(cyclopropylmethyl)[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-38-0P 335245-39-1P, N-[(S)-Cyclohexyl[4-(4-cyclohexylphenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine hydrochloride 335245-40-4P 335245-41-5P, N-[(S)-Cyclohexyl[4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine acetate 335245-46-0P, N-[(S)-Cyclohexyl[4-(4-methylthiophenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine 335245-47-1P, N-[(S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine 335245-48-2P, N-[(S)-[4-[3,5-Bis(trifluoromethyl)phenyl]-1H-imidazol-2-yl](cyclohexyl)methyl]cyclohexanamine 335245-51-7P, N-[(S)-Cyclohexyl[4-(3,4-difluorophenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine 335245-53-9P, (S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-cyclohexyl-N-(cyclohexylmethyl)methanamine 335245-54-0P, 4-[2-[(S)-Cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335245-55-1P, 2,6-Di-tert-butyl-4-[2-[(S)-cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]phenol hydrochloride 335245-56-2P, 4-[2-[(S)-Cyclohexyl[(cyclohexylamino)methyl]-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335245-57-3P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine 335245-59-5P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-60-8P, N-[(S)-Cyclohexyl[4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine hydrochloride 335245-61-9P, N-[(S)-[4-(3-Bromophenyl)-1H-imidazol-2-yl](cyclohexyl)methyl]cyclohexanamine hydrochloride 335245-62-0P, N-[(S)-Cyclohexyl[4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine 335245-65-3P, N-[(S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]cycloheptanamine 335245-68-6P, N-[(S)-Cyclohexyl[4-(3-(trifluoromethyl)phenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine 335245-69-7P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-(trifluoromethyl)phenyl)-1H-imidazol-2-yl]methanamine 335245-70-0P, (S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-cyclohexyl-N-(cyclohexylmethyl)methanamine hydrochloride 335245-71-1P,

717914-20-0P 717914-22-2P 717914-23-3P 717914-25-5P 717914-26-6P 717914-27-7P 717914-28-8P 717914-29-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USSS (Uses)
(preparation of 5-membered heterocycle derivs. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)
RN 167983-80-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 175531-38-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- (9CI) (CA INDEX NAME)



RN 218944-40-2 CAPLUS
CN Benzamide, N-[(4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]-N-methyl-4-nitro- (9CI) (CA INDEX NAME)




RN 218944-41-3 CAPLUS
CN Benzamide, 4-amino-N-[(4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 218944-66-2 CAPLUS
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[[methyl(4-

nitrophenyl]amino)methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 218944-68-4 CAPLUS
CN Phenol, 4-[2-[[[(4-aminophenyl)methylamino)methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 252279-15-5 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-55-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl- α -(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-16-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335242-92-7 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -cyclohexyl-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.





RN 335242-94-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl- α -(4-methylpentyl)- (9CI) (CA INDEX NAME)




RN 335242-95-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- α -hexyl- (9CI) (CA INDEX NAME)



RN 335242-98-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-13-1 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252309-65-2 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 280775-44-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335242-80-3 CAPLUS
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[(methylamino)methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)

RN 335242-99-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-00-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N,N, α -triethyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-01-1 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-N-2-pyrimidinyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-03-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-methyl- α -(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-04-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-(2-phenylethyl)- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-05-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-N,α-bis(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-07-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-10-2 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-14-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-butyl-1-methyl-α-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335243-24-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(4-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-26-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(2-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-27-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(2-fluorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-28-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N-butyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-29-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-N-(3-methylbutyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-15-7 CAPLUS
CN Carbamic acid, [1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-16-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-19-1 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-20-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-diethyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-23-7 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(2,6-dichlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-30-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N,α-diethyl- (9CI) (CA INDEX NAME)




RN 335243-31-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-N-pentyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-32-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-33-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-34-0 CAPLUS
CN Carbamic acid, [4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 335243-35-1 CAPLUS
CN 1H-imidazole-2-methanamine, N-cyclopentyl-α-hexyl-4-phenyl- (9CI)
(CA INDEX NAME)



RN 335243-36-2 CAPLUS
CN 1H-imidazole-2-methanamine, α-cyclohexyl-4-phenyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335243-41-9 CAPLUS
CN 1H-imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-42-0 CAPLUS
CN 1H-imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-[4-(trifluoromethyl)phenyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335243-52-2 CAPLUS
CN Benzamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 335243-53-3 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-56-6 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-(4-nitrophenyl)-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-43-1 CAPLUS
CN 1H-imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(3-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-50-0 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-51-1 CAPLUS
CN 1H-indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-57-7 CAPLUS
CN Carbamic acid, [(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-59-9 CAPLUS
CN 1H-indole-3-ethanamine, 6-fluoro-α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-60-2 CAPLUS
CN 1H-indole-3-ethanamine, α-(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335243-62-4 CAPLUS
CN 1H-indole-3-ethanamine, N-(2-phenoxyethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-65-7 CAPLUS
CN 1H-imidazole-2-methanamine, α-(benzo[b]thien-3-ylmethyl)-4-phenyl-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-68-0 CAPLUS
CN Carbamic acid, [2-(6-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-70-4 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-71-5 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-74-8 CAPLUS
CN Carbamic acid, [(1R)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

(CA INDEX NAME)




RN 335243-84-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -(cyclohexylmethyl)-4-phenyl-N-(phenylmethyl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-85-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(2-phenylethyl)-N-(phenylmethyl)-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-86-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- α -(4,4,4-trifluorobutyl)- (9CI) (CA INDEX NAME)




RN 335243-87-3 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-88-4 CAPLUS

Absolute stereochemistry.




RN 335243-75-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-N-(phenylmethyl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-79-3 CAPLUS
CN Carbamic acid, [(1R)-3-phenyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-80-6 CAPLUS
CN Carbamic acid, [(1R)-2-cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335243-83-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α ,4-diphenyl-N-(phenylmethyl)- (9CI)

CN 1H-Imidazole-2-methanamine, N, α -dicyclohexyl-4-(4-methylsulfonylphenyl)-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-91-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-94-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-95-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-02-5 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-04-7 CAPLUS
CN Carbamic acid, [(1R)-1-(4-{[1,1'-biphenyl]-4-yl}-1H-imidazol-2-yl)-2-cyclohexylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-11-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-{[1,1'-biphenyl]-4-yl}-α-(cyclohexylmethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-12-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-{[1,1'-biphenyl]-4-yl}-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335244-26-3 CAPLUS
CN Carbamic acid, [(4-{[1,1'-biphenyl]-4-yl}-1H-imidazol-2-yl)methyl](phenylmethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-35-4 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-43-4 CAPLUS
CN Carbamic acid, [1-(4-(4-methylphenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-44-5 CAPLUS
CN Carbamic acid, [1-(4-{[1,1'-biphenyl]-4-yl}-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-47-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-butyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-48-9 CAPLUS




RN 335244-28-5 CAPLUS
CN Carbamic acid, [(1R)-1-(4-{[1,1'-biphenyl]-4-yl}-1H-imidazol-2-yl)-3-phenylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-29-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-{[1,1'-biphenyl]-4-yl}-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335244-30-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-{[1,1'-biphenyl]-4-yl}-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-31-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-{[1,1'-biphenyl]-4-yl}-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CN Carbamic acid, [1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-50-3 CAPLUS
CN Carbamic acid, [1-(4-(3-bromophenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-53-6 CAPLUS
CN Carbamic acid, [1-(4-{[1,1'-biphenyl]-4-yl}-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-54-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-56-9 CAPLUS
CN Carbamic acid, [(1S)-1-(4-{[1,1'-biphenyl]-4-yl}-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-57-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-60-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-ethyl-N-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-63-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-64-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α-pentyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-68-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




RN 335244-76-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)-α-propyl-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-77-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(3-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335244-78-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-79-6 CAPLUS
CN Benzonitrile, 4-[2-[1-[(phenylmethyl)amino]heptyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335244-84-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-butyl-α-ethyl-, (αS)- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 335244-69-4 CAPLUS
CN Carbamic acid, [(1R)-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-70-7 CAPLUS
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-74-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-75-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)-α-propyl-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 335244-85-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-methyl-4-phenyl-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-86-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl-N-propyl- (9CI) (CA INDEX NAME)




RN 335244-89-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-N-[(4-methoxyphenyl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 335244-96-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-N-(2-methylpropyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 335244-98-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-99-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335245-03-9 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335245-04-0 CAPLUS
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-05-1 CAPLUS
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-23-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-25-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-(4-fluorophenyl)-N-(1-methylethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-26-6 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -cyclohexyl-4-(3,4-difluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-06-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N, α -dicyclohexyl-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-11-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-N-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 335245-18-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl- (9CI) (CA INDEX NAME)




RN 335245-22-2 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-(3,4-difluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-28-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N, α -dicyclohexyl-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl.

RN 335245-29-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclohexylmethyl)-4-phenyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-31-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclopropylmethyl)-4-phenyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-34-6 CAPIUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(4-(trifluoromethoxy)phenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-37-9 CAPIUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclopropylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-38-0 CAPIUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclopentyl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 335245-39-1 CAPIUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(4-(4-fluorophenyl)-cyclohexylphenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-40-4 CAPIUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(1-methylethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-41-5 CAPIUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(4-(trifluoromethyl)phenyl)-, (aS)-, acetate (9CI) (CA INDEX NAME)

CM 1


CRN 335243-42-0
CMF C21 H26 F3 N3

Absolute stereochemistry.




CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 335245-46-0 CAPIUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-(4-(methylthio)phenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-47-1 CAPIUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-48-2 CAPIUS
CN 1H-Imidazole-2-methanamine, 4-[3,5-bis(trifluoromethyl)phenyl]-N,α-dicyclohexyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-51-7 CAPIUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-(3,4-difluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-53-9 CAPIUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-cyclohexyl-N-(cyclohexylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-54-0 CAPIUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(4-(diethylamino)phenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-55-1 CAPLUS
CN Phenol, 4-[(S)-cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-56-2 CAPLUS
CN 1H-imidazole-2-methanamine, N,α-dicyclohexyl-4-[(4-(diethylamino)phenyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-57-3 CAPLUS
CN 1H-imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(4-


Absolute stereochemistry.



●x HCl


RN 335245-62-0 CAPLUS
CN 1H-imidazole-2-methanamine, N,α-dicyclohexyl-4-[(3-(trifluoromethyl)phenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-65-3 CAPLUS
CN 1H-imidazole-2-methanamine, N-cycloheptyl-α-cyclohexyl-4-(4-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-68-6 CAPLUS
CN 1H-imidazole-2-methanamine, N,α-dicyclohexyl-4-[(3-(trifluoromethyl)phenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-59-5 CAPLUS
CN 1H-imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-60-8 CAPLUS
CN 1H-imidazole-2-methanamine, N,α-dicyclohexyl-4-[(4-(trifluoromethyl)phenyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-61-9 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-N,α-dicyclohexyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)




RN 335245-69-7 CAPLUS
CN 1H-imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[(3-(trifluoromethyl)phenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-70-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-α-cyclohexyl-N-(cyclohexylmethyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-71-1 CAPLUS
CN 1H-imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[(3-(trifluoromethyl)phenyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-73-3 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-74-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-[4-(diethylamino)phenyl]-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-75-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(3-fluorophenyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-82-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(4-(tert-butyl)-2-hydroxyphenyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335246-23-6 CAPLUS
CN Phenol, 4-[2-[(1S)-aminocyclohexylmethyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 335246-24-7 CAPLUS
CN Phenol, 4-[2-[(1S)-aminocyclohexylmethyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-76-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(3-fluorophenyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-78-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-(3-fluorophenyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




●x HCl

RN 335245-80-2 CAPLUS
CN Phenol, 4-[2-[(1S)-aminocyclohexylmethyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-41-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-pentyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-42-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-43-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-44-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl-α-hexyl-, (9CI) (CA INDEX NAME)




RN 335246-46-3 CAPLUS

CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -cyclohexyl-4-phenyl-,
(α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-47-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-4-(4-fluorophenyl)- α -hexyl-
(9CI) (CA INDEX NAME)



RN 335246-50-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(phenylmethyl)- (9CI) (CA
INDEX NAME)




RN 335246-51-0 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl- α -(4-phenyl-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)




RN 335246-54-3 CAPLUS
CN 1H-Indole-3-ethanamine, 6-chloro- α -(4-phenyl-1H-imidazol-2-yl)-
(9CI) (CA INDEX NAME)


CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methylphenyl)- (9CI) (CA
INDEX NAME)




RN 335246-70-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(2-methoxyphenyl)- (9CI) (CA
INDEX NAME)




RN 335246-71-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -hexyl- (9CI)
(CA INDEX NAME)



RN 335246-72-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methoxyphenyl)- (9CI) (CA
INDEX NAME)




RN 335246-73-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- α -hexyl- (9CI) (CA
INDEX NAME)




RN 335246-74-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -ethyl-,
(α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-56-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(2-phenylethyl)-, (α R)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-57-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α -(cyclohexylmethyl)-4-phenyl-,
(α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-58-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)




RN 335246-67-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(2-phenylethyl)-
, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-69-0 CAPLUS



RN 335246-76-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methylphenyl)-N-
(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-77-0 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX
NAME)




RN 335246-78-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -propyl-,
(α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-79-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -propyl-, (α R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 335246-80-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- α -hexyl-
(9CI) (CA INDEX NAME)




RN 335246-81-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α -methyl-4-phenyl-, (αR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.




RN 335246-83-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)- α -hexyl- (9CI) (CA INDEX NAME)




RN 335246-84-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- α -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-85-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)- α -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-86-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- α -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-93-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- α -(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 335246-94-1 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-(3,4-difluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-95-2 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-96-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclopropyl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 335246-87-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)- α -hexyl- (9CI)
(CA INDEX NAME)




RN 335246-89-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)- α -hexyl- (9CI) (CA INDEX NAME)




RN 335246-90-7 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro- α -[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 335246-91-8 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro- α -[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 335246-92-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-cyclobutyl-5-fluoro- α -[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 335246-97-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)- α -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-98-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclohexylmethyl)-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-99-6 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl- α -cyclopropyl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 335247-00-2 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclopropylmethyl)-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-01-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclopropylmethyl)-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-02-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -cyclohexyl-4-(4-cyclohexylphenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-04-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclohexylmethyl)-4-[4-(diethylamino)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-05-7 CAPLUS
CN Phenol, 4-[2-[(S)-cyclohexyl[(cyclohexylmethyl)amino)methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-06-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N, α -dicyclohexyl-4-[4-(diethylamino)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-07-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N, α -dicyclohexyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-08-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -(cyclohexylmethyl)-4-(4-fluorophenyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-09-1 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-[4-(diethylamino)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-10-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-11-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclohexylmethyl)-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-12-6 CAPLUS
CN 1H-Imidazole-2-methanamine, N, α -dicyclohexyl-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-13-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335247-14-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- α -(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335247-16-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- α -


(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-17-1 CAPLUS
CN 1H-imidazole-2-methanamine, N-(cyclohexylmethyl)-4-(4-fluorophenyl)-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-20-6 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(cyclohexylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-37-5 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl- (9CI) (CA INDEX NAME)




RN 396135-27-6 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl- (9CI) (CA INDEX NAME)

RN 473541-84-3 CAPLUS
CN Phenol, 4-[2-(aminomethyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 717914-12-0 CAPLUS
CN 1H-indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 717914-13-1 CAPLUS
CN 1H-imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-, monohydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


RN 717914-14-2 CAPLUS
CN 1H-imidazole-2-methanamine, α-pentyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



RN 396135-28-7 CAPLUS
CN 1H-imidazole-2-methanamine, α-butyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 473540-88-4 CAPLUS
CN 1H-imidazole-2-methanamine, N-methyl-4-(10H-phenothiazin-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)





● HCl

RN 473541-06-9 CAPLUS
CN Phenol, 4-[2-(aminomethyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 473541-81-0 CAPLUS
CN 1H-imidazole-2-methanamine, N-methyl-4-(10H-phenothiazin-2-yl)- (9CI) (CA INDEX NAME)




● HCl

RN 717914-15-3 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-16-4 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-17-5 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-20-0 CAPLUS
CN 1H-imidazole-2-methanamine, N-cyclobutyl-4-(4-fluorophenyl)-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-22-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-23-3 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl-α-(4-phenyl-1H-imidazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-25-5 CAPLUS
CN 1H-Indole-3-ethanamine, 6-chloro-α-(4-phenyl-1H-imidazol-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 717914-30-2P 717914-32-4P 717914-33-5P
717914-34-6P 717914-35-7P 717914-36-8P
717914-37-9P 717914-38-0P 717914-39-1P
717914-40-4P 717914-42-6P 717914-44-8P
717914-45-9P 717914-46-0P 717914-47-1P
717914-48-2P 717914-50-6P 717914-51-7P
717914-52-8P 717914-53-9P 717914-54-0P
717914-55-1P 717914-56-2P 717914-57-3P
717914-58-4P 717914-59-5P 717914-60-8P
717914-61-9P 717914-62-0P 717914-63-1P
717914-64-2P 717914-65-3P 717914-66-4P
717914-67-5P 717914-68-6P 717914-69-7P
717914-70-0P 717914-71-1P 717914-72-2P
717914-74-4P 717914-75-5P 717914-76-6P
717915-64-5P 717915-66-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-membered heterocycle derivs. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)
RN 717914-30-2 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-32-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(2-phenylethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 717914-33-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl-, monohydrochloride (9CI) (CA INDEX NAME)

RN 717914-26-6 CAPLUS
CN Carbamic acid, phenyl[(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 717914-27-7 CAPLUS
CN 1H-Imidazole-2-methanamine, N,4-diphenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-28-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-(2-phenylethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 717914-29-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(cyclohexylmethyl)-4-phenyl-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl




● HCl

RN 717914-34-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α-butyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-35-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-36-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-37-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-38-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methoxyphenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-39-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- α -hexyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-40-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- α -hexyl-N-(phenylmethyl)-, monoacetate (9CI) (CA INDEX NAME)

CM 1
CRN 335244-54-7
CMP C23 H28 Br N3




CM 2

CRN 64-19-7
CMP C2 H4 O2



● HCl


RN 717914-47-1 CAPLUS
CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-48-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -propyl-, monohydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 717914-50-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- α -hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl




RN 717914-42-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -ethyl-, monohydrochloride, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 717914-44-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methylphenyl)-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-45-9 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-46-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -propyl-, monohydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 717914-51-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α -methyl-4-phenyl-, monohydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 717914-52-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- α -hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-53-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)- α -hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-54-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-55-1 CAPLUS
CN Benzonitrile, 4-[2-[1-((phenylmethyl)amino)heptyl]-1H-imidazol-4-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-56-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-57-3 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(2-chlorophenyl)-α-hexyl-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-58-4 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(4-(diethylamino)phenyl)-α-hexyl-N-(phenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

CRN 64-19-7
CMF C2 H4 O2




RN 717914-62-0 CAPLUS
CN 1H-imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-63-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-cyclohexyl-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-64-2 CAPLUS
CN 1H-indole-3-ethanamine, 5-fluoro-α-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-65-3 CAPLUS
CN 1H-indole-3-ethanamine, N-cyclobutyl-5-fluoro-α-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-59-5 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-60-8 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 717914-61-9 CAPLUS
CN 1H-imidazole-2-methanamine, α-hexyl-N-(2-methylpropyl)-4-phenyl-, monoacetate (9CI) (CA INDEX NAME)

CM 1

CRN 335244-96-7
CMF C20 H31 N3




CM 2




● HCl

RN 717914-66-4 CAPLUS
CN 1H-imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(3-methylbutyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 717914-67-5 CAPLUS
CN 1H-imidazole-2-methanamine, α-cyclopropyl-4-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-68-6 CAPLUS
CN 1H-imidazole-2-methanamine, N-(cyclohexylmethyl)-α-hexyl-4-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-69-7 CAPLUS
CN 1H-imidazole-2-methanamine, N-cyclohexyl-α-cyclopropyl-4-(4-

fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 717914-70-0 CAPIUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl-α-(4-fluorophenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 717914-71-1 CAPIUS
CN 1H-Imidazole-2-methanamine, α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 717914-72-2 CAPIUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 717915-64-5 CAPIUS
CN 1,1-Hexanediamine, N-[(4-{[1,1'-biphenyl]-4-yl}-1H-imidazol-2-yl)methyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 717915-66-7 CAPIUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N5-(phenylmethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 3 OF 36 CAPIUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:142985 CAPIUS
DOCUMENT NUMBER: 140:199746
TITLE: Preparation of growth hormone-releasing peptides
INVENTOR(S): Zheng, Xin Dong
PATENT ASSIGNEE(S): Societe de Conseil de Recherches et d'Applications Scientifiques, S.A.S., Fr.
SOURCES: PCT Int. Appl., 77 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014415	A1	20040219	WO 2003-US24834	20030808
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RN:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,			



● HCl

RN 717914-74-4 CAPIUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-(phenylmethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 717914-75-5 CAPIUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(phenylmethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 717914-76-6 CAPIUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(phenylmethyl)-, monohydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BP, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: US 2002-402263P P 20020809
OTHER SOURCE(S): MARPAT 140:199746
AB Disclosed are peptide and peptidomimetic compds. R1-A1-A2-A3-A4-A5-R2 [A1 is Aib (α-aminoisobutyric acid), Apc (4-amino-4-piperidinecarboxylic acid), or Inp (isonipecotic acid); A2, A3 are D-Bal (3-benzothienylalanine), D-Bip (4,4'-biphenylalanine), D-Bpa (4-benzoylphenylalanine), D-Dip (β,β-diphenylalanine), D-1Nal (β-1-naphthylalanine), D-2Nal, D-Ser(Bzl), or D-Trp; A4 is 2Pua (β-2-furylalanine), Orn, 2Pal (β-2-pyridylalanine), 3Pal, 4Pal, Pff (pentafluorophenylalanine), Phe, Pim (4-phenyl-2-imidazolyl), Taz (β-4-thiazolylalanine), 2Thi (β-2-thienylalanine), 3Thi, or Thr(Bzl); A5 is Apc, Dab (2,4-diaminobutyric acid), Dap (2,3-diaminopropionic acid), Lys, Orn, or deleted; R1 is H, alkyl, aryl, alkylaryl, cycloalkyl, or acyl; R2 is OH or NH2; (with provisos)] and their pharmaceutically-acceptable salts which are useful as GHRP analogs. Thus, claimed peptide H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 was prepared by the solid-phase method using a Rink Amide MBHA resin.
IT 661472-77-1P 661472-78-2P 661472-79-3P
661472-80-6P 661472-81-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of growth hormone-releasing peptides)
RN 661472-77-1 CAPIUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-1-(2-naphthalenylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 661472-78-2 CAPIUS
CN 4-Piperidinecarboxamide, N-[(1R)-2-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-1-(2-naphthalenylmethyl)-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 661472-79-3 CAPLUS
CN 4-Piperidinecarboxamide, N-[(1R)-1-(benzo[b]thien-3-ylmethyl)-2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-2-oxoethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 661472-80-6 CAPLUS
CN D-Serinamide, 2-methylalanyl-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 661472-81-7 CAPLUS
CN 1H-Indole-3-propanamide, N-[(1R)-2-(2-naphthalenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-O-(4-piperidinylcarbonyl)amino]-, (αR)- (9CI) (CA INDEX NAME)

OTHER SOURCE(S):
GI

MARPAT 140:146136


US 2002-329329 A2 20021223
US 2003-446170 A2 20030523
US 2003-457034 A 20030606



AB The invention relates to heterocyclic compds. (shown as I; e.g. (1H-benzimidazol-2-ylmethyl)(piperidin-3-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amine trihydrobromide) consisting of a core N atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolylmethyl and tetrahydroquinolyl, and the 3rd pendant group contains N and optionally contains addnl. rings. The compds. bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). Many I exhibit IC50 values of 5-5.5 nM for inhibition of HIV-1 (NL4.3) replication in peripheral blood mononuclear cells and 5 nM-5 μM for inhibition of SDF-1α induced Ca flux in CCRF-CEM cells, a T-lymphoblastoid cell line that expresses CXCR4. It is also stated that the compds. I behave in a manner similar to 1,1'-[1,4-phenylene-bis(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane (AMD3100) which showed to elevate progenitor cell levels (data given). Although the methods of preparation are not claimed, >170 example preps. are included. For I: X and Y = N or CR1; Z is S, O, NR1 or CR12; each R1-R6 = H or a noninterfering substituent; n1 is 0-4; n2 is 0-1, wherein the a signifies C.tpbond.C may be substituted for CR5:CR5; n3 is 0-4; wherein n1 + n2 + n3 = > 2; b is 0-2; wherein the following combinations of R groups may be coupled to generate a ring, which ring may be (un)saturated: R2 + R2, one R2 + R3, R3 + one R4, R4 + R4, one R5 + another R5, one R5 + one R6, and R6 + R6; wherein the ring may not be aromatic when the participants in ring formation are two R5; and wherein when n2 is 1, neither n1 nor n3 can be 0.

IT 558441-83-1P, N1-[(5-(4-Fluorophenyl)-1H-imidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of chemokine receptor binding benzimidazolylmethyl tetrahydroquinolyl amines and related heterocyclic compds. with enhanced efficacy against AIDS and other disorders)
RN 558441-83-1 CAPLUS
CN 1,4-Butanediamine, N-[(4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl]-N-(5,6,7,8-tetrahydro-8-quinolyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:80349 CAPLUS
DOCUMENT NUMBER: 140:146136
TITLE: Preparation of chemokine receptor binding (benzimidazol-2-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amines and related heterocyclic compounds with enhanced efficacy against AIDS and other disorders
INVENTOR(S): Bridger, Gary; Kaller, Al; Harwig, Curtis; Skerlj, Renato; Bogucki, David; Wilson, Trevor R.; Crawford, Jason; McEachern, Ernest J.; Atama, Ben; Nan, Sigiao; Zhou, Yuanxi; Schols, Dominique; Smith, Christopher D.; Di Fluri, Maria R.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. No. 446,170.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004019058	A1	20040129	US 2003-457034	20030606
US 2003220341	A1	20031127	US 2002-329329	20021223
WO 2004106493	A2	20041209	WO 2004-US15977	20040521

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2001-342716P P 20011221
US 2002-350822P P 20020117





L12 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:80193 CAPLUS
DOCUMENT NUMBER: 140:146135
TITLE: New derivatives of arylimidazoles, their preparation, and their use as inhibitors of nitric oxide (NO) synthase and as modulators of sodium channels
INVENTOR(S): Bigg, Dennis; Liberatore, Anne Marie; Chabrier De Lasseuniere, Pierre Etienne
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques SCRAS, Fr.
SOURCE: Fr. Demande, 50 pp.
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2842808	A1	20040130	FR 2002-9416	20020725
FR 2842808	B1	20040910		
WO 2004011402	A2	20040205	WO 2003-FR2336	20030724
WO 2004011402	A3	20040429		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
FR 2002-9416 A 20020725
OTHER SOURCE(S): MARPAT 140:146135
GI



AB Title compds. I [wherein R1 = H, cyclo/cycloalkyl/alkyl, (un)substituted aryl, aralkyl; R2 = H, alkyl; R3 = H, alkyl, aralkyl; X = a bond or alkylene; Y = H, cycloalkyl, NH2 and deriva., (un)substituted aryl, etc.; A = a bond or phenylene; B = independently cyclo/alkyl, NH2 and deriva., SR4, (un)substituted aryl carbocyclyl or aryl heterocyclyl R4 = (un)substituted alkyl; their racemates, stereoisomers, and their salts] were prepared as inhibitors of nitric oxide (NO) synthases and as modulators of the sodium channels for treatment of pain, multiple sclerosis, as well as of the central and peripheral nervous system. For example, Z-isomer of II was prepared by reacting N-BOC-β-alanine with 4-azidophenacyl bromide to form the 4-aminophenylimidazole intermediate, and its condensation with 2-thiophenecarboximidamide (preparation given). Selected I exhibited IC50 values < 10 μM towards binding to sodium channels of the cerebral cortex of rats. Selected I gave IC50 values < 10 μM for inhibiting rat neuronal NO synthase in vitro.


IT 651354-13-1P, N-[4-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-20-0P, N'-[3-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-21-1P, N-[4-[2-[(cyclohexyl(methyl)amino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-22-2P, N-[4-[2-[(dibenzylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-23-3P, N'-[4-[2-[(benzylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-24-4P, N'-[3-[2-(aminomethyl)-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-38-0P, N'-[3-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide 651354-39-1P, N'-[4-[2-[(cyclohexyl(methyl)amino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide 651354-40-4P, N'-[4-[2-[(dibenzylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide 651354-41-5P, N'-[4-[2-[(benzylamino)methyl]-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide 651354-42-6P, N'-[3-[2-(aminomethyl)-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide 652965-45-2P, 652965-46-3P 652965-98-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(inhibitor of nitric oxide synthase; preparation of arylimidazoles as inhibitors of nitric oxide (NO) synthase and as modulators of sodium channels)


RN 651354-13-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)

RN 651354-23-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(phenylmethyl)amino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 651354-24-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[2-(aminomethyl)-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 651354-38-0 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 651354-39-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(cyclohexylmethylamino)methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 651354-40-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(bis(phenylmethyl)amino)methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




● HCl

RN 651354-20-0 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 651354-21-1 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(cyclohexylmethylamino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 651354-22-2 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(bis(phenylmethyl)amino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl




RN 651354-41-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(phenylmethyl)amino)methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 651354-42-6 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[2-(aminomethyl)-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 652965-45-2 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[2-[(E)-(amino-2-thienylmethylene)amino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 652965-46-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(E)-(amino-2-thienylmethylene)amino)methyl]-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 652965-98-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(E)-(amino-2-thienylmethylene)amino]methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




IT 651354-18-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(inhibitor of nitric oxide synthase; preparation of arylimidazoles as inhibitors of nitric oxide (NO) synthase and s modulators of sodium channels)

RN 651354-18-6 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-[(cyclohexylamino)methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




IT 651354-15-3P, tert-Butyl [[4-(4-azidophenyl)-1H-imidazol-2-yl]methyl]carbamate 651354-16-4P, tert-Butyl [[4-(4-aminophenyl)-1H-imidazol-2-yl]methyl]carbamate 651354-17-5P, N'-[4-[2-(Aminomethyl)-1H-imidazol-4-yl]phenyl]thiophene-2-carboximidamide hydrochloride 651354-25-5P, tert-Butyl [[4-(3-nitrophenyl)-1H-imidazol-2-yl]methyl]carbamate 652965-43-0P, tert-Butyl [[4-[4-[(E)-(amino-2-thienylmethylene)amino]phenyl]-1H-imidazol-2-yl]methyl]carbamate 652965-44-1P, tert-Butyl [[4-[3-[(E)-(amino-2-thienylmethylene)amino]phenyl]-1H-imidazol-2-yl]methyl]carbamate 652965-97-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of arylimidazoles as inhibitors of nitric oxide (NO) synthase and s modulators of sodium channels)

RN 652965-44-1 CAPLUS
CN Carbamic acid, [[4-[3-[(E)-(amino-2-thienylmethylene)amino]phenyl]-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 652965-97-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[3-[2-[(E)-(amino-2-thienylmethylene)amino]methyl]-1H-imidazol-4-yl]phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN


ACCESSION NUMBER: 2003:591202 CAPLUS
DOCUMENT NUMBER: 139:145836
TITLE: Synthetic peptide substrates of human aggrecanase-1 and -2 for drug screening applications
INVENTOR(S): Fourie, Anne; Karlsson, Lars; Coles, Fawn
PATENT ASSIGNEE(S): Ortho McNeil Pharmaceutical, Inc., USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062263	A2	20030731	WO 2003-US1327	20030115
WO 2003062263	A3	20040115		
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NS, SN, TD, TG			
US 2003166037	A1	20030904	US 2002-50200	20020116
EP 1474509	A2	20041110	EP 2003-702145	20030115
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRIORITY APPL. INFO.:			US 2002-50200	A 20020116


RN 651354-15-3 CAPLUS
CN Carbamic acid, [[4-(4-azidophenyl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 651354-16-4 CAPLUS
CN Carbamic acid, [[4-(4-aminophenyl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 651354-17-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[2-(aminomethyl)-1H-imidazol-4-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 651354-25-5 CAPLUS
CN Carbamic acid, [[4-(3-nitrophenyl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 652965-43-0 CAPLUS
CN Carbamic acid, [[4-[4-[(E)-(amino-2-thienylmethylene)amino]phenyl]-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




WO 2003-US1327 W 20030115
AB The present invention describes synthetic peptide substrates of the metalloproteases, aggrecanase-1 and/or -2 suitable for assays of enzyme activity. The substrates are peptides less than 40 amino acids in length having a cleavage site between Glu on the N-terminal side of the cleavage site and a non-polar or uncharged residue on the C-terminal side of the cleavage site. The invention also describes methods using these peptides to discover pharmaceutical agents that modulate these proteases.

IT 56952-30-8
RL: BSU (Biological study, unclassified); BIOL (Biological study) (aggrecanase inhibition by; synthetic peptide substrates of human aggrecanase-1 and -2 for drug screening applications)

RN 56952-30-8 CAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-2-(2-methylpropyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L12 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:532661 CAPLUS
DOCUMENT NUMBER: 139:101128
TITLE: Preparation of chemokine receptor binding (benzimidazol-2-ylmethyl) (5,6,7,8-tetrahydroquinolin-8-yl)amines and related heterocyclic compounds with enhanced efficacy against AIDS and other disorders
INVENTOR(S): Bridger, Gary J.; Skerlj, Renato T.; Kaller, Al; Harwig, Curtis; Bogucki, David; Wilson, Trevor; Crawford, Jason; McEachern, Ernest J.; Atama, Bem; Nan, Siqiao; Zhou, Yuanxi; Schols, Dominique; Smith, Christopher Dennis; Di Fluri, Rosaria Maria
PATENT ASSIGNEE(S): Anormed Inc., Can.; et al.
SOURCE: PCT Int. Appl., 360 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055876	A1	20030710	WO 2002-US41407	20021223
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NS, SN, TD, TG			
BR 2002015050	A	20041013	BR 2002-15050	20021223
EP 1465889	A1	20041013	EP 2002-805977	20021223

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
PRIORITY APPLN. INFO.: US 2001-342716P P 20011221
US 2002-350822P P 20020117
WO 2002-US41407 W 20021223
OTHER SOURCE(S): MARPAT 139:101128
GI



AB The invention relates to heterocyclic compds. (shown as I; e.g. (1H-benzimidazol-2-ylmethyl)(piperidin-3-ylmethyl)(5,6,7,8-tetrahydroquinolin-8-yl)amine trihydrobromide) consisting of a core N atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolylmethyl and tetrahydroquinolyl, and the 3rd pendant group contains N and optionally contains addnl. rings. The compds. bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV). Many I exhibit IC50 values of 5-5.5 nM for inhibition of HIV-1 (NL4.3) replication in peripheral blood mononuclear cells and 5 nM-5 µM for inhibition of SDF-1α induced Ca flux in CCRP-CEM cells, a T-lymphoblastoid cell line that expresses CXCR4. Although the methods of preparation are not claimed, >170 example preps. are included. For I: X and Y = N or CR1; Z is S, O, NR1 or CR12; each R1-R6 = H or a noninterfering substituent; n1 is 0-4; n2 is 0-1, wherein the a signifies C.tplbond.C may be substituted for CR5:CR6; n3 is 0-4; wherein n1 + n2 + n3 = > 2; b is 0-2; wherein the following combinations of R groups may be coupled to generate a ring, which ring may be (un)saturated: R2 + R2, one R2 + R3, R3 + one R4, R4 + R4, one R5 + another R5, one R5 + one R6, and R6 + R6; wherein the ring may not be aromatic when the participants in ring formation are two R5; and wherein when n2 is 1, neither n1 nor n3 can be 0.

IT 558441-83-1P, N1-[(5-(4-Fluorophenyl)-1H-imidazol-2-yl)methyl]-N1-(5,6,7,8-tetrahydroquinolin-8-yl)butane-1,4-diamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of chemokine receptor binding benzimidazolylmethyl tetrahydroquinolyl amines and related heterocyclic compds. with enhanced efficacy against AIDS and other disorders)


RN 558441-83-1 CAPLUS
CN 1,4-Butanediamine, N-[[4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl]-N-(5,6,7,8-tetrahydro-8-quinolyl)]- (9CI) (CA INDEX NAME)

UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

US 6335445 B1 20020101 US 1999-456205 19991207
US 2002007062 A1 20020117 US 2001-882264 20010615
US 6630461 B2 20031007

FR 1997-3528 A 19970324
FR 1997-7701 A 19970620
WO 1998-FR288 W 19980216
WO 1998-FR1250 W 19980615
US 1999-456205 A3 19991207
US 2001-882264 A2 20010615
US 1999-381749 A2 19990922


OTHER SOURCE(S): MARPAT 138:337988
GI



AB Title compds., e.g., N-[4-[[[4-(3,5-di-tert-butyl-4-hydroxyphenyl)-1,3-thiazol-2-yl)methyl]amino]methyl]phenyl]thiophene-2-carboximidamide (I) are prepared. The compds. are inhibitors of NO synthase, and are also antioxidants which inhibit lipid peroxidn. Approx. 70 examples are prepared. I had IC50 for inhibiting rat neuronal NO synthase in vitro < 3.5 µM, and the IC50 for inhibiting rat cerebral lipid peroxidn. in vitro is < 30 µM.

IT 218944-42-4P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-(4-[[imino(2-thienyl)methyl]amino]benzoyl)-N-methyl-1H-imidazole-2-methanamine hydrochloride 218944-69-5P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[4-[[imino(2-thienyl)methyl]amino]phenyl]-N-methyl-1H-imidazole-2-methanamine hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and testing of 2-[[iminomethyl]amino]phenyl derivs. as inhibitors of NO synthase and lipid peroxidn.)


RN 218944-42-4 CAPLUS
CN Benzamide, N-[[5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]-4-[[imino(2-thienyl)methyl]amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:319488 CAPLUS
DOCUMENT NUMBER: 138:337988
TITLE: Novel 2-[[iminomethyl]amino]phenyl derivatives useful as inhibitors of NO synthase and lipid peroxidation, their preparation, their application as medicines, and pharmaceutical compositions containing them
INVENTOR(S): Chabrier De Lassautiere, Pierre Etienne; Aurin, Serge; Bigg, Dennis; Auguet, Michel; Harnett, Jeremiah
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et D'Applications scientifiques (S.C.R.A.S.), Fr.
SOURCE: U.S. Pat. Appl. Publ., 78 pp., Cont.-in-part of U.S. Ser. No. 882,264.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003078420	A1	20030424	US 2002-191950	20020709
US 6809088	B2	20041026		
FR 2761066	A1	19980925	FR 1997-3528	19970324
FR 2761066	B1	20001124		
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		
WO 9842696	A1	19981001	WO 1998-FR288	19980216
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, GH, GM, GU, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
WO 9858934	A1	19981230	WO 1998-FR1250	19980615
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, GH, GM, GU, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,				



● HCl


RN 218944-69-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]methylamino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


IT 218944-36-6P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-[[phenylmethoxy]carbonyl]-1H-imidazole-2-methanamine 218944-40-2P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-nitrobenzoyl)-1H-imidazole-2-methanamine 218944-41-3P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-aminobenzoyl)-1H-imidazole-2-methanamine 218944-66-2P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-nitrophenyl)-1H-imidazole-2-methanamine 218944-68-4P, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-aminophenyl)-1H-imidazole-2-methanamine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and testing of 2-[[iminomethyl]amino]phenyl derivs. as inhibitors of NO synthase and lipid peroxidn.)

RN 218944-36-6 CAPLUS
CN Carbamic acid, [[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 218944-40-2 CAPLUS
CN Benzamide, N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-


2-yl)methyl]-N-methyl-4-nitro- (9CI) (CA INDEX NAME)




RN 218944-41-3 CAPLUS
CN Benzamide, 4-amino-N-[[4-(3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl)-1H-imidazol-2-yl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 218944-66-2 CAPLUS
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[[methyl(4-nitrophenyl)amino]methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 218944-68-4 CAPLUS
CN Phenol, 4-[2-[[4-(aminophenyl)methylamino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:58808 CAPLUS
DOCUMENT NUMBER: 138:106702
TITLE: Preparation of 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype

RN 179333-51-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N-methyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:814116 CAPLUS
DOCUMENT NUMBER: 137:325417
TITLE: Preparation and application of 5-membered heterocycles as medicaments
INVENTOR(S): Harnett, Jeremiah; Bigg, Dennis; Liberatore, Anne-Marie; Rolland, Alain
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (SCRAS), Fr.
SOURCE: PCT Int. Appl., 132 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083656	A2	20021024	WO 2002-FR1218	20020409
WO 2002083656	A3	20030103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
FR 2823208	A1	20021011	FR 2001-4943	20010410
FR 2823208	B1	20040319		
CA 2443403	AA	20021024	CA 2002-2443403	20020409
EP 1379514	A2	20040114	EP 2002-761921	20020409
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004531526	T2	20041014	JP 2002-581412	20020409
NZ 528645	A	20041126	NZ 2002-528645	20020409
NO 2003004524	A	20031029	NO 2003-4524	20031009
PRIORITY APPLN. INFO.:			FR 2001-4943	A 20010410
			FR 2002-1811	A 20020214
			WO 2002-FR1218	W 20020409

GI

INVENTOR(S): specific ligands
Thurkauf, Andrew; Horvath, Raymond F.; Yuan, Jun; Peterson, John M.
PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 37 pp., Cont. of U.S. Ser. No. 281,169.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003018025	A1	20030123	US 2002-156262	20020528
PRIORITY APPLN. INFO.:			US 1995-478291	B1 19950607
			US 1999-281169	A1 19990330


OTHER SOURCE(S): MARPAT 138:106702
GI





AB The imidazoles I (R1 = optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl; X, Z, and Y = optionally substituted nitrogen or carbon atoms; R2 = H, alkyl; m = 0, 1 or 2; and R3 and R4 = H, alkyl, R3R4N may form a ring) and the pharmaceutically acceptable addition salts thereof, which compds. are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Thus, 2-phenyl-4-(hydroxymethyl)imidazole was treated with SOCl2 followed by 1-(2-methoxyphenyl)piperazine to give 2-phenyl-4(5)-[[4-(2-methoxyphenyl)piperazin-1-yl)methyl]imidazole. 2-Phenyl-4(5)-[[4-(2-pyrimidinyl)piperazin-1-yl)methyl]imidazole dihydrochloride was shown to bind to the dopamine D4 receptor site (Ki = 1033, 8200, 2.7 for D2, D3, D4 binding sites, resp.).

IT 179332-49-1P 179333-51-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole derive. as dopamine receptor partial agonists or antagonists for memory enhancement and treatment of schizophrenia and depression and Parkinsonism)

RN 179332-49-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-methyl-4-phenyl-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl




II


AB The invention relates to thiazole, oxazole or imidazole derive. having at least one of the following pharmacol. activities: inhibition of monoamine oxydases (MAO); inhibition of lipid peroxidn.; modulation of sodium channels. The inventive compds. comprise, for example, 2,6-di(tert-butyl)-4-[[2-[[2-(methylamino)ethyl]-1,3-thiazol-4-yl]phenol (I); and 4-methylpentyl 2-[[4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl]ethyl carbamate (II). Thus, I-HCl was prepared from N-methyl-β-alaninetrile via N-protection with (Boc)2O in CH2Cl2 containing EtN(CHMe2)2, sulfuration with H2S in EtOH containing Et3N, cyclocondensation with α-bromo-1-(3,5-di(tert-butyl)-4-hydroxyphenyl)ethanone and acid-catalyzed deprotection with HCl in EtOAc. By virtue of their pharmacol. properties, said compds. can be used to treat one of the following disorders or diseases: Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression, psychoses, migraine or pain, especially neuropathic pain. The pharmacol. activity of I was determined [CI50 ≤ 10 μM vs. monoamine oxydase B; CI50 ≤ 10 μM vs. lipid peroxidn.; CI50 ≤ 1.0 μM on sodium channels from the cerebral cortex of rats].

IT 473541-90-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-deprotection in; preparation of 5-membered heterocycles


with one of the following pharmacol. activities: monoamine oxydase inhibition, lipid peroxydation or sodium channel modulation)
RN 473541-90-1 CAPLUS
CN Carbamic acid, methyl[[4-(10H-phenothiazin-2-yl)-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 473541-95-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and hydrogenolysis of, in; preparation of 5-membered heterocycles with one of the following pharmacol. activities: monoamine oxydase inhibition, lipid peroxydation or sodium channel modulation)
 RN 473541-95-6 CAPLUS
 CN Carbamic acid, {4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl}-, phenylmethyl ester (9CI) (CA INDEX NAME)




IT 473540-88-4P 473541-06-9P 473541-81-0P
 473541-84-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 5-membered heterocycles with one of the following pharmacol. activities: monoamine oxydase inhibition, lipid peroxydation or sodium channel modulation)
 RN 473540-88-4 CAPLUS
 CN 1H-Imidazole-2-methanamine, N-methyl-4-(10H-phenothiazin-2-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 473541-06-9 CAPLUS
 CN Phenol, 4-[2-(aminomethyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 473541-81-0 CAPLUS
 CN 1H-Imidazole-2-methanamine, N-methyl-4-(10H-phenothiazin-2-yl)- (9CI) (CA INDEX NAME)



RN 473541-84-3 CAPLUS
 CN Phenol, 4-[2-(aminomethyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




L12 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:532824 CAPLUS
 DOCUMENT NUMBER: 138:250527
 TITLE: Fluorescence polarization assay and SDS-PAGE confirms matrilysin degrades fibronectin and collagen IV whereas gelatinase A degrades collagen IV but not fibronectin
 AUTHOR(S): Kraft, Patricia J.; Haynes-Johnson, Donna E.; Patel, Lekha; Lenhart, Judy A.; Zivin, Robert A.; Palmer, Stephen S.
 CORPORATE SOURCE: The R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA
 SOURCE: Connective Tissue Research (2001), 42(2), 149-163
 CODEN: CVTRBC; ISSN: 0300-8207
 PUBLISHER: Gordon & Breach Science Publishers
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Matrilysin and gelatinase A are hypothesized to have significant roles in uterine and ovarian function. However, proteolytic activity assays for these enzymes are limited. We describe the development of simple and rapid assays for the proteolysis of fluorescein-labeled full-length substrates, collagen IV (Col-IV) and fibronectin (FN), and demonstrate the selectivity of matrilysin (MMP-7) compared to gelatinase A (MMP-2) for fibronectin. Changes in fluorescence intensity (FIU) and fluorescence

polarization (mP) resulting from the protease activity of matrilysin and gelatinase A were measured. These studies show that the fluorescently labeled substrates, Col-IV and FN, are as reliable and amenable to rapid in vitro assay as peptide substrates. In addition, they are easier to use than previously described, non-fluorescent methods. The results demonstrate that assays using full-length, biol. matrix proteins are more sensitive indicators of MMP-specific substrate activity than peptide based assays.

IT 181361-72-8, RWJ 68257
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (metalloproteinase inhibitor; fluorescently labeled fibronectin and collagen IV substrates for assay of matrilysin and gelatinase A)
 RN 181361-72-8 CAPLUS
 CN Butanediamide, N4-hydroxy-N1-[(1S)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:220576 CAPLUS
 DOCUMENT NUMBER: 136:263160
 TITLE: Preparation of azolylmethylaminotetrahydroquinolines and related compounds as chemokine receptor binding agents.
 INVENTOR(S): Bridger, Gary; Skerlj, Renato; Kaller, Al; Harwig, Curtis; Bogucki, David; Wilson, Trevor R.; Crawford, Jason; McEachern, Ernest J.; Atama, Ben; Nan, Siqiao; Zhou, Yuanxi; Schols, Dominique; Smith, Christopher Dennis; Di, Fluri Rosaria Maria
 PATENT ASSIGNEE(S): Anormed Inc., Can.
 SOURCE: PCT Int. Appl., 254 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022600	A2	20020321	WO 2001-CA1326	20010917
WO 2002022600	A3	20020510		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2419224	AA	20020321	CA 2001-2419224	20010917

AU 2001091569 A5 20020326 AU 2001-91569 20010917
 US 2003018046 A1 20030123 US 2001-957682 20010917
 EP 1317445 A2 20030611 EP 2001-971574 20010917
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 BR 2001013930 A 20030624 BR 2001-13930 20010917
 TR 200300322 T2 20030922 TR 2003-200300322 20010917
 JP 2004508422 T2 20040318 JP 2002-526853 20010917
 ZA 2003001398 A 20040521 ZA 2003-1398 20030220
 NO 2003001179 A 20030314 NO 2003-1179 20030314
 US 2004171638 A1 20040902 US 2004-799386 20040311
 US 2004220207 A1 20041104 US 2004-858910 20040601
 PRIORITY APPLN. INFO.: US 2000-232891P P 20000915
 US 2000-234510P P 20000922
 US 2001-957682 A3 20010917
 WO 2001-CA1326 W 20010917
 US 2002-31812 A1 20020328
 OTHER SOURCE(S): MARPAT 136:263160
 GI









RN 405171-56-4 CAPLUS
 CN 1,4-Benzenedimethanamine, N-[(4-phenyl-1H-imidazol-2-yl)methyl]-N-(2-pyridinylmethyl)-N'-(5,6,7,8-tetrahydro-8-quinolinyll)- (9CI) (CA INDEX NAME)



RN 405171-84-8 CAPLUS
 CN 1,4-Benzenedimethanamine, N-[[4-(4-methoxyphenyl)-1H-imidazol-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyll)- (9CI) (CA INDEX NAME)




RN 405171-85-9 CAPLUS
 CN 1,4-Benzenedimethanamine, N-[[4-(4-nitrophenyl)-1H-imidazol-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyll)- (9CI) (CA INDEX NAME)




RN 405171-89-3 CAPLUS
 CN 1,4-Benzenedimethanamine, N-[[4-(3-methoxyphenyl)-1H-imidazol-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyll)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 405171-90-6 CAPLUS
CN 1,4-Benzenedimethanamine, N-[(4-{[1,1'-biphenyl]-4-yl}-1H-imidazol-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyll)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 405171-91-7 CAPLUS
CN 1,4-Benzenedimethanamine, N'-(2-pyridinylmethyl)-N-[(4-{(5,6,7,8-tetrahydro-2-naphthalenyl)-1H-imidazol-2-yl)methyl]-N-(5,6,7,8-tetrahydro-8-quinolinyll)-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 405171-92-8 CAPLUS
CN 1,4-Benzenedimethanamine, N-[(4-{(3-bromo-2-methoxyphenyl)-1H-imidazol-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyll)-(9CI) (CA INDEX NAME)



PAGE 1-A



PAGE 2-A





RN 405171-95-1 CAPLUS
CN 1,4-Benzenedimethanamine, N-[(4-{(4-fluorophenyl)-1H-imidazol-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyll)-, hydrobromide (10:39) (9CI) (CA INDEX NAME)





●39/10 HBr

RN 405174-41-6 CAPLUS
CN 1,4-Benzenedimethanamine, N-[[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinoliny)- (9CI) (CA INDEX NAME)



IT 405174-06-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azolymethylaminotetrahydroquinolines and related compds. as chemokine receptor binding agents)
RN 405174-06-3 CAPLUS
CN Benzenesulfonamide, 4-nitro-N-[[4-[[[4-phenyl-1H-imidazol-2-yl]methyl] (5,6,7,8-tetrahydro-8-quinoliny)amino]methyl]phenyl]methyl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:107321 CAPLUS
DOCUMENT NUMBER: 136:167373
TITLE: Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors
INVENTOR(S): Thureau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Gordon, Thomas D.; Morgan, Barry A.; Moinet, Christophe Philippe; Bigg, Dennis
PATENT ASSIGNER(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: PCT Int. Appl., 369 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002010140	A2	20020207	WO 2001-US23959	20010731
WO 2002010140	A3	20020808		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,

SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG
CA 2417204 AA 20020207 CA 2001-2417204 20010731
EP 1305294 A2 20030502 EP 2001-957342 20010731
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004518613 T2 20040624 JP 2002-516272 20010731
NZ 523774 A 20040924 NZ 2001-523774 20010731
NO 2003000473 A 20030130 NO 2003-473 20030130
PRIORITY APPLN. INFO.: US 2000-222584P P 20000801
OTHER SOURCE(S): MARPAT 136:167373
GI WO 2001-US23959 W 20010731

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Imidazole derivs. I [R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, etc.; Z1 = (un)substituted benzo(b)thiophene, Ph, naphthyl, etc.; m = 0-6; R2 = H, alkyl; R1 and R2 taken together with the nitrogen atoms to which they are attached form II-IV; R3 = (CH2)mS(CH2)mZ2; S = O, S, CO, etc.; Z2 = H, alkyl, NH2, etc.; R4 = H, (CH2)mA1; A1 = C(:Y)NX1X2; C(:Y)X2; C(:NH)X2; X2; Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)mZ4; Z4 = (un)substituted Ph, naphthyl, indolyl, etc.], which are useful as agonists or antagonists of somatostatin receptors (no data) and for inhibiting the proliferation of Helicobacter pylori, were prepared. Thus, activating 2-furancarboxylic acid with carbonyldiimidazole followed by addition of 2-[(1S)-1-amino-2-(indol-3-yl)ethyl]-4-phenyl-1H-imidazole afforded 94% the title compound V. Compds. I are effective at 0.01-10.0 mg/kg/day.
IT 252292-69-6P 252302-96-8P 335244-94-5P
335246-59-8P 335246-68-9P 335246-82-7P
335247-34-2P 335247-37-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)
RN 252292-69-6 CAPLUS
CN Carbanic acid, [(1S)-2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-96-8 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-94-5 CAPLUS
CN Carbamic acid, [1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methylhexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335246-59-8 CAPLUS
CN 1H-Imidazole-2-methanamine, alpha-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335246-68-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335246-82-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-alpha-hexyl- (9CI) (CA INDEX NAME)



RN 335247-34-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-alpha-(4-methylpentyl)- (9CI) (CA INDEX NAME)


252303-10-9P 252303-12-1P 252303-13-2P
252303-14-3P 252303-15-4P 252303-16-5P
252303-17-6P 252303-18-7P 252303-19-8P
252303-21-2P 252303-22-3P 252303-25-6P
252303-26-7P 252303-27-8P 252303-28-9P
252303-29-0P 252303-30-3P 252303-32-5P
252303-33-6P 252303-34-7P 252303-35-8P
252303-36-9P 252303-38-1P 252303-39-2P
252303-40-5P 252303-41-6P 252303-42-7P
252303-44-9P 252303-46-1P 252303-47-2P
252303-50-7P 252303-53-0P 252303-54-1P
252303-57-4P 252304-37-3P 252304-38-4P
252304-39-5P 252304-40-8P 252304-42-0P
252304-43-1P 252304-45-3P 252304-46-4P
252304-47-5P 252304-48-6P 252304-49-7P
252304-50-0P 252304-51-1P 252304-52-2P
252304-53-3P 252304-58-8P 252304-60-2P
252304-62-4P 252304-64-6P 252304-66-8P
252304-70-4P 252304-72-6P 252304-75-9P
252304-76-0P 252304-77-1P 252304-79-3P
252304-80-6P 252304-81-7P 252304-82-8P
252304-83-9P 252304-85-1P 252304-87-3P
252304-88-4P 252304-90-8P 252304-93-1P
252304-94-2P 252304-99-7P 252305-49-0P
252305-50-3P 252305-51-4P 252305-52-5P
252305-53-6P 252305-54-7P 252305-55-8P
252305-56-9P 252305-57-0P 252305-58-1P
252305-59-2P 252305-60-5P 252305-61-6P
252305-63-8P 252305-64-9P 252305-65-0P
252305-66-1P 252305-67-2P 252305-68-3P
252305-69-4P 252305-70-7P 252305-71-8P
252305-72-9P 252305-73-0P 252305-74-1P
252305-75-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)

RN 167983-80-4 CAPLUS
CN 1H-Imidazole-2-methanamine, alpha-(2-methylpropyl)-4-phenyl-, (alphaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 175531-38-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- (9CI) (CA INDEX NAME)



RN 252279-15-5 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, (alphaR)- (9CI) (CA INDEX NAME)




RN 335247-37-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl- (9CI) (CA INDEX NAME)




IT 167983-80-4P 175531-38-1P 252279-15-5P
252292-70-9P 252292-72-1P 252292-74-3P
252292-75-4P 252301-46-5P 252301-47-6P
252301-48-7P 252301-49-8P 252301-50-1P
252301-51-2P 252301-52-3P 252301-53-4P
252301-54-5P 252301-56-7P 252301-57-8P
252301-58-9P 252301-60-3P 252301-61-4P
252301-62-5P 252301-63-6P 252301-64-7P
252301-65-8P 252301-66-9P 252301-67-0P
252301-70-5P 252301-71-6P 252301-72-7P
252301-73-8P 252301-74-9P 252301-75-0P
252301-76-1P 252301-77-2P 252301-79-4P
252301-81-8P 252301-83-0P 252301-85-2P
252301-86-3P 252301-87-4P 252301-88-5P
252301-89-6P 252301-90-9P 252301-91-0P
252301-92-1P 252301-93-2P 252301-94-3P
252301-95-4P 252301-96-5P 252301-97-6P
252301-98-7P 252301-99-8P 252302-00-4P
252302-01-5P 252302-02-6P 252302-03-7P
252302-04-8P 252302-05-9P 252302-06-0P
252302-07-1P 252302-08-2P 252302-09-3P
252302-10-6P 252302-11-7P 252302-12-8P
252302-13-9P 252302-14-0P 252302-15-1P
252302-16-2P 252302-17-3P 252302-18-4P
252302-19-5P 252302-20-8P 252302-21-9P
252302-22-0P 252302-23-1P 252302-24-2P
252302-25-3P 252302-27-5P 252302-28-6P
252302-29-7P 252302-31-1P 252302-32-2P
252302-35-5P 252302-37-7P 252302-39-9P
252302-41-3P 252302-43-5P 252302-44-6P
252302-46-8P 252302-47-9P 252302-48-0P
252302-49-1P 252302-50-4P 252302-51-5P
252302-52-6P 252302-53-7P 252302-54-8P
252302-55-9P 252302-56-0P 252302-58-2P
252302-60-6P 252302-61-7P 252302-63-9P
252302-65-1P 252302-67-3P 252302-69-5P
252302-71-9P 252302-74-2P 252302-77-5P
252302-79-7P 252302-80-0P 252302-81-1P
252302-82-2P 252302-83-3P 252302-84-4P
252302-85-5P 252302-86-6P 252302-88-8P
252302-89-9P 252302-90-2P 252302-91-3P
252302-92-4P 252302-93-5P 252302-95-7P
252302-97-9P 252302-98-0P 252302-99-1P
252303-00-7P 252303-02-9P 252303-03-0P
252303-04-1P 252303-05-2P 252303-06-3P
252303-07-4P 252303-08-5P 252303-09-6P

Absolute stereochemistry.




RN 252292-70-9 CAPLUS
CN 2-Furancarboxamide, N-([[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-72-1 CAPLUS
CN 2,5-Pyrrolidinedione, 1-([[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyloxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-74-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-methoxyphenyl)methyl]-alpha-(4-phenyl-1H-imidazol-2-yl)-, (alphaR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-75-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252301-46-5 CAPLUS
CN Carbamic acid, [5-[[[imino(phenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-47-6 CAPLUS
CN Carbamic acid, [5-[[[2-chlorophenyl]iminomethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-51-2 CAPLUS
CN Carbamic acid, [5-[[[4-(1,1-dimethylethyl)phenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-52-3 CAPLUS
CN Carbamic acid, [5-[[[2,4-difluorophenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-53-4 CAPLUS
CN Carbamic acid, [5-[[[imino(4-(trifluoromethoxy)phenyl)methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-48-7 CAPLUS
CN Carbamic acid, [5-[[[4-chlorophenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-49-8 CAPLUS
CN Carbamic acid, [5-[[[imino(4-methoxyphenyl)methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-50-1 CAPLUS
CN Carbamic acid, [5-[[[imino(4-(trifluoromethyl)phenyl)methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-54-5 CAPLUS
CN Carbamic acid, [5-[[[2,6-dichlorophenyl]iminomethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-56-7 CAPLUS
CN Carbamic acid, [5-[[[2-[[[1,1-dimethylethyl]sulfonyl]-1-iminoethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-57-8 CAPLUS
CN Carbamic acid, [5-[[[imino(2-thienylmethyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252301-58-9 CAPLUS
CN Carbamic acid, [5-[(1-iminoethyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 252301-60-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-61-4 CAPLUS
CN Ethanimidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-62-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1S)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-63-6 CAPLUS
CN Ethanimidamide, N-[(1S)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-64-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252301-65-8 CAPLUS
CN Ethanimidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252301-66-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252301-67-0 CAPLUS
CN Ethanimidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 252301-70-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-71-6 CAPLUS
CN Ethanimidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-72-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252301-73-8 CAPLUS
CN Ethanimidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI


RN 252301-74-9 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3-pyridinylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-75-0 CAPLUS
CN Carbamic acid, [5-[[[(2-chloro-3-quinolinyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-76-1 CAPLUS




RN 252301-85-2 CAPLUS
CN Carbamic acid, [5-[[[(1-methyl-1H-indol-3-yl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-86-3 CAPLUS
CN Carbamic acid, [5-[[[(4-phenyl-1H-imidazol-2-yl)-5-[(phenylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-87-4 CAPLUS
CN Carbamic acid, [5-[[[(2-hydroxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-88-5 CAPLUS
CN Carbamic acid, [5-[[[(4-hydroxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-quinolinylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-77-2 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(4-pyridinylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252301-79-4 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-pyridinylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-81-8 CAPLUS
CN Carbamic acid, [5-[(1H-indol-3-ylmethyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-83-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[[5-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)


RN 252301-89-6 CAPLUS
CN Carbamic acid, [5-[[[(4-fluorophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-90-9 CAPLUS
CN Carbamic acid, [5-[[[(3-methoxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-91-0 CAPLUS
CN Carbamic acid, [5-[[[(4-methoxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-92-1 CAPLUS
CN Carbamic acid, [5-[[[(2-methoxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-93-2 CAPLUS
CN Carbamic acid, [5-[[[(2-nitrophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-94-3 CAPLUS
CN Carbamic acid, [5-[[[4-nitrophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-95-4 CAPLUS
CN Carbamic acid, [5-[[[3,4-dichlorophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-96-5 CAPLUS
CN Carbamic acid, [5-[[[3-methoxy-2-nitrophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-97-6 CAPLUS
CN Carbamic acid, [5-[[[4-bromophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-02-6 CAPLUS
CN Carbamic acid, [5-[[[4-(phenylmethoxy)ethyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252302-03-7 CAPLUS
CN Carbamic acid, [5-[[[4-(trifluoromethyl)phenyl)methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-04-8 CAPLUS
CN Carbamic acid, [5-[[[4-(trifluoromethyl)phenyl)methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-05-9 CAPLUS
CN Carbamic acid, [5-[[[4-(trifluoromethyl)phenyl)methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-98-7 CAPLUS
CN Carbamic acid, [5-[[[4-bromophenyl)methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252301-99-8 CAPLUS
CN Carbamic acid, [5-[[[4-bromophenyl)methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-00-4 CAPLUS
CN Carbamic acid, [5-[[[4-bromophenyl)methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-01-5 CAPLUS
CN Carbamic acid, [5-[[[4-bromophenyl)methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252302-06-0 CAPLUS
CN Carbamic acid, [5-[[[4-(dimethylamino)phenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-07-1 CAPLUS
CN Carbamic acid, [5-[[[4-(trifluoromethoxy)phenyl)methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-08-2 CAPLUS
CN Carbamic acid, [5-[[[4-(3-(dimethylamino)propoxy)phenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-09-3 CAPLUS
CN Carbamic acid, [5-[[[4-(3-fluoro-4-methoxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-10-6 CAPLUS
CN Carbamic acid, [5-[[[4-(1,1-dimethylethyl)phenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252302-11-7 CAPLUS
CN Carbamic acid, [5-[[[3-(4-bromophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-12-8 CAPLUS
CN Carbamic acid, [5-[[[3-(4-methoxyphenoxy)phenyl]methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-13-9 CAPLUS
CN 3-Quinolinemethanamine, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-14-0 CAPLUS
CN 2-Quinolinemethanamine, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-18-4 CAPLUS
CN 3-Quinolinemethanamine, 2-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-19-5 CAPLUS
CN 2-Quinolinemethanamine, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-20-8 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(4-pyridinylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-15-1 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(4-pyridinylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-16-2 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(2-pyridinylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-17-3 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(3-pyridinylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-21-9 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(2-pyridinylmethyl)-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252302-22-0 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-23-1 CAPLUS
CN 3-Quinolinemethanamine, 2-chloro-N-[2-(1H-indol-3-yl)-1-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)





RN 252302-24-2 CAPIUS
CN 2-Quinolinemethanamine, N-(2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl)- (9CI) (CA INDEX NAME)



RN 252302-25-3 CAPIUS
CN 1H-Indole-3-ethanamine, alpha-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-27-5 CAPIUS
CN 1H-Indole-3-ethanamine, alpha-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-35-5 CAPIUS
CN 1H-Indole-3-ethanamine, alpha-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-(2-pyridinylmethyl)-, (alphaR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252302-37-7 CAPIUS
CN 1H-Indole-3-ethanamine, alpha-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-(3-pyridinylmethyl)-, (alphaS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-39-9 CAPIUS
CN 3-Quinolinemethanamine, 2-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 252302-28-6 CAPIUS
CN 1H-Indole-3-ethanamine, alpha-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-(3-pyridinylmethyl)-, (alphaR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-29-7 CAPIUS
CN 3-Quinolinemethanamine, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-31-1 CAPIUS
CN 2-Quinolinemethanamine, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-32-2 CAPIUS
CN 1H-Indole-3-ethanamine, alpha-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-(4-pyridinylmethyl)-, (alphaR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-41-3 CAPIUS
CN 2-Quinolinemethanamine, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-43-5 CAPIUS
CN 1H-Indole-3-ethanamine, alpha-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-(4-pyridinylmethyl)-, (alphaS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-44-6 CAPIUS
CN 1H-Indole-3-ethanamine, alpha-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-(2-pyridinylmethyl)-, (alphaS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-46-8 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-47-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-48-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-butyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-53-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-54-8 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-(1,1-dimethylethyl)phenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-55-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-49-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-pentyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-50-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-(3-(methylthio)propyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-51-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-52-6 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[2-(phenylmethoxy)ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252302-56-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252302-58-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252302-60-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-butyl-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252302-61-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-pentyl- (9CI) (CA INDEX NAME)




RN 252302-63-9 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[3-(methylthio)propyl]- (9CI) (CA INDEX NAME)




RN 252302-65-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252302-67-3 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 252302-69-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 252302-71-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252302-74-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252302-77-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-79-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-80-0 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-pentyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-81-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-82-2 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[2-(phenylmethoxy)ethyl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-83-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-84-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-85-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-86-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-88-8 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-89-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-butyl- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-90-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-91-3 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[2-(phenylmethoxy)ethyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-92-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-93-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-95-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252302-97-9 CAPLUS
CN Phenol, 2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252302-98-0 CAPLUS


CN Phenol, 4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252302-99-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-00-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxyphenyl)methyl]- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-05-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-06-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-07-4 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-N-(2-thienylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 252303-02-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-methoxyphenyl)methyl]- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-03-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-nitrophenyl)methyl]- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-04-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-08-5 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-09-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-10-9 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-N-[[4-(trifluoromethoxy)phenyl]methyl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252303-12-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-([4-(3-(dimethylamino)propoxy)phenyl]methyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-13-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-([3-fluoro-4-methoxyphenyl]methyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-18-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-19-8 CAPLUS
CN Carbamic acid, [(5S)-5-((4-morpholinylcarbonyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-21-2 CAPLUS
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-[(3-thiazolidinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 252303-14-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-15-4 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(phenylmethoxy)ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-16-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-17-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-([4-(1,1-dimethylethyl)phenyl]methyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-22-3 CAPLUS
CN Carbamic acid, [(5S)-5-([4-(aminocarbonyl)-1-piperidinyl]carbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-25-6 CAPLUS
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-([4-(phenyl-1-piperazinyl)carbonyl]amino)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-26-7 CAPLUS
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-([1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl]carbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-27-8 CAPIUS
CN Carbamic acid, [(5S)-5-((4-phenyl-1H-imidazol-2-yl)-5-[[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-28-9 CAPIUS
CN Carbamic acid, [(5S)-5-((4-(4-fluorophenyl)-1-piperazinyl)carbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-29-0 CAPIUS
CN Carbamic acid, [(5S)-5-((4-(2-methoxyphenyl)-1-piperazinyl)carbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-34-7 CAPIUS
CN Carbamic acid, [(5S)-5-((4-(4-chlorophenyl)-1-piperazinyl)carbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-35-8 CAPIUS
CN Carbamic acid, [(5S)-5-((4-phenyl-1H-imidazol-2-yl)-5-[[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]amino]pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-36-9 CAPIUS
CN Carbamic acid, [(5S)-5-((4-phenyl-1H-imidazol-2-yl)-5-[[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-30-3 CAPIUS
CN Carbamic acid, [(5S)-5-((4-(3-chlorophenyl)-1-piperazinyl)carbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-32-5 CAPIUS
CN Carbamic acid, [(5S)-5-((4-(4-nitrophenyl)-1-piperazinyl)carbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-33-6 CAPIUS
CN Carbamic acid, [(5S)-5-((3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)carbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-38-1 CAPIUS
CN Carbamic acid, [(5S)-5-((4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl)carbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-39-2 CAPIUS
CN Carbamic acid, [(5S)-5-((4-phenyl-1H-imidazol-2-yl)-5-[[[4-(3-(trifluoromethyl)phenyl)-1-piperazinyl]carbonyl]amino]pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-40-5 CAPIUS
CN Carbamic acid, [(5S)-5-((4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)carbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-41-6 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-42-7 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(4-hydroxyphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-44-9 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(2,4-dimethylphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252303-53-0 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-54-1 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-57-4 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-46-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-47-2 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-50-7 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 252304-37-3 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-38-4 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-chloro-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-39-5 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-chloro-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-40-8 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-42-0 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-43-1 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(1,1-dimethylethyl)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-45-3 CAPLUS




● HI

RN 252304-49-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252304-50-0 CAPLUS
CN Ethanimidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-51-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,4-difluoro-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-46-4 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 252304-47-5 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,6-dichloro-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-48-6 CAPLUS
CN Ethanimidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-[(1,1-dimethylethyl)sulfonyl]-, monohydriodide (9CI) (CA INDEX NAME)


RN 252304-52-2 CAPLUS
CN 3-Thiazolidinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-53-3 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-58-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-60-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-62-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-64-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-66-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-70-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-77-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252304-79-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-80-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-72-6 CAPLUS
CN 2-(1H)-Isoquinolinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252304-75-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-76-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 252304-81-7 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-carboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-82-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-83-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-85-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-87-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-88-4 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-90-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252305-49-0 CAPLUS
CN 1H-Indole-5-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-50-3 CAPLUS
CN 1H-Indole-3-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)



RN 252305-51-4 CAPLUS
CN 1H-Indole-4-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-52-5 CAPLUS
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252304-93-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-94-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-99-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252305-53-6 CAPLUS
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 252305-54-7 CAPLUS
CN 1H-Indole-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-55-8 CAPLUS
CN 1H-Indole-3-butamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 252305-56-9 CAPLUS
CN 1H-Indole-3-propanamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 252305-57-0 CAPLUS
CN 1H-Indole-3-propanamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-58-1 CAPLUS
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-59-2 CAPLUS
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-bromo- (9CI) (CA INDEX NAME)




RN 252305-60-5 CAPLUS
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 252305-61-6 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-63-8 CAPLUS
CN Benzo[b]thiophene-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-69-4 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 252305-70-7 CAPLUS
CN 2-Furancarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-71-8 CAPLUS
CN 2-Pyridinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-72-9 CAPLUS
CN Acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(phenylthio)- (9CI) (CA INDEX NAME)




RN 252305-73-0 CAPLUS
CN 1-Naphthalenecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-64-9 CAPLUS
CN 2-Benzofurancarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-65-0 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 252305-66-1 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252305-67-2 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252305-68-3 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 252305-74-1 CAPLUS
CN 2-Quinolinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-75-2 CAPLUS
CN 8-Quinolinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




IT 252305-76-3P 252305-78-5P 252305-79-6P
252305-80-9P 252305-82-1P 252305-83-2P
252305-84-3P 252305-85-4P 252305-86-5P
252305-87-6P 252305-88-7P 252305-89-8P
252305-90-1P 252305-91-2P 252305-92-3P
252305-93-4P 252305-94-5P 252305-95-6P
252305-96-7P 252305-97-8P 252305-99-0P
252306-00-6P 252306-01-7P 252306-02-8P
252306-03-9P 252306-05-1P 252306-06-2P
252306-07-3P 252306-08-4P 252306-09-5P
252306-10-8P 252306-11-9P 252306-12-0P
252306-13-1P 252306-14-2P 252306-15-3P
252306-16-4P 252306-17-5P 252306-19-7P

252306-20-0P 252306-21-1P 252306-22-2P
 252306-23-3P 252306-24-4P 252306-25-5P
 252306-26-6P 252306-27-7P 252306-29-9P
 252306-31-1P 252306-32-4P 252306-34-6P
 252306-35-7P 252306-36-8P 252306-37-9P
 252306-39-1P 252306-40-4P 252306-41-5P
 252306-42-6P 252306-65-3P 252306-66-4P
 252306-67-5P 252306-68-6P 252306-69-7P
 252306-70-0P 252306-71-1P 252306-72-2P
 252306-73-3P 252306-74-4P 252306-84-6P
 252306-85-7P 252306-86-8P 252306-87-9P
 252306-88-0P 252306-89-1P 252306-90-4P
 252306-91-5P 252306-92-6P 252306-93-7P
 252306-94-8P 252306-95-9P 252306-96-0P
 252306-97-1P 252306-98-2P 252306-99-3P
 252307-00-9P 252307-01-0P 252307-02-1P
 252307-04-3P 252307-05-4P 252307-06-5P
 252307-07-6P 252307-09-8P 252307-10-1P
 252307-11-2P 252307-12-3P 252307-13-4P
 252307-17-8P 252307-19-0P 252307-21-4P
 252307-22-5P 252307-23-6P 252307-24-7P
 252307-26-9P 252307-27-0P 252307-28-1P
 252307-29-2P 252307-30-5P 252307-31-6P
 252307-32-7P 252307-33-8P 252307-34-9P
 252307-36-1P 252307-37-2P 252307-38-3P
 252307-39-4P 252307-40-7P 252307-41-8P
 252307-42-9P 252307-43-0P 252307-45-2P
 252307-46-3P 252307-47-4P 252307-48-5P
 252307-49-6P 252307-50-9P 252307-51-0P
 252307-52-1P 252307-53-2P 252307-54-3P
 252307-55-4P 252307-56-5P 252307-57-6P
 252307-58-7P 252307-59-8P 252307-60-1P
 252307-61-2P 252307-62-3P 252307-63-4P
 252307-64-5P 252307-65-6P 252307-67-8P
 252307-68-9P 252307-69-0P 252307-70-3P
 252307-71-4P 252307-72-5P 252307-73-6P
 252307-75-8P 252307-76-9P 252307-77-0P
 252307-78-1P 252307-79-2P 252307-80-5P
 252307-81-6P 252307-82-7P 252307-83-8P
 252307-85-0P 252307-86-1P 252307-88-3P
 252307-89-4P 252307-90-7P 252307-91-8P
 252307-92-9P 252307-93-0P 252307-94-1P
 252307-95-2P 252307-96-3P 252307-97-4P
 252307-98-5P 252307-99-6P 252308-01-3P
 252308-02-4P 252308-03-5P 252308-04-6P
 252308-05-7P 252308-06-8P 252308-07-9P
 252308-08-0P 252308-10-4P 252308-11-5P
 252308-13-7P 252308-14-8P 252308-15-9P
 252308-16-0P 252308-17-1P 252308-18-2P
 252308-19-3P 252308-21-7P 252308-22-8P
 252308-23-9P 252308-24-0P 252308-25-1P
 252308-26-2P 252308-27-3P 252308-28-4P
 252308-30-8P 252308-31-9P 252308-32-0P
 252308-33-1P 252308-35-3P 252308-36-4P
 252308-37-5P 252308-38-6P 252308-39-7P
 252308-41-1P 252308-42-2P 252308-43-3P
 252308-44-4P 252308-45-5P 252308-46-6P
 252308-47-7P 252308-48-8P 252308-49-9P
 252308-52-4P 252308-53-5P 252308-54-6P
 252308-55-7P 252308-57-9P 252308-58-0P
 252308-59-1P 252308-60-4P 252308-62-6P
 252308-63-7P 252308-64-8P 252308-65-9P
 252308-66-0P 252308-67-1P 252308-79-5P
 252308-81-9P 252308-82-0P 252308-83-1P
 252308-84-2P 252308-85-3P 252308-86-4P


(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 252305-82-1 CAPLUS
 CN 2-Thiopheneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-83-2 CAPLUS
 CN Acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(2-pyrimidinylthio)- (9CI) (CA INDEX NAME)



RN 252305-84-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-85-4 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 252305-86-5 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-chloro- (9CI) (CA INDEX NAME)


252308-87-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazolyl deriva. as agonists or antagonists of somatostatin receptors)
 RN 252305-76-3 CAPLUS
 CN 3-Quinolincarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-78-5 CAPLUS
 CN 4-Quinolincarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-79-6 CAPLUS
 CN 1-Isoquinolincarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-80-9 CAPLUS
 CN Propanamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3- (9CI) (CA INDEX NAME)




RN 252305-87-6 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 252305-88-7 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-bromo- (9CI) (CA INDEX NAME)




RN 252305-89-8 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-bromo- (9CI) (CA INDEX NAME)




RN 252305-90-1 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-bromo- (9CI) (CA INDEX NAME)




RN 252305-91-2 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252305-92-3 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 252305-93-4 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 252305-94-5 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252305-95-6 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252305-96-7 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252306-03-9 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252306-05-1 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252306-06-2 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 252306-07-3 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-08-4 CAPLUS
CN 1,5-Pentanediamine, N1-[(2-chloro-3-quinolinyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252305-97-8 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252305-99-0 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252306-00-6 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252306-01-7 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252306-02-8 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252306-09-5 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-10-8 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-11-9 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-12-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 252306-13-1 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-14-2 CAPLUS
CN Phenol, 2-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 252306-15-3 CAPLUS
CN Phenol, 4-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 252306-16-4 CAPLUS
CN 1,5-Pentanediamine, N1-[(4-fluorophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-17-5 CAPLUS
CN 1,5-Pentanediamine, N1-[(3-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-19-7 CAPLUS
CN 1,5-Pentanediamine, N1-[(4-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-20-0 CAPLUS
CN 1,5-Pentanediamine, N1-[(2-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-21-1 CAPLUS
CN 1,5-Pentanediamine, N1-[(2-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-22-2 CAPLUS
CN 1,5-Pentanediamine, N1-[(4-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-23-3 CAPLUS
CN 1,5-Pentanediamine, N1-[(3,4-dichlorophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-24-4 CAPLUS
CN 1,5-Pentanediamine, N1-[(3-methoxy-2-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-25-5 CAPLUS
CN 1,5-Pentanediamine, N1-[(4-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-26-6 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-27-7 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252306-29-9 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252306-31-3 CAPLUS
CN 1,5-Pentanediamine, N1-[(2-fluorophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-32-4 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[[2-(trifluoromethyl)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252306-34-6 CAPLUS
CN 1,5-Pentanediamine, N1-[[1,1'-biphenyl]-4-ylmethyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-35-7 CAPLUS
CN 1,5-Pentanediamine, N1-[(2-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-36-8 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252306-37-9 CAPLUS
CN 1,5-Pentanediamine, N1-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-39-1 CAPLUS
CN 1,5-Pentanediamine, N1-[(3-fluoro-4-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-40-4 CAPLUS
CN 1,5-Pentanediamine, N1-[4-(1,1-dimethylethyl)phenyl]methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 252306-41-5 CAPLUS
CN 1,5-Pentanediamine, N1-[(3-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 252306-42-6 CAPLUS
CN 1,5-Pentanediamine, N1-[(3-(4-methoxyphenoxy)phenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-65-3 CAPLUS
CN Propanamide, 3-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


(methylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-70-0 CAPLUS
CN Benzamide, 4-(aminomethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-71-1 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-72-2 CAPLUS
CN Pentanamide, 5-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-66-4 CAPLUS
CN Acetamide, 2-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-67-5 CAPLUS
CN Butanamide, 4-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-68-6 CAPLUS
CN Hexanamide, 6-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-69-7 CAPLUS
CN Acetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2- (9CI) (CA INDEX NAME)




RN 252306-73-3 CAPLUS
CN Benzamide, 4-(aminomethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-74-4 CAPLUS
CN Benzeneacetamide, 4-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-84-6 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-85-7 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-86-8 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-87-9 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-88-0 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-89-1 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-90-4 CAPLUS
CN Benzeneacetamide, 2-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-91-5 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-92-6 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-93-7 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-94-8 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-95-9 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-96-0 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-97-1 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-98-2 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-99-3 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-04-3 CAPLUS
CN Benzeneacetamide, 4-(dimethylamino)-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-05-4 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-06-5 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-00-9 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-01-0 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-02-1 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-07-6 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-09-8 CAPLUS
CN Benzeneacetamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-10-1 CAPLUS
CN Benzeneacetamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-11-2 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-12-3 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-13-4 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-22-5 CAPLUS
CN Benzeneacetamide, 2-fluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-23-6 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-24-7 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-17-8 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-19-0 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-21-4 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-26-9 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-27-0 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-28-1 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-29-2 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-30-5 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-31-6 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-32-7 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-33-8 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252307-34-9 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-36-1 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 252307-35-0
CMP C28 H26 N4 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMP C2 H F3 O2




RN 252307-37-2 CAPLUS
CN Benzeneacetamide, 4-(dimethylamino)-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-38-3 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-39-4 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-40-7 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-41-8 CAPIUS
CN Benzeneacetamide, 4-hydroxy-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-42-9 CAPIUS
CN Benzeneacetamide, 2,4-difluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252307-43-0 CAPIUS
CN Carbamic acid, [5-[(1H-indol-5-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-49-6 CAPIUS
CN Carbamic acid, [5-[(5-methoxy-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252307-50-9 CAPIUS
CN Carbamic acid, [5-[(5-hydroxy-1H-indol-2-yl)carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-51-0 CAPIUS
CN Carbamic acid, [5-[(5-methoxy-1H-indol-2-yl)carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-52-1 CAPIUS
CN Carbamic acid, [5-[(4-(1H-indol-3-yl)-1-oxobutyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-45-2 CAPIUS
CN Carbamic acid, [5-[(1H-indol-3-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-46-3 CAPIUS
CN Carbamic acid, [5-[(1H-indol-4-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-47-4 CAPIUS
CN Carbamic acid, [5-[(1H-indol-2-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-48-5 CAPIUS
CN Carbamic acid, [5-[(1H-indol-3-ylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252307-53-2 CAPIUS
CN Carbamic acid, [5-[(3-(1H-indol-3-yl)-1-oxopropyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-54-3 CAPIUS
CN Carbamic acid, [5-[(5-hydroxy-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-55-4 CAPIUS
CN Carbamic acid, [5-[(5-bromo-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-56-5 CAPIUS
CN Carbamic acid, [5-[(2-methyl-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-57-6 CAPIUS
CN Carbamic acid, [5-[(benzo[b]thien-2-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-58-7 CAPLUS
CN Carbamic acid, [5-[(benzo[b]thien-3-ylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-59-8 CAPLUS
CN Carbamic acid, [5-[(2-benzofuranylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-60-1 CAPLUS
CN Carbamic acid, [5-[(3,4-dichlorophenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-61-2 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3,4,5-trimethoxyphenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-67-8 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-pyridinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-68-9 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(phenylthio)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-69-0 CAPLUS
CN Carbamic acid, [5-[(1-naphthalenylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-70-3 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(4-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-62-3 CAPLUS
CN Carbamic acid, [5-[(4-methylphenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-63-4 CAPLUS
CN Carbamic acid, [5-[(4-hydroxyphenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-64-5 CAPLUS
CN Carbamic acid, [5-[(2,4-difluorophenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-65-6 CAPLUS
CN Carbamic acid, [5-[(2-furanylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


INDEX NAME)




RN 252307-71-4 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(8-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-72-5 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-73-6 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(4-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-75-8 CAPLUS
CN Carbamic acid, [5-[(1-isoquinolinylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-76-9 CAPLUS
CN Carbamic acid, [5-[(1-oxo-3-(phenylsulfonyl)propyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-77-0 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-thienylacetyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-82-7 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-chlorophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252307-83-8 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-bromophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-85-0 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3-bromophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-86-1 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(4-bromophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-78-1 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-pyrimidinylthio)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-79-2 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3-pyridinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-80-5 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-chlorophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-81-6 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3-chlorophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252307-88-3 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-fluorophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-89-4 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-fluorophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-90-7 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3-fluorophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-91-8 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(4-nitrophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-92-9 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3-nitrophenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-93-0 CAPLUS
CN Carbamic acid, [5-[[[(4-nitrophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-94-1 CAPLUS
CN Carbamic acid, [5-[[[(2-methoxyphenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-95-2 CAPLUS
CN Carbamic acid, [5-[[[(3-methoxyphenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-96-3 CAPLUS
CN Carbamic acid, [5-[[[(4-methoxyphenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-97-4 CAPLUS
CN Carbamic acid, [5-[[[(2-methoxyphenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-98-5 CAPLUS
CN Carbamic acid, [5-[[[(3-methoxyphenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-99-6 CAPLUS
CN Carbamic acid, [5-[[[(4-methoxyphenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-01-3 CAPLUS
CN Carbamic acid, [5-[[[(phenylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-02-4 CAPLUS
CN Carbamic acid, [5-[[[(4-(dimethylamino)phenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-03-5 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-04-6 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-05-7 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252308-06-8 CAPLUS
CN Benzeneacetamide, 4-hydroxy-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-07-9 CAPLUS
CN Benzeneacetamide, 2,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-08-0 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)



RN 252308-10-4 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-11-5 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252308-13-7 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)


CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-17-1 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252308-18-2 CAPLUS
CN Benzeneacetamide, 4-hydroxy-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




yl)ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 252308-14-8 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 252308-15-9 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-16-0 CAPLUS


RN 252308-19-3 CAPLUS
CN Benzeneacetamide, 2,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-21-7 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252308-22-8 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)



RN 252308-23-9 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252308-24-0 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 252308-25-1 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,4-difluoro- (9CI) (CA INDEX NAME)


CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-30-8 CAPLUS
CN Benzeneacetamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-31-9 CAPLUS
CN Benzeneacetamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-32-0 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252308-26-2 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-27-3 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-28-4 CAPLUS

Absolute stereochemistry.




RN 252308-33-1 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-35-3 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-36-4 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-37-5 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-38-6 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-39-7 CAPLUS
CN Benzeneacetamide, 2-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-41-1 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-42-2 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-43-3 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-44-4 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-45-5 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-46-6 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-47-7 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-48-8 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-49-9 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-52-4 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-53-5 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-54-6 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-59-1 CAPLUS
CN Carbamic acid, [4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-60-4 CAPLUS
CN Carbamic acid, [6-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-6-oxohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-62-6 CAPLUS
CN Carbamic acid, [2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-55-7 CAPLUS
CN Benzeneacetamide, 4-(dimethylamino)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-57-9 CAPLUS
CN Carbamic acid, [3-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-58-0 CAPLUS
CN Carbamic acid, [2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-63-7 CAPLUS
CN Carbamic acid, [4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-64-8 CAPLUS
CN Carbamic acid, [2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-65-9 CAPLUS
CN Carbamic acid, [5-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-5-oxopentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-66-0 CAPLUS
CN Carbamic acid, [[4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-67-1 CAPLUS
CN Carbamic acid, [4-[2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-2-oxoethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252308-79-5 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-84-2 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-85-3 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-86-4 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-81-9 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-82-0 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-83-1 CAPLUS
CN Benzenecarboximidamide, 4-methoxy-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-87-5 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI

IT 252308-88-6P 252308-89-7P 252308-90-0P
252308-91-1P 252308-92-2P 252308-93-3P
252308-94-4P 252308-95-5P 252308-96-6P
252308-97-7P 252308-98-8P 252308-99-9P
252309-00-5P 252309-01-6P 252309-02-7P
252309-03-8P 252309-04-9P 252309-05-0P
252309-06-1P 252309-07-2P 252309-08-3P
252309-09-4P 252309-10-7P 252309-11-8P
252309-12-9P 252309-13-0P 252309-14-1P
252309-15-2P 252309-16-3P 252309-18-5P
252309-19-6P 252309-20-9P 252309-21-0P
252309-22-1P 252309-23-2P 252309-24-3P
252309-25-4P 252309-26-5P 252309-27-6P
252309-28-7P 252309-29-8P 252309-30-1P
252309-42-5P 252309-43-6P 252309-44-7P
252309-45-8P 252309-46-9P 252309-47-0P
252309-48-1P 252309-49-2P 252309-50-5P
252309-51-6P 252309-53-8P 252309-54-9P
252309-55-0P 252309-56-1P 252309-57-2P
252309-58-3P 252309-59-4P 252309-61-8P
252309-63-0P 252309-64-1P 252309-65-2P
252309-66-3P 252309-67-4P 252309-68-5P
252309-69-6P 252309-70-9P 252309-71-0P
252309-73-2P 252309-74-3P 252309-75-4P
252309-76-5P 252309-77-6P 252309-79-8P
252309-80-1P 252309-81-2P 252309-82-3P
252309-84-5P 252309-85-6P 252309-86-7P
252309-87-8P 252309-88-9P 252309-89-0P
252309-90-3P 252309-91-4P 252309-92-5P


252309-93-6P 252309-95-8P 252309-96-9P
 252309-97-0P 252310-00-2P 252310-01-3P
 252310-02-4P 252310-03-5P 252310-04-6P
 252310-05-7P 252310-06-8P 252310-08-0P
 252310-09-1P 252310-10-4P 252310-11-5P
 252310-12-6P 252310-13-7P 252310-14-8P
 252310-15-9P 252310-16-0P 252310-17-1P
 252310-18-2P 252310-19-3P 252310-21-7P
 252310-22-8P 252310-23-9P 252310-24-0P
 252310-25-1P 252310-26-2P 252310-27-3P
 252310-28-4P 252310-29-5P 252310-31-9P
 252310-32-0P 252310-33-1P 252310-34-2P
 252310-35-3P 252310-36-4P 252310-38-6P
 252310-39-7P 252310-40-0P 252310-41-1P
 252310-43-3P 252310-44-4P 252310-45-5P
 252310-46-6P 252310-47-7P 252310-48-8P
 252310-49-9P 252310-50-2P 252310-51-3P
 252310-52-4P 252310-53-5P 252310-55-7P
 252310-56-8P 252310-58-0P 252310-59-1P
 252310-60-4P 252310-62-6P 252310-63-7P
 252310-64-8P 252310-65-9P 252310-66-0P
 252310-68-2P 252310-71-7P 252310-72-8P
 252310-73-9P 252310-74-0P 252310-75-1P
 252310-76-2P 252310-77-3P 252310-80-6P
 252310-81-9P 252310-82-0P 252310-83-1P
 252310-84-2P 252310-85-3P 252310-86-4P
 252310-87-5P 252310-88-6P 252310-89-7P
 252310-93-3P 252310-94-4P 252310-97-7P
 252310-98-8P 252313-17-0P 252313-18-1P
 252313-19-2P 252313-20-5P 252313-22-7P
 252313-23-8P 252313-24-9P 252313-25-0P
 252313-26-1P 252313-27-2P 252313-28-3P
 252313-29-4P 252313-30-7P 252313-31-8P
 252313-33-0P 252313-34-1P 252313-35-2P
 252313-36-3P 252313-37-4P 252313-38-5P
 252313-39-6P 252313-40-9P 252313-41-0P
 252313-42-1P 252313-43-2P 252313-45-4P
 252313-46-5P 252313-47-6P 252313-48-7P
 252313-50-1P 252313-51-2P 252313-52-3P
 252313-53-4P 252313-54-5P 252313-55-6P
 252313-57-8P 252313-58-9P 252313-59-0P
 252313-60-3P 252313-61-4P 252313-62-5P
 252313-63-6P 252313-64-7P 252313-65-8P
 252313-66-9P 252313-67-0P 252313-68-1P
 252313-69-2P 252313-70-5P 252313-71-6P
 252313-72-7P 252313-73-8P 252313-74-9P
 252313-75-0P 252313-77-2P 252313-78-3P
 252313-79-4P 252313-80-7P 252313-81-8P
 252313-82-9P 252313-83-0P 252313-84-1P
 252313-86-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of imidazolyl derivs. as agonists or antagonists of
 somatostatin receptors)

RN 252308-88-6 CAPLUS
 CN Benzenecarboximidamide, 2,6-dichloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-
 2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-89-7 CAPLUS
 CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1S)-1-(4-phenyl-1H-
 imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



● HI

RN 252308-90-0 CAPLUS
 CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-
 imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-91-1 CAPLUS
 CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-
 1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-
 imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



● HI

RN 252308-95-5 CAPLUS
 CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(4-methoxyphenyl)-
 1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX
 NAME)


Absolute stereochemistry.



● HI

RN 252308-96-6 CAPLUS
 CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-
 phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-92-2 CAPLUS
 CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-
 1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252308-93-3 CAPLUS
 CN Benzenecarboximidamide, 4-methoxy-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-
 1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI


RN 252308-94-4 CAPLUS



● HI

RN 252308-97-7 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-98-8 CAPLUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-99-9 CAPLUS

RN 252309-02-7 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-03-8 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-04-9 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-00-5 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HI

RN 252309-01-6 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI



● HI

RN 252309-05-0 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-06-1 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-07-2 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-08-3 CAPLUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-09-4 CAPLUS
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-12-9 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-13-0 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-10-7 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-11-8 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-14-1 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-15-2 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-16-3 CAPIUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-18-5 CAPIUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethoxy)-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-21-0 CAPIUS
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252309-22-1 CAPIUS
CN Benzenecarboximidamide, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)



● HI


RN 252309-23-2 CAPIUS
CN Benzenecarboximidamide, 4-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)



● HI

RN 252309-19-6 CAPIUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-20-9 CAPIUS
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-24-3 CAPIUS
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252309-25-4 CAPIUS
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252309-26-5 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252309-28-7 CAPLUS
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethoxy)-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252309-27-6 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)




● HI

RN 252309-29-8 CAPLUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)



● HI


RN 252309-30-1 CAPLUS
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)



● HI

RN 252309-42-5 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-43-6 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-

[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-44-7 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-45-8 CAPLUS
CN Benzenecarboximidamide, 4-methoxy-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-46-9 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-47-0 CAPLUS
CN Benzenecarboximidamide, 4-[(1,1-dimethylethyl)-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-48-1 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-49-2 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-50-5 CAPLUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-51-6 CAPLUS
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-53-8 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-54-9 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-55-0 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-56-1 CAPLUS
CN Benzenecarboximidamide, 4-methoxy-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-57-2 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-58-3 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-59-4 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-61-8 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-63-0 CAPLUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-64-1 CAPLUS
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-65-2 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-66-3 CAPLUS
CN Phenol, 2-[[[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-67-4 CAPLUS
CN Phenol, 4-[[[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-68-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-69-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxyphenyl)methyl]-alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-70-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-71-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252309-73-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-77-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-79-8 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(2-thienylmethyl)-, (αS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 252309-78-7
CMF C24 H22 N4 S

Absolute stereochemistry.




Absolute stereochemistry.




RN 252309-74-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-75-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252309-76-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 252309-80-1 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-81-2 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(2-fluorophenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-82-3 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(2-trifluoromethyl)phenyl]methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-84-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-85-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-(dimethylamino)phenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-86-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(4-(trifluoromethoxy)phenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252309-90-3 CAPLUS
CN Phenol, 4-[[[2-(1H-indol-3-yl)-1-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 252309-91-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252309-92-5 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252309-87-8 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252309-88-9 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252309-89-0 CAPLUS
CN Phenol, 2-[[[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 252309-93-6 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[[4-(methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252309-95-8 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(2-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252309-96-9 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(2-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252309-97-0 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-02-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-00-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-03-5 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 252310-01-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-04-6 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-05-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-09-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-(dimethylamino)phenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-06-8 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-10-4 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)



RN 252310-08-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-11-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-{3-(dimethylamino)propoxy}phenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 252310-12-6 CAPLUS

CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-13-7 CAPLUS

CN Phenol, 2-[[[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-14-8 CAPLUS

CN Phenol, 4-[[[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



RN 252310-18-2 CAPLUS

CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-methoxyphenyl)methyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-19-3 CAPLUS


CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-nitrophenyl)methyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-21-7 CAPLUS


CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-nitrophenyl)methyl]-, (α R)- (9CI) (CA INDEX NAME)



RN 252310-15-9 CAPLUS

CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-16-0 CAPLUS

CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-methoxyphenyl)methyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-17-1 CAPLUS

CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-methoxyphenyl)methyl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-22-8 CAPLUS

CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-23-9 CAPLUS


CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-24-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]- α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-25-1 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-(2-thienylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-26-2 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-27-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]- α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-28-4 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-[(2-(trifluoromethyl)phenyl)methyl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-29-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]- α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-31-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-(dimethylamino)phenyl)methyl]- α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-32-0 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-[(4-(trifluoromethoxy)phenyl)methyl]-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-33-1 CAPLUS


CN 1H-Indole-3-ethanamine, N-[(4-[3-(dimethylamino)propoxy]phenyl)methyl]- α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-34-2 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-35-3 CAPLUS
CN Phenol, 2-[[[[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-36-4 CAPLUS
CN Phenol, 4-[[[[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-38-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-39-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-methoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-40-0 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-methoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)


[(4-nitrophenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-45-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-46-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


[(4-methoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-41-1 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-methoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-43-3 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-nitrophenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-44-4 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-bromophenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)




RN 252310-47-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-48-8 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-thienyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-49-9 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-50-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-51-3 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-(trifluoromethyl)phenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-52-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)


CN 4-Morpholinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-58-0 CAPLUS
CN 3-Thiazolidinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-59-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-60-4 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252310-53-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-(dimethylamino)phenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-55-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-(trifluoromethoxy)phenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-56-8 CAPLUS




RN 252310-62-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-63-7 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide, 1,3,4,9-tetrahydro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-64-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-65-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-fluorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-66-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-68-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-(3-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-74-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-75-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-76-2 CAPLUS
CN 1,4-Dioxo-8-azaspiro[4.5]decane-8-carboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-71-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-72-8 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, 3,4-dihydro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-73-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-77-3 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-80-8 CAPLUS
CN 1-Piperazinecarboxamide, 4-(1,3-benzodioxol-5-ylmethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-81-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-82-0 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-carboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-83-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-84-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-hydroxyphenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-88-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-89-7 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-furanylcabonyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-93-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-85-3 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2,4-dimethylphenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-86-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, 3-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-87-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-94-4 CAPLUS
CN 1-Piperazinecarboxamide, 4-(diphenylmethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-97-7 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-fluorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-98-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252313-17-0 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-18-1 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-19-2 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-20-5 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-22-7 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-23-8 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-24-9 CAPLUS
CN Benzeneacetamide, 2-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-25-0 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-26-1 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-27-2 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-28-3 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-29-4 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-30-7 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-34-1 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-31-8 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-35-2 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-33-0 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-36-3 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-37-4 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-40-9 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 252313-38-5 CAPLUS
CN Benzeneacetamide, 4-(dimethylamino)-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-41-0 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 252313-39-6 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 252313-42-1 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-43-2 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-47-6 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 252313-45-4 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-48-7 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 252313-46-5 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252313-50-1 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-51-2 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-54-5 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-52-3 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-55-6 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-53-4 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-57-8 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-58-9 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-59-0 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-60-3 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-64-7 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-65-8 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-66-9 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-61-4 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 252313-62-5 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-63-6 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-67-0 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-68-1 CAPLUS
CN Benzeneacetamide, 2-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-69-2 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-70-5 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-73-8 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-71-6 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-74-9 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-72-7 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-75-0 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-77-2 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-80-7 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-78-3 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-81-8 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-79-4 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-82-9 CAPLUS
CN Benzeneacetamide, 4-(dimethylamino)-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 252313-83-0 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 252313-84-1 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-86-3 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)

335244-81-0P 335244-82-1P 335244-83-2P
335244-84-3P 335244-85-4P 335244-86-5P
335244-87-6P 335244-88-7P 335244-89-8P
335244-90-1P 335244-91-2P 335244-92-3P
335244-93-4P 335244-95-6P 335244-96-7P
335244-97-8P 335244-98-9P 335244-99-0P
335245-03-9P 335245-04-0P 335245-05-1P
335245-11-9P 335245-13-1P 335245-16-4P
335245-17-5P 335245-18-6P 335245-20-0P
335245-21-1P 335245-27-7P 335245-36-8P
335246-40-4P 335246-23-6P 335246-41-8P
335246-42-9P 335246-44-1P 335246-47-4P
335246-50-9P 335246-51-0P 335246-54-3P
335246-55-4P 335246-56-5P 335246-58-7P
335246-67-8P 335246-69-0P 335246-70-3P
335246-71-4P 335246-72-5P 335246-73-6P
335246-74-7P 335246-76-9P 335246-77-0P
335246-78-1P 335246-79-2P 335246-80-5P
335246-81-6P 335246-83-8P 335246-84-9P
335246-85-0P 335246-86-1P 335246-87-2P
335246-89-4P 335246-90-7P 335246-91-8P
335246-92-9P 335246-93-0P 335246-97-4P
396135-27-6P 396135-28-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)


RN 252313-87-4 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-89-6 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




IT 252313-87-4P 252313-89-6P 252313-90-9P
252313-91-0P 252313-92-1P 252313-93-2P
252313-94-3P 252313-96-5P 252313-97-6P
252313-99-8P 252314-00-4P 252314-01-5P
252314-02-6P 252314-03-7P 252314-04-8P
252314-05-9P 252314-96-8P 252314-97-9P
252314-98-0P 252314-99-1P 252315-01-8P
252315-03-0P 252315-05-2P 252315-07-4P
252315-09-6P 252315-11-0P 252315-33-6P
252315-35-8P 252315-37-0P 252315-40-5P
252315-42-7P 252315-44-9P 252315-47-2P
252315-49-4P 252315-96-1P 252315-97-2P
280775-44-2P 335242-94-9P 335242-95-0P
335242-98-3P 335242-99-4P 335243-00-0P
335243-01-1P 335243-03-3P 335243-04-4P
335243-05-5P 335243-07-7P 335243-09-9P
335243-10-2P 335243-12-4P 335243-14-6P
335243-15-7P 335243-16-8P 335243-19-1P
335243-20-4P 335243-21-5P 335243-22-6P
335243-23-7P 335243-24-8P 335243-25-9P
335243-26-0P 335243-27-1P 335243-28-2P
335243-29-3P 335243-30-6P 335243-31-7P
335243-32-8P 335243-33-9P 335243-34-0P
335243-35-1P 335243-37-3P 335243-40-8P
335243-46-4P 335243-47-5P 335243-50-0P
335243-51-1P 335243-52-2P 335243-53-3P
335243-56-6P 335243-57-7P 335243-59-9P
335243-60-2P 335243-62-4P 335243-65-7P
335243-68-0P 335243-72-6P 335243-74-8P
335243-75-9P 335243-76-0P 335243-78-2P
335243-79-3P 335243-81-7P 335243-83-9P
335243-85-1P 335243-87-3P 335243-91-9P
335243-92-0P 335243-95-3P 335244-02-5P
335244-12-7P 335244-26-3P 335244-27-4P
335244-29-6P 335244-31-0P 335244-35-4P
335244-36-5P 335244-42-3P 335244-43-4P
335244-44-5P 335244-45-6P 335244-46-7P
335244-47-8P 335244-48-9P 335244-49-0P
335244-50-3P 335244-51-4P 335244-52-5P
335244-53-6P 335244-54-7P 335244-55-8P
335244-56-9P 335244-57-0P 335244-58-1P
335244-60-5P 335244-62-7P 335244-63-8P
335244-64-9P 335244-67-2P 335244-68-3P
335244-69-4P 335244-70-7P 335244-71-8P
335244-72-9P 335244-73-0P 335244-74-1P
335244-75-2P 335244-76-3P 335244-77-4P
335244-78-5P 335244-79-6P 335244-80-9P




RN 252313-90-9 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-91-0 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252313-92-1 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 252313-93-2 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-fluorophenyl- (9CI) (CA INDEX NAME)




RN 252313-97-6 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-94-3 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-99-8 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-96-5 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252314-00-4 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252314-01-5 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252314-04-8 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252314-02-6 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 252314-05-9 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 252314-03-7 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252314-96-8 CAPLUS
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-97-9 CAPLUS
CN Benzamide, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)thioxomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-98-0 CAPLUS
CN Thiourea, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-99-1 CAPLUS
CN Thiourea, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-07-4 CAPLUS
CN Thiourea, N-hexyl-N'-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-09-6 CAPLUS
CN Thiourea, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-11-0 CAPLUS
CN Thiourea, N-(1,3-benzodioxol-5-ylmethyl)-N'-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-01-8 CAPLUS
CN Thiourea, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-03-0 CAPLUS
CN Thiourea, N-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-05-2 CAPLUS
CN Thiourea, N-(3-chlorophenyl)-N'-([(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-33-6 CAPLUS
CN Thiourea, N-([(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-35-8 CAPLUS
CN Benzamide, N-([(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino)thioxomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-37-0 CAPLUS
CN Thiourea, N-([(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-40-5 CAPLUS
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-42-7 CAPLUS
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(4-(phenylmethoxy)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-44-9 CAPLUS
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-97-2 CAPLUS
CN Thiophenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI


RN 280775-44-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335242-94-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl-α-(4-methylpentyl)- (9CI) (CA INDEX NAME)




RN 335242-95-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)



RN 335242-98-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)


RN 252315-47-2 CAPLUS
CN Thiourea, N-(3-chlorophenyl)-N'-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-49-4 CAPLUS
CN Thiourea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252315-96-1 CAPLUS
CN Thiophenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI



RN 335242-99-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-00-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N,N,α-trihexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-01-1 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-2-pyrimidinyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-03-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-methyl-α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-04-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-(2-phenylethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-05-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-N,α-bis(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-07-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-09-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335243-16-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-19-1 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-20-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-dihexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-21-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α-pentyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-22-6 CAPLUS




●x HCl

RN 335243-10-2 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-12-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335243-14-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-butyl-1-methyl-α-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335243-15-7 CAPLUS
CN Carbamic acid, [1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-23-7 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(2,6-dichlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-24-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(4-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-25-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-26-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(2-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-27-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(2-fluorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-28-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N-butyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-29-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-N-(3-methylbutyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-30-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N,α-diethyl- (9CI) (CA INDEX NAME)




RN 335243-31-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-N-pentyl-4-phenyl- (9CI) (CA INDEX NAME)




●x HCl

RN 335243-40-8 CAPLUS
CN 1H-Indole-3-ethanamine, N-cyclobutyl-4-(4-fluorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-46-4 CAPLUS
CN 1H-Indole-3-ethanamine, 4-phenyl-α-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-47-5 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl




RN 335243-32-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-33-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-34-0 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 335243-35-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclopentyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-37-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)


RN 335243-50-0 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-51-1 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335243-52-2 CAPLUS
CN Benzamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-53-3 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-56-6 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-57-7 CAPLUS
CN Carbamic acid, [(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-59-9 CAPLUS
CN 1H-Indole-3-ethanamine, 6-fluoro-α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-60-2 CAPLUS
CN 1H-Indole-3-ethanamine, 6-chloro-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335243-74-8 CAPLUS
CN Carbamic acid, [(1R)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-75-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-76-0 CAPLUS
CN Carbamic acid, [phenyl(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-78-2 CAPLUS
CN 1H-Imidazole-2-methanamine, α,4-diphenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335243-62-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-(2-phenoxyethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-65-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(benzo[b]thien-3-ylmethyl)-4-phenyl-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-68-0 CAPLUS
CN Carbamic acid, [2-(6-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-72-6 CAPLUS
CN 1H-Indole-3-ethanamine, 6-chloro-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335243-79-3 CAPLUS
CN Carbamic acid, [(1R)-3-phenyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-81-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-(2-phenylethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335243-83-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α,4-diphenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-85-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-(2-phenylethyl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-87-3 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-91-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-, hydrochloride (9CI) (CA INDEX NAME)





●x HCl

RN 335243-92-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335243-95-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




●x HCl

RN 335244-31-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(2-phenylethyl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-35-4 CAPLUS
CN Carbamic acid, [1-[4-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-36-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-butyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-42-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α-butyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)

RN 335244-02-5 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-12-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-26-3 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-27-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(2-phenylethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-29-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335244-43-4 CAPLUS
CN Carbamic acid, [1-[4-(4-methylphenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-44-5 CAPLUS
CN Carbamic acid, [1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-45-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(4-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-46-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(2-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335244-47-8 CAPLUS
CN 1H-Imidazole-2-methanamine, alpha-butyl-4-phenyl-N-(phenylmethyl)- (9CI)
(CA INDEX NAME)



RN 335244-48-9 CAPLUS
CN Carbamic acid, [1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-49-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-alpha-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-50-3 CAPLUS
CN Carbamic acid, [1-(4-(3-bromophenyl)-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-55-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-alpha-hexyl-N-(phenylmethyl)-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 335244-54-7
CMF C23 H28 Br N3




CM 2

CRN 64-19-7
CMF C2 H4 O2





RN 335244-56-9 CAPLUS
CN Carbamic acid, [(1S)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-57-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-alpha-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-51-4 CAPLUS
CN 1H-Imidazole-2-methanamine, alpha-hexyl-4-(4-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-52-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-alpha-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-53-6 CAPLUS
CN Carbamic acid, [1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-54-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-alpha-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

RN 335244-58-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-alpha-ethyl-, hydrochloride, (alphaS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




●x HCl

RN 335244-60-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-alpha-ethyl-N-(phenylmethyl)-, (alphaS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-62-7 CAPLUS
CN 1H-Imidazole-2-methanamine, alpha-hexyl-4-(4-methylphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-63-8 CAPLUS
CN 1H-Imidazole-2-methanamine, alpha-hexyl-4-(2-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-64-9 CAPLUS
CN 1H-Imidazole-2-methanamine, alpha-pentyl-4-phenyl-N-(phenylmethyl)-

(9CI) (CA INDEX NAME)




RN 335244-67-2 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-, hydrochloride (9CI)
(CA INDEX NAME)




●x HCl

RN 335244-68-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




RN 335244-69-4 CAPLUS
CN Carbamic acid, [(1R)-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-70-7 CAPLUS
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-74-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-75-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-76-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)-α-propyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-77-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(3-chlorophenyl)methyl]-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335244-71-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-propyl-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl


RN 335244-72-9 CAPLUS
CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-73-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-α-propyl-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335244-78-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-79-6 CAPLUS
CN Benzonitrile, 4-[2-[(1-((phenylmethyl)amino)heptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335244-80-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-81-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α-methyl-4-phenyl-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-82-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-83-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-84-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-butyl- α -ethyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-85-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α -methyl-4-phenyl-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-86-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-phenyl-N-propyl- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 335244-87-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-88-7 CAPLUS
CN Benzonitrile, 4-[2-[1-[(phenylmethyl)amino]heptyl]-1H-imidazol-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-89-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-N-[(4-methoxyphenyl)methyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 335244-90-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- α -hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-91-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)- α -hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-92-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-(diethylamino)phenyl)- α -hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-93-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335244-95-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- α -(4-methylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)



RN 335244-99-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335245-03-9 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335245-04-0 CAPLUS
CN Carbamic acid, [(1S)-1-(4-[(1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)ethyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-05-1 CAPLUS
CN Carbamic acid, [(1R)-1-(4-[(1,1'-biphenyl]-4-yl)-1H-imidazol-2-yl)ethyl]-, butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-11-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-N-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 335245-20-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-cyclobutyl-5-fluoro- α -[4-(4-fluorophenyl)-1H-imidazol-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-21-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- α -(3-methylbutyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-27-7 CAPLUS
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)- α -hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-36-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl- α -(4-methylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 335245-13-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-16-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[(1,1'-biphenyl)-4-yl]-N-cyclohexyl- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-17-5 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro- α -[4-(4-fluorophenyl)-1H-imidazol-2-yl]-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335245-18-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl- (9CI) (CA INDEX NAME)




●x HCl

RN 335245-40-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- α -(1-methylethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-23-6 CAPLUS
CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 335246-41-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α -pentyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-42-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-44-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl- α -hexyl- (9CI) (CA INDEX NAME)




RN 335246-47-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-4-(4-fluorophenyl)- α -hexyl- (9CI) (CA INDEX NAME)




RN 335246-50-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-51-0 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl- α -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-54-3 CAPLUS
CN 1H-Indole-3-ethanamine, 6-chloro- α -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-70-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-71-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -hexyl- (9CI) (CA INDEX NAME)



RN 335246-72-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-73-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- α -hexyl- (9CI) (CA INDEX NAME)




RN 335246-74-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -ethyl-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-55-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α ,4-diphenyl- (9CI) (CA INDEX NAME)




RN 335246-56-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(2-phenylethyl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-58-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)




RN 335246-67-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(2-phenylethyl)-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-69-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 335246-76-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-77-0 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335246-78-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -propyl-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-79-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -propyl-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-80-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- α -hexyl-

(9CI) (CA INDEX NAME)




RN 335246-81-6 CAPLUS
CN 1H-Imidazole-2-methanamine, alpha-methyl-4-phenyl-, (aR)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.




RN 335246-83-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-alpha-hexyl- (9CI) (CA INDEX NAME)




RN 335246-84-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-alpha-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-85-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-alpha-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-86-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-alpha-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-93-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-alpha-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 335246-97-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-alpha-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 396135-27-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-alpha-butyl- (9CI) (CA INDEX NAME)




RN 396135-28-7 CAPLUS
CN 1H-Imidazole-2-methanamine, alpha-butyl-4-phenyl- (9CI) (CA INDEX NAME)




IT 252279-08-6 252315-91-6 252315-92-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)
RN 252279-08-6 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)




RN 335246-87-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-alpha-hexyl- (9CI) (CA INDEX NAME)




RN 335246-89-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)-alpha-hexyl- (9CI) (CA INDEX NAME)



RN 335246-90-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-cyclohexyl-alpha-hexyl- (9CI) (CA INDEX NAME)




RN 335246-91-8 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro-alpha-[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 335246-92-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-cyclobutyl-5-fluoro-alpha-[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-91-6 CAPLUS
CN Carbamic acid, [(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry..




RN 252315-92-7 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




IT 252279-09-7P 335247-35-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)
RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335247-35-3 CAPLUS
CN Carbamic acid, [1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




L12 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:6386 CAPLUS
DOCUMENT NUMBER: 136:69731
TITLE: Preparation of N-phenylthiophenecarboxamides and analogs as NO synthase and lipid peroxidation inhibitors
INVENTOR(S): Chabrier de Lassauniere, Pierre Etienne; Auvin, Serge; Bigg, Dennis; Auguet, Michel; Harnett, Jeremiah
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: U.S., 63 pp., Cont.-in-part of U. S. Ser. No. 381,749. CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6335445	B1	20020101	US 1999-456205	19991207
FR 2761066	A1	19980925	FR 1997-3528	19970324
FR 2761066	B1	20001124		
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		
WO 9842696	A1	19981001	WO 1998-FR288	19980216
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GU, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SF, BJ, CP, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 6340700	B1	20020122	US 1999-381749	19990922
US 2002007062	A1	20020117	US 2001-882264	20010615
US 6630461	B2	20031007		
US 2002045753	A1	20020418	US 2001-945782	20010904
US 6599903	B2	20030729		
US 2002042511	A1	20020411	US 2001-953682	20010917
US 6586454	B2	20030701		
US 2003078420	A1	20030424	US 2002-191950	20020709
US 6809088	B2	20041026		

PRIORITY APPLN. INFO.:


FR 1997-3528	A	19970324
FR 1997-7701	A	19970620
WO 1998-FR288	W	19980216
US 1999-381749	A2	19990922
WO 1998-FR1250	W	19980615
US 1999-456205	A3	19991207
US 2001-882264	A3	20010615

OTHER SOURCE(S): MARPAT 136:69731




● HCl

RN 384833-39-0 CAPLUS
CN Benzamide, N-[[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-4-[[imino-2-thienylmethyl]amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 384833-51-6 CAPLUS
CN 2-Thiophenecarboximidamide, N-[[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]methylamino]phenyl]- (9CI) (CA INDEX NAME)




IT 218944-36-6P 218944-40-2P 218944-41-3P
218944-66-2P 218944-68-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-phenylthiophenecarboxamides and analogs as NO synthase and lipid peroxidn. inhibitors)
RN 218944-36-6 CAPLUS
CN Carbamic acid, [[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

GI




AB RZZ1223N:C(NH2)R1 [1; R = H, (un)substituted C6H4OR3, indolyl, etc.; R1 = alkyl or (un)substituted (hetero)aryl; R3 = H, alkyl, etc.; Z = bond, CO, alkylene(carbonyl), CONH, etc.; Z1 = bond or heterocyclylene; Z2 = bond, alkylene(oxy), etc.; Z3 = (un)substituted phenylene] were prepared Thus, 4-(O2N)C6H4NH2 was amidated by 3,5-di-tert-butyl-4-hydroxybenzoic acid and the reduced product amidated by S-methyl-2-thiophenethiocarboximide hydroiodide to give title compound II. Data for biol. activity of I were given.
IT 218944-42-4P 218944-69-5P 384833-39-0P
384833-51-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-phenylthiophenecarboxamides and analogs as NO synthase and lipid peroxidn. inhibitors)

RN 218944-42-4 CAPLUS
CN Benzamide, N-[[5-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-4-[[imino-2-thienylmethyl]amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 218944-69-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[[4-[[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]methylamino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




RN 218944-40-2 CAPLUS
CN Benzamide, N-[[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-4-[[imino-2-thienylmethyl]amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)




RN 218944-41-3 CAPLUS
CN Benzamide, 4-amino-N-[[4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]-N-methyl-, (9CI) (CA INDEX NAME)



RN 218944-66-2 CAPLUS
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[[2-[[methyl(4-nitrophenyl)amino]methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 218944-68-4 CAPLUS
CN Phenol, 4-[[2-[[[4-aminophenyl]methylamino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:527784 CAPLUS

DOCUMENT NUMBER: 135:251427

TITLE: Identification of Potent Non-Peptide Somatostatin Antagonists with sst3 Selectivity

AUTHOR(S): Poitout, Lydie; Roubert, Pierre; Contour-Galceran, Marie-Odile; Moinet, Christophe; Lannoy, Jacques; Pomier, Jacques; Plas, Pascale; Bigg, Dennis; Thuriereau, Christophe

CORPORATE SOURCE: Institut Henri Beaufour, Les Ulis, F-91966, Fr.

SOURCE: Journal of Medicinal Chemistry (2001), 44(18), 2990-3000

CODEN: JMCWAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:251427

AB Using a solution-phase parallel synthesis strategy, a series of non-peptide somatostatin analogs were prepared, and their binding affinities to the five human somatostatin receptor subtypes (sst1-5) were determined. Imidazolyl derivs. were found to bind with moderate affinity but with high selectivity to the sst3 receptor subtype. Further modifications of these structures led to a more potent class of ligands, the tetrahydro- β -carboline derivs. Among these, compds. BN81644 and BN81674 bind selectively and with high affinity to the sst3 receptor subtype (K_i = 0.64 and 0.92 nM, resp.). Furthermore, BN81644 and BN81674 reverse the inhibition of cAMP accumulation induced by 1 nM somatostatin via sst3 receptors, with IC_{50} = 2.7 and 0.84 nM, resp. The most potent compound BN81674 was shown to be a competitive antagonist of human sst3 receptors by increasing the EC_{50} of SRIF-14-mediated inhibition of cAMP accumulation with a K_B of 2.8 nM (where K_B is the concentration of antagonist that shifts

the agonist dose-response 2-fold). These new derivs. are, to the authors knowledge, the first potent and highly selective non-peptide human sst3 antagonists known and, as such, are useful tools for investigating the physiol. role of sst3 receptors.

IT 252279-08-6P 252279-09-7P 252279-24-6P

335243-50-0P 349668-19-5P, tert-Butyl

(1S)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylcarbamate

361576-57-0P 361576-59-2P 361576-60-5P

361576-63-8P 361576-64-9P 361576-65-0P

361576-66-1P 361576-67-2P 361576-69-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(identification of potent non-peptide somatostatin receptor antagonists

with sst3 selectivity)


RN 252279-08-6 CAPLUS

CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, (α S)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 361576-57-0 CAPLUS

CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)-2-[5-(phenylmethoxy)-1H-indol-3-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 361576-59-2 CAPLUS

CN Carbamic acid, [2-(5-methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361576-60-5 CAPLUS


CN Carbamic acid, [2-(5-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 361576-63-8 CAPLUS

CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252279-09-7 CAPLUS

CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, (α R)-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252279-24-6 CAPLUS

CN Carbamic acid, [(1R)-2-benzo(b)thien-3-yl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-50-0 CAPLUS

CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 349668-19-5 CAPLUS

CN Carbamic acid, [(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 361576-64-9 CAPLUS

CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 361576-65-0 CAPLUS

CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-5-(phenylmethoxy)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 361576-66-1 CAPLUS


CN 1H-Indole-3-ethanamine, 5-methyl- α -(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl


RN 361576-67-2 CAPLUS
CN 1H-Indole-3-ethanamine, 5-chloro-α-(4-phenyl-1H-imidazol-2-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 361576-69-4 CAPLUS
CN 1H-Indazole-2-methanamine, α-(benzo[b]thien-3-ylmethyl)-4-phenyl-, dihydrochloride, (αR)- (9CI) (CA INDEX NAME)





Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN
ACCESSION NUMBER: 2001:283789 CAPLUS
DOCUMENT NUMBER: 134:311210
TITLE: 5-Membered heterocycle derivatives useful as monoamine oxidase inhibitors, lipid peroxidation inhibitors, and sodium channel modulators, and the production thereof, and use thereof as medicaments
INVENTOR(S): Chabrier de Lassaunier, Pierre-Etienne; Harnett, Jeremiah; Bigg, Dennis; Pommier, Jacques; Lannoy, Jacques; Liberatore, Anne-Marie; Thureau, Christophe
PATENT ASSIGNEE(S): Societe de Conseil de Recherches et d'Applications Scientifiques (S.C.R.A.S., Fr.
SOURCE: PCT Int. Appl., 261 pp.



AB The invention relates to pharmaceutical use of heterocyclic compds. of general formula Het(A)(B)-(CH₂)_n-CR₁R₂-Q [I; wherein the substituted heterocyclic ring Het(A)(B) = Q1-Q4; A = various aryl or heteroaryl systems, especially a substituted Ph or biphenyl radical, or also alkyl, cycloalkyl, or cycloalkylalkyl; B = especially H or alkyl, or also aryl or substituted alkyl; X = especially NH or S, or also substituted NH; Y = O or S; n = 0-6; R₁, R₂ = especially H, alkyl, or cycloalkyl; Q = NR₃R₄ or OR₅; R₃ and R₄ = especially H, alkyl, cycloalkyl, alkynyl, cyanoalkyl, alkoxyalkyl, aralkoxyalkyl or (cycloalkyl)alkoxyalkyl; R₅ = H, alkyl, alkynyl, or cyanoalkyl]. I and their racemates, enantiomers, and/or salts can be used for producing medicaments for inhibiting monoamine oxidases (MAO), inhibiting lipid peroxidn., and/or for acting as modulators of sodium channels. The resulting medicaments are particularly for use in treating Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression, psychosis, pain and epilepsy. Approx. 350 synthetic examples of I and their salts are given, and numerous free bases of I are claimed. For instance, protection of sarcosinamide-HCl with BOC anhydride gave 72% BOC-N(Me)CH₂CONH₂, which was converted to the thioamide with (P2S5)₂ in 65% yield. Cyclocondensation of the thioamide with 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (28%), followed by deprotection (73%) and salification (92%), gave thiazole derivative II as the HCl salt. II inhibited binding of the MAO-B specific ligand [3H]-Ro-19-6327 to rat mitochondrial preps. with IC₅₀ < 10 μM. Selected I also inhibited formation of malondialdehyde by lipid peroxidn. in rat cerebral cortex preps., and inhibited specific binding of [3H]-batrachotoxin to voltage-dependent sodium channels in rat cerebral cortex homogenates.

IT 252302-96-8P, (1R)-N-Benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335244-94-5P, (R,S)-tert-Butyl [1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl]carbamate 335246-82-7P, (R,S)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


DOCUMENT TYPE: CODEN: PIXXD2
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 2 French
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
CA 2388505	AA	20010419	CA 2000-2388505	20001010
BR 2000014649	A	20020618	BR 2000-14649	20001010
EP 1223933	A2	20020724	EP 2000-967988	20001010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511416	T2	20030325	JP 2001-529718	20001010
NZ 518304	A	20040730	NZ 2000-518304	20001010
NO 2002001689	A	20020530	NO 2002-1689	20020410
US 2004132788	A1	20040708	US 2003-681002	20031008
PRIORITY APPLN. INFO.:				
			FR 1999-12643	A 19991011
			FR 2000-10151	A 20000801
			FR 2000-11169	A 20000901
			EP 2000-967988	A3 20001010
			EP 2002-76763	A3 20001010
			WO 2000-FR2805	W 20001010
			JP 1989-4943	A 20010410
			JP 1990-1811	A 20020214
			US 2002-89993	A2 20020404


OTHER SOURCE(S): MARPAT 134:311210
GI

(drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
RN 252302-96-8 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-94-5 CAPLUS
CN Carbamic acid, [1-(4-(3-bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335246-82-7 CAPLUS
CN 1H-Indazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




IT 252279-09-7, (1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335246-59-8, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)heptylamine 335246-68-9, N-Benzyl[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]methanamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-59-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335246-68-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-{1,1'-biphenyl}-4-yl-N-(phenylmethyl)- (9CI)
(CA INDEX NAME)



IT 252309-65-2P, (1S)-N-Benzyl-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 280775-44-2P, N-Benzyl(4-phenyl-1H-imidazol-2-yl)methanamine 335242-80-3P, 4-[3,5-Bis(1,1'-dimethylethyl)-4-hydroxyphenyl]-N-methyl-1H-imidazole-2-methanamine 335242-92-7P, N-[(S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335242-94-9P, N-[1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-5-methylhexyl]-N-(cyclohexyl)amine 335242-95-0P, N-[1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]heptyl]cyclohexanamine 335242-98-3P, N-Benzyl-N-[[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]methyl]-1-hexanamine 335242-99-4P, N-Benzyl[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-N-methylmethanamine 335243-00-0P, (R,S)-N,N-Dihexyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-01-1P, N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-pyrimidinamine 335243-03-3P, (1R)-N-Benzyl-2-(1H-indol-3-yl)-N-methyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-04-4P, (1R)-2-(1H-Indol-3-yl)-N-(2-phenylethyl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-05-5P, (1R)-N-Benzyl-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-07-7P, (4-Phenyl-1H-imidazol-2-yl)methanamine hydrochloride 335243-09-9P, N-[(1S)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-hexanamine hydrochloride 335243-10-2P, (R,S)-tert-Butyl[1-(4-phenyl-1H-imidazol-2-yl)heptyl]carbamate 335243-12-4P, (1S)-3-Methyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine hydrochloride 335243-14-6P, (R,S)-N-[2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-butanamine 335243-15-7P, (R,S)-4-[2-[1-[(tert-Butoxycarbonyl)amino]pentyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335243-16-8P, (R,S)-N-Benzyl-1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-1-pentanamine 335243-19-1P, (R,S)-tert-Butyl[1-(4-phenyl-1H-imidazol-2-yl)hexyl]carbamate 335243-20-4P, (R,S)-N-Hexyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-21-5P, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)hexylamine

yl)ethanamine 335243-85-1P, (1R)-N-Benzyl-3-phenyl-1-(4-phenyl-1H-imidazol-2-yl)-1-propanamine 335243-86-2P, (R,S)-N-[5,5,5-Trifluoro-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]pentyl]cyclohexanamine 335243-87-3P, 4-[2-[(tert-Butoxycarbonyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335243-88-4P, N-[(S)-Cyclohexyl[4-(4-methylsulfonylphenyl)-1H-imidazol-2-yl]methyl]cyclohexanamine 335243-91-9P, [4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]methanamine hydrochloride 335243-92-0P, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)heptylamine hydrochloride 335243-94-2P, N,N-Dibenzyl[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]methanamine 335243-95-3P, (R,S)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335244-02-5P, 4-[2-[(tert-Butoxycarbonyl)(methyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-04-7P, 4-[2-[(1R)-1-[(tert-Butoxycarbonyl)amino]-2-cyclohexylethyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-11-6P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-2-cyclohexylethanamine hydrochloride 335244-12-7P, [4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-N-methylmethanamine hydrochloride 335244-26-3P, 4-[2-[(Benzyl)(tert-butoxycarbonyl)amino]methyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-27-4P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-3-phenyl-1-propanamine hydrochloride 335244-28-5P, 4-[2-[(1R)-1-[(tert-Butoxycarbonyl)amino]-3-phenylpropyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-29-6P, N-Benzyl[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]methanamine hydrochloride 335244-30-9P, (1R)-N-Benzyl-1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-2-cyclohexylethanamine 335244-31-0P, (1R)-N-Benzyl-1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-3-phenyl-1-propanamine 335244-35-4P, (R,S)-tert-Butyl[1-(4-phenyl-1H-imidazol-2-yl)pentyl]carbamate 335244-36-5P, (R,S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-pentanamine hydrochloride 335244-42-3P, (R,S)-1-(4-Phenyl-1H-imidazol-2-yl)pentylamine hydrochloride 335244-43-4P, (R,S)-tert-Butyl[1-[4-(4-methylphenyl)-1H-imidazol-2-yl]heptyl]carbamate 335244-44-5P, (R,S)-tert-Butyl[1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]heptyl]carbamate 335244-45-6P, (R,S)-1-[4-(4-Methylphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-46-7P, (R,S)-1-[4-(2-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335244-47-8P, (R,S)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1-pentanamine 335244-48-9P, (R,S)-tert-Butyl[1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)heptyl]carbamate 335244-49-0P, (R,S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-50-3P, (R,S)-tert-Butyl[1-[4-(3-bromophenyl)-1H-imidazol-2-yl]heptyl]carbamate 335244-51-4P, (R,S)-1-[4-(4-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335244-52-5P, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-53-6P, (R,S)-4-[2-[1-[(tert-Butoxycarbonyl)amino]heptyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-55-8P, (R,S)-N-Benzyl-1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-1-heptanamine acetate 335244-56-9P, 4-[2-[(1S)-1-[(tert-Butoxycarbonyl)amino]propyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-57-0P, (R,S)-N-Benzyl-1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-1-heptanamine 335244-58-1P, (1S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-propanamine hydrochloride 335244-60-5P, (1S)-N-Benzyl-1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-1-propanamine 335244-62-7P, (R,S)-N-Benzyl-1-[4-(4-methylphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-63-8P, (R,S)-N-Benzyl-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine 335244-64-9P, (R,S)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1-hexanamine 335244-67-2P, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]benzonitrile hydrochloride 335244-68-3P, (R,S)-1-[4-(4-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335244-69-4P, (1R)-tert-Butyl[1-(4-phenyl-1H-imidazol-2-yl)butyl]carbamate 335244-70-7P, 4-[2-[(1R)-1-[(tert-Butoxycarbonyl)amino]butyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335244-71-8P, (1R)-1-[4-[1,1'-


hydrochloride 335243-22-6P, (R,S)-N-Benzyl-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335243-23-7P, (R,S)-N-(2,6-Dichlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-24-8P, (R,S)-N-(4-Chlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-25-9P, (R,S)-1-[4-(3-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine hydrochloride 335243-26-0P, (R,S)-N-(2-Chlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-27-1P, (R,S)-N-(2-Fluorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-28-2P, (R,S)-N-Butyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-29-3P, (R,S)-N-Isopentyl-N-[1-(4-phenyl-1H-imidazol-2-yl)heptyl]amine 335243-30-6P, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-N-hexyl-1-heptanamine 335243-31-7P, (R,S)-N-Pentyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335243-32-8P, (R,S)-N-[1-(4-Phenyl-1H-imidazol-2-yl)heptyl]cyclohexanamine 335243-33-9P, (R,S)-N-Benzyl-1-[4-(3,4-dichlorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335243-34-0P, Butyl[[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]methyl]carbamate 335243-35-1P, (R,S)-N-[1-(4-Phenyl-1H-imidazol-2-yl)heptyl]cyclopentanamine 335243-36-2P, (S)-Cyclohexyl[4-(phenyl-1H-imidazol-2-yl)methyl]amine hydrochloride 335243-37-3P, (R,S)-N-[1-(4-(2-Chlorophenyl)-1H-imidazol-2-yl)heptyl]cyclohexanamine hydrochloride 335243-39-5P, (S)-N-[(Cyclohexyl)(4-phenyl-1H-imidazol-2-yl)methyl]cyclobutanamine hydrochloride 335243-40-8P, (R,S)-N-[1-(4-(4-Fluorophenyl)-1H-imidazol-2-yl)heptyl]cyclobutanamine hydrochloride 335243-41-9P, N-[(S)-Cyclohexyl[4-(3-fluoro-4-methoxyphenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335243-42-0P, N-[(S)-Cyclohexyl[4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335243-43-1P, N-[(S)-Cyclohexyl[4-(3-fluorophenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335243-46-4P, (R,S)-2-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-47-5P, (R,S)-2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride 335243-50-0P, (1R)-tert-Butyl[2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 335243-51-1P, (1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-52-2P, N-[(1R)-2-(1H-Indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]benzamide 335243-53-3P, (1R)-Benzyl[2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 335243-56-6P, (1R)-tert-Butyl[2-(1H-indol-3-yl)-1-(4-(4-nitrophenyl)-1H-imidazol-2-yl)ethyl]carbamate 335243-57-7P, tert-Butyl[[4-phenyl-1H-imidazol-2-yl]methyl]carbamate 335243-59-9P, (R,S)-N-Benzyl-2-(6-fluoro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-60-2P, (1R)-2-(1H-Indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine hydrochloride 335243-62-4P, (1R)-2-(1H-Indol-3-yl)-N-(2-phenoxyethyl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-65-7P, (1R)-2-(1-Benzothien-3-yl)-N-benzyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335243-68-0P, (R,S)-tert-Butyl[2-(6-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 335243-72-6P, (R,S)-2-(6-Chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine hydrochloride 335243-74-8P, (1R)-tert-Butyl[3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]carbamate 335243-75-9P, (1R)-N-Benzyl-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine 335243-76-0P, (R,S)-tert-Butyl[phenyl(4-phenyl-1H-imidazol-2-yl)methyl]carbamate 335243-78-2P, (R,S)-Phenyl[4-(phenyl-1H-imidazol-2-yl)methyl]amine hydrochloride 335243-79-3P, (1R)-tert-Butyl[3-phenyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]carbamate 335243-80-6P, (1R)-tert-Butyl[2-cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]carbamate 335243-81-7P, (1R)-3-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)-1-propanamine hydrochloride 335243-82-8P, (1R)-2-Cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335243-83-9P, (R,S)-N-Benzyl(phenyl)(4-phenyl-1H-imidazol-2-yl)methanamine 335243-84-0P, (1R)-N-Benzyl-2-cyclohexyl-1-(4-phenyl-1H-imidazol-2-

Biphenyl]-4-yl-1H-imidazol-2-yl)-1-butanamine hydrochloride 335244-72-9P, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-2,6-di(tert-butyl)phenol hydrochloride 335244-73-0P, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)-1-butanamine hydrochloride 335244-74-1P, (R,S)-N-Benzyl-1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335244-75-2P, (1R)-N-Benzyl-1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]-1-butanamine 335244-76-3P, (1R)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine 335244-77-4P, (R,S)-N-(3-Chlorobenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335244-78-5P, (R,S)-N-Benzyl-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine 335244-79-6P, (R,S)-4-[2-[1-(Benzylamino)heptyl]-1H-imidazol-4-yl]benzonitrile 335244-80-9P, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335244-81-0P, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)ethanamine hydrochloride 335244-82-1P, (R,S)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-83-2P, (R,S)-1-[4-(2-Chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-84-3P, N-[(1S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]propyl]-1-butanamine 335244-85-4P, (1R)-N-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335244-86-5P, (R,S)-N-[1-(4-Phenyl-1H-imidazol-2-yl)heptyl]-N-propylamine 335244-87-6P, (R,S)-N-Benzyl-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-88-7P, (R,S)-4-[2-[1-(Benzylamino)heptyl]-1H-imidazol-4-yl]benzonitrile hydrochloride 335244-89-8P, (R,S)-N-(4-Methoxybenzyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335244-90-1P, (R,S)-N-Benzyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-91-2P, (R,S)-N-Benzyl-1-[4-(2-chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-92-3P, (R,S)-N-Benzyl-N-[1-[4-(4-diethylamino)phenyl]-1H-imidazol-2-yl]heptyl]amine hydrochloride 335244-93-4P, (R,S)-1-[4-(3,4-Dichlorophenyl)-1H-imidazol-2-yl]-1-heptanamine hydrochloride 335244-95-6P, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine hydrochloride 335244-97-8P, (R,S)-N-Isobutyl-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine acetate 335244-98-9P, (R,S)-N-Benzyl-1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine 335244-99-0P, (R,S)-N-Benzyl-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-1-heptanamine 335245-03-9P, (R,S)-N-[1-(4-Phenyl-1H-imidazol-2-yl)heptyl]cyclobutanamine 335245-04-0P, 4-[2-[(1S)-1-[(Butoxycarbonyl)amino]ethyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335245-05-1P, 4-[2-[(1R)-1-[(Butoxycarbonyl)amino]ethyl]-1H-imidazol-4-yl]-1,1'-biphenyl 335245-06-2P, N-[(S)-Cyclohexyl[4-phenyl-1H-imidazol-2-yl]methyl]cyclohexanamine 335245-11-9P, (R,S)-N-Isopropyl-N-[1-(4-phenyl-1H-imidazol-2-yl)heptyl]amine 335245-13-1P, (R,S)-N-[1-[4-(3,4-Dichlorophenyl)-1H-imidazol-2-yl]heptyl]cyclohexanamine hydrochloride 335245-16-4P, (R,S)-N-[1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]heptyl]cyclohexanamine hydrochloride 335245-17-5P, (R,S)-2-(5-Fluoro-1H-indol-3-yl)-1-(4-(4-fluorophenyl)-1H-imidazol-2-yl)ethylamine hydrochloride 335245-18-6P, N-[(4-(3-Bromophenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335245-20-0P, (R,S)-N-[2-(5-Fluoro-1H-indol-3-yl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethyl]cyclobutanamine hydrochloride 335245-21-1P, (R,S)-N-[1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-4-methylpentyl]cyclohexanamine hydrochloride 335245-22-2P, (S)-Cyclohexyl[4-(3,4-difluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-23-3P, (S)-Cyclohexyl[4-(3-fluoro-4-methoxyphenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-24-4P, (R,S)-Cyclopropyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-25-5P, N-[(S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-2-propanamine 335245-26-6P, N-[(S)-Cyclohexyl[4-(3,4-difluorophenyl)-1H-imidazol-2-yl]methyl]cyclobutanamine 335245-27-7P, (R,S)-N-(Cyclohexylmethyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine hydrochloride 335245-28-8P, N-[(S)-Cyclohexyl[4-(4-fluorophenyl)-


1H-imidazol-2-yl)methyl]cyclohexanamine hydrochloride 335245-29-9P
 (S)-Cyclohexyl-N-(cyclohexylmethyl)(4-phenyl-1H-imidazol-2-yl)methanamine hydrochloride 335245-30-2P, (R,S)-N-[Cyclopropyl[4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine hydrochloride 335245-31-3P, (S)-Cyclohexyl-N-(cyclopropylmethyl)(4-phenyl-1H-imidazol-2-yl)methanamine hydrochloride 335245-34-6P, N-[(S)-Cyclohexyl[4-(4-(trifluoromethoxy)phenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine 335245-36-8P, (R,S)-N-[1-(4-(3-Bromophenyl)-1H-imidazol-2-yl)-5-methylhexyl]cyclohexanamine hydrochloride 335245-37-9P, (S)-Cyclohexyl-N-(cyclopropylmethyl)[4-(4-fluorophenyl)-1H-imidazol-2-yl)methanamine hydrochloride 335245-38-0P, (R,S)-N-[Cyclopentyl[4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine 335245-39-1P, N-[(S)-Cyclohexyl[4-(4-cyclohexylphenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine hydrochloride 335245-40-4P, N-[(1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-methylpropyl]cyclohexanamine 335245-41-5P, N-[(S)-Cyclohexyl[4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine acetate 335245-46-0P, N-[(S)-Cyclohexyl[4-(4-(methylthio)phenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335245-47-1P, N-[(S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335245-48-2P, N-[(S)-[4-[3,5-Bis(trifluoromethyl)phenyl]-1H-imidazol-2-yl](cyclohexyl)methyl]cyclohexanamine 335245-51-7P, N-[(S)-Cyclohexyl[4-(3,4-difluorophenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335245-53-9P, (S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-cyclohexyl-N-(cyclohexylmethyl)methanamine 335245-54-0P, 4-[2-[(S)-Cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335245-55-1P, 2,6-Di-tert-butyl-4-[2-[(S)-cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]phenol hydrochloride 335245-56-2P, 4-[2-[(S)-Cyclohexyl[(cyclohexylamino)methyl]-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335245-57-3P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine 335245-59-5P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-60-8P, N-[(S)-Cyclohexyl[4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine hydrochloride 335245-61-9P, N-[(S)-[4-(3-Bromophenyl)-1H-imidazol-2-yl](cyclohexyl)methyl]cyclohexanamine hydrochloride 335245-62-0P, N-[(S)-Cyclohexyl[4-(4-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335245-65-3P, N-[(S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl]cycloheptanamine 335245-68-6P, N-[(S)-Cyclohexyl[4-(3-(trifluoromethyl)phenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335245-69-7P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-(trifluoromethyl)phenyl)-1H-imidazol-2-yl]methanamine 335245-70-0P, (S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-cyclohexyl-N-(cyclohexylmethyl)methanamine hydrochloride 335245-71-1P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-(trifluoromethyl)phenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-72-2P, (1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethanamine hydrochloride 335245-73-3P, N-[(1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethyl]cyclohexanamine 335245-74-4P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-N,N-diethylaniline hydrochloride 335245-75-5P, (S)-1-Cyclohexyl-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-76-6P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl]methanamine hydrochloride 335245-78-8P, N-[(S)-Cyclohexyl[4-(3-fluorophenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine hydrochloride 335245-79-9P, N-[(1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethyl]cyclohexanamine hydrochloride 335245-80-2P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-2,6-di-tert-butylphenol hydrochloride 335245-82-4P, (R)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine

hydrochloride 335245-88-0P
 (1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine hydrochloride 335245-91-5P, N-[(1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethyl]cyclohexanamine hydrochloride 335245-92-6P, (1R)-N-(Cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine hydrochloride 335246-24-7P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-2,6-di-tert-butylphenol 335246-43-0P, (S)-Cyclohexyl[4-(phenyl-1H-imidazol-2-yl)methyl]amine 335246-46-3P, N-[(S)-Cyclohexyl[4-(phenyl-1H-imidazol-2-yl)methyl]cyclobutanamine 335246-57-6P, (1R)-2-Cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335246-94-1P, (S)-Cyclohexyl[4-(3,4-difluorophenyl)-1H-imidazol-2-yl]methanamine 335246-95-2P, (S)-Cyclohexyl[4-(3-fluoro-4-methoxyphenyl)-1H-imidazol-2-yl]methanamine 335246-96-3P, (R,S)-Cyclopropyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine 335246-98-5P, (S)-Cyclohexyl-N-(cyclohexylmethyl)(4-phenyl-1H-imidazol-2-yl)methanamine 335246-99-6P, (R,S)-N-[Cyclopropyl[4-(4-fluorophenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335247-00-2P, (S)-Cyclohexyl-N-(cyclopropylmethyl)(4-phenyl-1H-imidazol-2-yl)methanamine 335247-01-3P, (S)-Cyclohexyl-N-(cyclopropylmethyl)[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine 335247-02-4P, N-[(S)-Cyclohexyl[4-(4-cyclohexylphenyl)-1H-imidazol-2-yl)methyl]cyclobutanamine 335247-04-6P, 4-[2-[(S)-Cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]-N,N-diethylaniline 335247-05-7P, 2,6-Di-tert-butyl-4-[2-[(S)-cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]phenol 335247-06-8P, 4-[2-[(S)-Cyclohexyl[(cyclohexylamino)methyl]-1H-imidazol-4-yl]-N,N-diethylaniline 335247-07-9P, N-[(S)-[4-(3-Bromophenyl)-1H-imidazol-2-yl](cyclohexyl)methyl]cyclohexanamine 335247-08-0P, (1R)-2-Cyclohexyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethanamine 335247-09-1P, 4-[2-[(S)-Amino(cyclohexyl)methyl]-1H-imidazol-4-yl]-N,N-diethylaniline 335247-10-4P, (S)-1-Cyclohexyl-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl]methanamine 335247-11-5P, (S)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(3-fluorophenyl)-1H-imidazol-2-yl]methanamine 335247-12-6P, N-[(S)-Cyclohexyl[4-(3-fluorophenyl)-1H-imidazol-2-yl)methyl]cyclohexanamine 335247-13-7P, (R)-1-Cyclohexyl-N-(cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine 335247-14-8P, (1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine 335247-17-1P, (1R)-N-(Cyclohexylmethyl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-2-phenylethanamine 335247-20-6P, (1R)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-2-cyclohexylethanamine 335247-25-1P, N-[(R)-[4-[3,5-Bis(trifluoromethyl)phenyl]-1H-imidazol-2-yl](cyclohexyl)methyl]cyclohexanamine
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxid. inhibitors, and sodium channel modulators)
 RN 252309-65-2 CAPLUS
 CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 280775-44-2 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335242-80-3 CAPLUS
 CN Phenol, 2,6-bis[1,1-dimethylethyl]-4-[2-[(methylamino)methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335242-92-7 CAPLUS
 CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(4-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335242-94-9 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl-α-(4-methylpentyl)- (9CI) (CA INDEX NAME)




RN 335242-95-0 CAPLUS
 CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)


RN 335242-98-3 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335242-99-4 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-00-0 CAPLUS
 CN 1H-Imidazole-2-methanamine, N,N,α-trihexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-01-1 CAPLUS
 CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-2-pyrimidinyl-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-03-3 CAPLUS

CN 1H-Indole-3-ethanamine, N-methyl- α -(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-04-4 CAPLUS

CN 1H-Indole-3-ethanamine, N-(2-phenylethyl)- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-05-5 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-phenyl-N, α -bis(phenylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-07-7 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335243-09-9 CAPLUS

CN 1H-Indole-3-ethanamine, N-hexyl- α -(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)




RN 335243-16-8 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -butyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-19-1 CAPLUS

CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)hexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-20-4 CAPLUS

CN 1H-Imidazole-2-methanamine, N, α -dihexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-21-5 CAPLUS

CN 1H-Imidazole-2-methanamine, α -pentyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


Absolute stereochemistry.



●x HCl

RN 335243-10-2 CAPLUS


CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-12-4 CAPLUS

CN 1H-Imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335243-14-6 CAPLUS


CN 1H-Indole-3-ethanamine, N-butyl-1-methyl- α -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 335243-15-7 CAPLUS

CN Carbamic acid, [1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 335243-22-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335243-23-7 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[(2,6-dichlorophenyl)methyl]- α -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-24-8 CAPLUS

CN 1H-Imidazole-2-methanamine, N-[(4-chlorophenyl)methyl]- α -hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-25-9 CAPLUS


CN 1H-Imidazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-26-0 CAPLUS


CN 1H-Imidazole-2-methanamine, N-[(2-chlorophenyl)methyl]- α -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-27-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-((2-fluorophenyl)methyl)-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-28-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N-butyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-29-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-N-(3-methylbutyl)-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-30-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N,α-dihexyl- (9CI) (CA INDEX NAME)




RN 335243-31-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-N-pentyl-4-phenyl- (9CI) (CA INDEX NAME)



●x HCl


RN 335243-37-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335243-39-5 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-phenyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl


RN 335243-40-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-4-(4-fluorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 335243-32-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335243-33-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-34-0 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]-, butyl ester (9CI) (CA INDEX NAME)




RN 335243-35-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclopentyl-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 335243-36-2 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-phenyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335243-41-9 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-42-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-[4-(trifluoromethyl)phenyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-43-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-(3-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-46-4 CAPLUS
CN 1H-Indazole-2-methanamine, 4-phenyl-α-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335243-47-5 CAPLUS
CN 1H-Indole-3-ethanamine, 1-methyl-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-50-0 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335243-51-1 CAPLUS



RN 335243-57-7 CAPLUS
CN Carbamic acid, [(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-59-9 CAPLUS
CN 1H-Indole-3-ethanamine, 6-fluoro-α-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-60-2 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335243-62-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-(2-phenoxyethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335243-52-2 CAPLUS
CN Benzamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-53-3 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-56-6 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-(4-nitrophenyl)-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-65-7 CAPLUS
CN 1H-Indazole-2-methanamine, α-(benzo[b]thien-3-ylmethyl)-4-phenyl-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-68-0 CAPLUS
CN Carbamic acid, [2-(6-chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-72-6 CAPLUS
CN 1H-Indole-3-ethanamine, 6-chloro-α-(4-phenyl-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335243-74-8 CAPLUS
CN Carbamic acid, [(1R)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-75-9 CAPLUS
CN 1H-imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-N-(phenylmethyl)-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-76-0 CAPLUS
CN Carbamic acid, [phenyl(4-phenyl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335243-78-2 CAPLUS
CN 1H-imidazole-2-methanamine, α ,4-diphenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-79-3 CAPLUS
CN Carbamic acid, [(1R)-3-phenyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

RN 335243-83-9 CAPLUS
CN 1H-imidazole-2-methanamine, α ,4-diphenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335243-84-0 CAPLUS
CN 1H-imidazole-2-methanamine, α -(cyclohexylmethyl)-4-phenyl-N-(phenylmethyl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-85-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4-phenyl- α -(2-phenylethyl)-N-(phenylmethyl)-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-86-2 CAPLUS
CN 1H-imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- α -(4,4,4-trifluorobutyl)- (9CI) (CA INDEX NAME)




RN 335243-87-3 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335243-80-6 CAPLUS
CN Carbamic acid, [(1R)-2-cyclohexyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335243-81-7 CAPLUS
CN 1H-imidazole-2-methanamine, 4-phenyl- α -(2-phenylethyl)-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




●x HCl

RN 335243-82-8 CAPLUS
CN 1H-imidazole-2-methanamine, α -(cyclohexylmethyl)-4-phenyl-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl




RN 335243-88-4 CAPLUS
CN 1H-imidazole-2-methanamine, N, α -dicyclohexyl-4-[4-(methylsulfonyl)phenyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-91-9 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335243-92-0 CAPLUS
CN 1H-imidazole-2-methanamine, α -hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335243-94-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N,N-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-95-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-phenyl-N-(phenylmethyl)- (9CI)
(CA INDEX NAME)




RN 335244-02-5 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-04-7 CAPLUS
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)-2-cyclohexylethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-11-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(cyclohexylmethyl)-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-12-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-26-3 CAPLUS
CN Carbamic acid, [(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)methyl)methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-27-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(2-phenylethyl)-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




●x HCl

RN 335244-28-5 CAPLUS
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)-3-phenylpropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-29-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-30-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(cyclohexylmethyl)-N-(phenylmethyl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-31-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(2-phenylethyl)-N-(phenylmethyl)-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-35-4 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-36-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -butyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-42-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -butyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335244-43-4 CAPLUS
CN Carbamic acid, [1-[4-(4-methylphenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-44-5 CAPLUS
CN Carbamic acid, [1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-45-6 CAPLUS
CN 1H-imidazole-2-methanamine, α -hexyl-4-(4-methylphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-46-7 CAPLUS
CN 1H-imidazole-2-methanamine, α -hexyl-4-(2-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-47-8 CAPLUS
CN 1H-imidazole-2-methanamine, α -butyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-48-9 CAPLUS
CN Carbamic acid, [1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



●x HCl


RN 335244-53-6 CAPLUS
CN Carbamic acid, [1-[4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 335244-55-8 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)- α -hexyl-N-(phenylmethyl)-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 335244-54-7
CMF C23 H28 Br N3




CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 335244-56-9 CAPLUS
CN Carbamic acid, [(1S)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-49-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-50-3 CAPLUS
CN Carbamic acid, [1-[4-(3-bromophenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 335244-51-4 CAPLUS
CN 1H-imidazole-2-methanamine, α -hexyl-4-(4-methoxyphenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-52-5 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(3-bromophenyl)- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 335244-57-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-58-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -ethyl-, hydrochloride, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




●x HCl

RN 335244-60-5 CAPLUS
CN 1H-imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -ethyl-N-(phenylmethyl)-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-62-7 CAPLUS
CN 1H-imidazole-2-methanamine, α -hexyl-4-(4-methylphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 335244-63-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(2-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-64-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -pentyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335244-67-2 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-68-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)- α -hexyl- (9CI) (CA INDEX NAME)




RN 335244-69-4 CAPLUS



●x HCl


RN 335244-73-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -propyl-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-74-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-bromophenyl)- α -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-75-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-(phenylmethyl)- α -propyl-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-76-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)- α -propyl-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CN Carbamic acid, [(1R)-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-70-7 CAPLUS
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335244-71-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -propyl-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl


RN 335244-72-9 CAPLUS
CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)




RN 335244-77-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-[(3-chlorophenyl)methyl]- α -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335244-78-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-79-6 CAPLUS
CN Benzonitrile, 4-[2-[1-[(phenylmethyl)amino]heptyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335244-80-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-81-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -methyl-4-phenyl-, hydrochloride, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335244-82-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-83-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-84-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(1,1'-biphenyl)-4-yl-N-butyl-N-ethyl-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-85-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-methyl-4-phenyl-N-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)




RN 335244-90-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-91-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-α-hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335244-92-3 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]-α-hexyl-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-93-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)-α-hexyl-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-86-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-phenyl-N-propyl-, (9CI) (CA INDEX NAME)




RN 335244-87-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-4-(3-methoxyphenyl)-N-(phenylmethyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-88-7 CAPLUS
CN Benzonitrile, 4-[2-{1-[(phenylmethyl)amino]heptyl}-1H-imidazol-4-yl]-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-89-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-N-[(4-methoxyphenyl)methyl]-4-phenyl-, (9CI) (CA INDEX NAME)



●x HCl

RN 335244-95-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335244-97-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-hexyl-N-(2-methylpropyl)-4-phenyl-, acetate (9CI) (CA INDEX NAME)


CM 1

CRN 335244-96-7
CMF C20 H31 N3




CM 2


CRN 64-19-7
CMF C2 H4 O2




RN 335244-98-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335244-99-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methoxyphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335245-03-9 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335245-04-0 CAPLUS
CN Carbamic acid, [(1S)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-05-1 CAPLUS
CN Carbamic acid, [(1R)-1-(4-[1,1'-biphenyl]-4-yl-1H-imidazol-2-yl)ethyl]-, butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-06-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N- α -dicyclohexyl-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-11-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-N-(1-methylethyl)-4-phenyl- (9CI) (CA INDEX NAME)




RN 335245-13-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-16-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-cyclohexyl- α -hexyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-17-5 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro- α -(4-(4-fluorophenyl)-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-18-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl- (9CI) (CA INDEX NAME)




RN 335245-20-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-cyclobutyl-5-fluoro- α -(4-(4-fluorophenyl)-1H-imidazol-2-yl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335245-21-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- α -(3-methylbutyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335245-22-2 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-(3,4-difluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-23-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●x HCl


RN 335245-24-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclopropyl-4-(4-fluorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl


RN 335245-25-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-(4-fluorophenyl)-N-(1-methylethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-26-6 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -cyclohexyl-4-(3,4-difluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-27-7 CAPLUS
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)- α -hexyl-4-phenyl-, hydrochloride (9CI) (CA INDEX NAME)



●x HCl

RN 335245-28-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N, α -dicyclohexyl-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




●x HCl

RN 335245-34-6 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -cyclohexyl-4-(4-(trifluoromethoxy)phenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-36-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N-cyclohexyl- α -(4-methylpentyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-37-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclopropylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



●x HCl


RN 335245-29-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclohexylmethyl)-4-phenyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-30-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl- α -cyclopropyl-4-(4-fluorophenyl)-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 335245-31-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclopropylmethyl)-4-phenyl-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)




●x HCl

RN 335245-38-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -cyclopentyl-4-(4-fluorophenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)



RN 335245-39-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -cyclohexyl-4-(4-cyclohexylphenyl)-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-40-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)- α -(1-methylethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-41-5 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-[4-(trifluoromethyl)phenyl]-, (aS)-, acetate (9CI) (CA INDEX NAME)

CM 1


CRN 335243-42-0
CMF C21 H26 F3 N3

Absolute stereochemistry.




CM 2

CRN 64-19-7
CMF C2 H4 O2




RN 335245-46-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[4-(methylthio)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-47-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)



RN 335245-54-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[4-(diethylamino)phenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-55-1 CAPLUS
CN Phenol, 4-[2-[(1S)-cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-56-2 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[4-(diethylamino)phenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


(aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-48-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[3,5-bis(trifluoromethyl)phenyl]-N,α-dicyclohexyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335245-51-7 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-(3,4-difluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-53-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N,α-dicyclohexyl-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-57-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[4-(diethylamino)phenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-59-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[4-(diethylamino)phenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-60-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[4-(trifluoromethyl)phenyl]-, hydrochloride, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-61-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N,α-dicyclohexyl-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-62-0 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[4-(trifluoromethyl)phenyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-65-3 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cycloheptyl-α-cyclohexyl-4-(4-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-71-1 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[3-(trifluoromethyl)phenyl]-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 335245-72-2 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-73-3 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, (αR)- (9CI) (CA INDEX NAME)




RN 335245-68-6 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-[3-(trifluoromethyl)phenyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335245-69-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-[3-(trifluoromethyl)phenyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335245-70-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-cyclohexyl-N-(cyclohexylmethyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.



RN 335245-74-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-[4-(diethylamino)phenyl]-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-75-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(3-fluorophenyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-76-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(3-fluorophenyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-78-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-(3-fluorophenyl)-, hydrochloride, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-79-9 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-α-(cyclohexylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-80-2 CAPLUS
CN Phenol, 4-[2-[(S)-aminocyclohexylmethyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-92-6 CAPLUS
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-4-(4-fluorophenyl)-α-(phenylmethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335246-24-7 CAPLUS
CN Phenol, 4-[2-[(S)-aminocyclohexylmethyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335246-43-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Absolute stereochemistry.



●x HCl

RN 335245-82-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl

RN 335245-88-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-(phenylmethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 335245-91-5 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(phenylmethyl)-, hydrochloride, (αR)- (9CI) (CA INDEX NAME)


RN 335246-46-3 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl-α-cyclohexyl-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-57-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(cyclohexylmethyl)-4-phenyl-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-94-1 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(3,4-difluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-95-2 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(3-fluoro-4-methoxyphenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-96-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclopropyl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 335246-98-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclohexylmethyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-99-6 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl- α -cyclopropyl-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 335247-00-2 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclopropylmethyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-05-7 CAPLUS
CN Phenol, 4-[2-[(S)-cyclohexyl[(cyclohexylmethyl)amino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-06-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N, α -dicyclohexyl-4-[4-(diethylamino)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-07-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-N, α -dicyclohexyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-01-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclopropylmethyl)-4-(4-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-02-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclobutyl- α -cyclohexyl-4-(4-cyclohexylphenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-04-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclohexylmethyl)-4-[4-(diethylamino)phenyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-08-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -(cyclohexylmethyl)-4-(4-fluorophenyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-09-1 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-(4-(diethylamino)phenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-10-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-11-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -cyclohexyl-N-(cyclohexylmethyl)-4-(3-fluorophenyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-12-6 CAPLUS
CN 1H-Imidazole-2-methanamine, N,α-dicyclohexyl-4-(3-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-13-7 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-N-(cyclohexylmethyl)-4-(4-fluorophenyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335247-14-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 335247-17-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-4-(4-fluorophenyl)-


yl)ethyl]benzenecarboximidamide 335243-71-5,
N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxybenzenecarboximidamide 335244-54-7, (R,S)-N-Benzyl-1-[4-(3-bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-20-3,
4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-(4-aminobenzoyl)-1H-imidazole-2-methanamine 335246-23-6, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-2,6-di-(tert-butyl)phenol 335246-41-8,
(R,S)-1-(4-Phenyl-1H-imidazol-2-yl)hexylamine 335246-42-9,
(R,S)-1-[4-(3-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine 335246-44-1, (R,S)-N-[1-[4-(2-Chlorophenyl)-1H-imidazol-2-yl]heptyl]cyclohexanamine 335246-47-4, (R,S)-N-[1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]heptyl]cyclobutanamine 335246-50-9,
(R,S)-2-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 335246-51-0, (R,S)-2-(1-Methyl-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine 335246-54-3, (R,S)-2-(6-Chloro-1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethylamine 335246-55-4,
(R,S)-Phenyl(4-phenyl-1H-imidazol-2-yl)methylamine 335246-56-5,
(1R)-3-Phenyl-1-(4-phenyl-1H-imidazol-2-yl)-1-propanamine 335246-58-7, [4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]methanamine 335246-67-8, (1R)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-3-phenyl-1-propanamine 335246-69-0, (R,S)-1-[4-(4-Methylphenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-70-3, (R,S)-1-[4-(2-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine 335246-71-4,
(R,S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-heptanamine 335246-72-5, (R,S)-1-[4-(4-Methoxyphenyl)-1H-imidazol-2-yl]heptylamine 335246-73-6, (R,S)-1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-74-7, (1S)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-propanamine 335246-76-9,
(R,S)-N-Benzyl-1-[4-(4-methylphenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-77-0, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]benzonitrile 335246-78-1, (1R)-1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-1-butanamine 335246-79-2, (1R)-1-(4-Phenyl-1H-imidazol-2-yl)-1-butanamine 335246-80-5, (R,S)-4-[2-(1-Aminoheptyl)-1H-imidazol-4-yl]-N,N-diethylaniline 335246-81-6,
(1R)-1-(4-Phenyl-1H-imidazol-2-yl)ethanamine 335246-83-8,
(R,S)-1-[4-(2-Chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-84-9, (R,S)-N-Benzyl-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-85-0, (R,S)-N-Benzyl-1-[4-(2-chlorophenyl)-1H-imidazol-2-yl]-1-heptanamine 335246-86-1,
(R,S)-N-Benzyl-N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]heptyl]amine 335246-87-2, (R,S)-1-(4-(3,4-Dichlorophenyl)-1H-imidazol-2-yl)heptyl]cyclohexanamine 335246-90-7, (R,S)-N-[1-[4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]heptyl]cyclohexanamine 335246-91-8, (R,S)-2-(5-Fluoro-1H-indol-3-yl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethylamine 335246-92-9, (R,S)-N-[2-(5-Fluoro-1H-indol-3-yl)-1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]ethyl]cyclobutanamine 335246-93-0,
(R,S)-N-[1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-4-methylpentyl]cyclohexanamine 335246-97-4, (R,S)-N-(Cyclohexylmethyl)-1-(4-phenyl-1H-imidazol-2-yl)-1-heptanamine 335247-16-0, N-[(1R)-1-[4-(4-Fluorophenyl)-1H-imidazol-2-yl]-2-phenylethyl]cyclohexanamine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(drug candidate; preparation of five-membered heterocycle deriva. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)

RN 167983-80-4 CAPLUS
CN 1H-Imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-20-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-α-(cyclohexylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335247-25-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[3,5-bis(trifluoromethyl)phenyl]-N,α-dicyclohexyl-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 167983-80-4, (1S)-3-Methyl-1-(4-phenyl-1H-imidazol-2-yl)-1-butanamine 175531-38-1, (4-Phenyl-1H-imidazol-2-yl)methanamine 218944-40-2, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-nitrobenzoyl)-1H-imidazole-2-methanamine 218944-41-3,
4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-aminobenzoyl)-1H-imidazole-2-methanamine 218944-66-2,
4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-nitrophenyl)-1H-imidazole-2-methanamine 218944-68-4, 4-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-N-(4-aminophenyl)-1H-imidazole-2-methanamine 252279-15-5, (1R)-2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethanamine 252301-86-3,
(R,S)-tert-Butyl [5-(benzylamino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]carbamate 252302-55-9, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-1-hexanamine 252303-16-5,
(1R)-N-(Cyclohexylmethyl)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethanamine 252306-13-1, (R,S)-N1-Benzyl-1-(4-phenyl-1H-imidazol-2-yl)-1,5-pentanediamine 335243-70-4,
N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-




RN 175531-38-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- (9CI) (CA INDEX NAME)




RN 218944-40-2 CAPLUS
CN Benzamide, N-[(4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]-N-methyl-4-nitro- (9CI) (CA INDEX NAME)



RN 218944-41-3 CAPLUS
CN Benzamide, 4-amino-N-[(4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 218944-66-2 CAPLUS
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[(methyl(4-nitrophenyl)amino)methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 218944-68-4 CAPLUS


CN Phenol, 4-[2-(((4-aminophenyl)methylamino)methyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



RN 252279-15-5 CAPLUS


CN 1H-Indole-3-ethanamine, α -[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252301-86-3 CAPLUS


CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[(phenylmethyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252302-55-9 CAPLUS

CN 1H-Indole-3-ethanamine, N-hexyl- α -(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-16-5 CAPLUS

CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- α -(4-phenyl-1H-imidazol-2-yl)-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-20-3 CAPLUS

CN Benzamide, 4-amino-N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]- (9CI) (CA INDEX NAME)




RN 335246-23-6 CAPLUS

CN Phenol, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)




RN 335246-41-8 CAPLUS

CN 1H-Imidazole-2-methanamine, α -pentyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335246-42-9 CAPLUS

CN 1H-Imidazole-2-methanamine, α -hexyl-4-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-44-1 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)-N-cyclohexyl- α -hexyl-



RN 252306-13-1 CAPLUS


CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 335243-70-4 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335243-71-5 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335244-54-7 CAPLUS


CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- α -hexyl-N-

(9CI) (CA INDEX NAME)




RN 335246-47-4 CAPLUS

CN 1H-Imidazole-2-methanamine, N-cyclobutyl-4-(4-fluorophenyl)- α -hexyl- (9CI) (CA INDEX NAME)




RN 335246-50-9 CAPLUS

CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-51-0 CAPLUS

CN 1H-Indole-3-ethanamine, 1-methyl- α -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-54-3 CAPLUS

CN 1H-Indole-3-ethanamine, 6-chloro- α -(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 335246-55-4 CAPLUS

CN 1H-Imidazole-2-methanamine, α ,4-diphenyl- (9CI) (CA INDEX NAME)




RN 335246-56-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -(2-phenylethyl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-58-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)




RN 335246-67-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -(2-phenylethyl)-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-69-0 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methylphenyl)- (9CI) (CA INDEX NAME)



RN 335246-70-3 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-77-0 CAPLUS
CN Benzonitrile, 4-[2-(1-aminoheptyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 335246-78-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -propyl-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-79-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-phenyl- α -propyl-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335246-80-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- α -hexyl- (9CI) (CA INDEX NAME)




RN 335246-81-6 CAPLUS
CN 1H-Imidazole-2-methanamine, α -methyl-4-phenyl-, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-71-4 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -hexyl- (9CI) (CA INDEX NAME)



RN 335246-72-5 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 335246-73-6 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)- α -hexyl- (9CI) (CA INDEX NAME)




RN 335246-74-7 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl- α -ethyl-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 335246-76-9 CAPLUS
CN 1H-Imidazole-2-methanamine, α -hexyl-4-(4-methylphenyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-83-8 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)- α -hexyl- (9CI) (CA INDEX NAME)




RN 335246-84-9 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-fluorophenyl)- α -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-85-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(2-chlorophenyl)- α -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-86-1 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[4-(diethylamino)phenyl]- α -hexyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 335246-87-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3,4-dichlorophenyl)- α -hexyl- (9CI) (CA INDEX NAME)




RN 335246-89-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(3,4-dichlorophenyl)-α-hexyl- (9CI) (CA INDEX NAME)




RN 335246-90-7 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro-α-[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 335246-91-8 CAPLUS
CN 1H-Indole-3-ethanamine, 5-fluoro-α-[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 335246-92-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-cyclobutyl-5-fluoro-α-[4-(4-fluorophenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 335246-93-0 CAPLUS




RN 335247-30-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α-cyclohexyl-4-(4-fluorophenyl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 335247-34-2 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(3-bromophenyl)-α-(4-methylpentyl)- (9CI) (CA INDEX NAME)




RN 335247-35-3 CAPLUS
CN Carbamic acid, [1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 335247-37-5, [4-[1,1'-Biphenyl]-4-yl-1H-imidazol-2-yl]-N-methylmethanamine
RL: RCT (Reactant); RACT (Reactant or reagent)
(precursor; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
RN 335247-37-5 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-[1,1'-biphenyl]-4-yl-N-methyl- (9CI) (CA INDEX NAME)

CN 1H-Imidazole-2-methanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(3-methylbutyl)- (9CI) (CA INDEX NAME)




RN 335246-97-4 CAPLUS
CN 1H-Imidazole-2-methanamine, N-(cyclohexylmethyl)-α-hexyl-4-phenyl- (9CI) (CA INDEX NAME)




RN 335247-16-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-cyclohexyl-4-(4-fluorophenyl)-α-(phenylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 335247-29-5P, tert-Butyl [(S)-cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]carbamate 335247-30-8P, (S)-Cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methanamine 335247-34-2P, 1-[4-(3-Bromophenyl)-1H-imidazol-2-yl]-5-methyl-1-hexanamine 335247-35-3P, tert-Butyl [1-[4-(4-fluorophenyl)-1H-imidazol-2-yl]heptyl]carbamate
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
RN 335247-29-5 CAPLUS
CN Carbamic acid, [(S)-cyclohexyl[4-(4-fluorophenyl)-1H-imidazol-2-yl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2001:279029 CAPLUS
DOCUMENT NUMBER: 135:107278
TITLE: Novel non-peptide ligands for the somatostatin est3 receptor
AUTHOR(S): Moinet, C.; Contour-Galcer, M.-O.; Poitout, L.; Morgan, B.; Gordon, T.; Roubert, P.; Thurieu, C.
CORPORATE SOURCE: ZA de Courtaboeuf, Institut Henri Beaufour, Les Ulis, F-91966, Fr.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2001), 11(8), 991-995
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A series of imidazole derivs. has been prepared using high throughput parallel synthesis. Several compds. showed high affinity (Ki in 10-6-10-8 M range) and selectivity at recombinant human somatostatin receptor subtype 3 (hst3).
IT 252279-09-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of phenylimidazolyl(indolyl)ethylamines as somatostatin receptor antagonists)
RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252308-47-7P 252309-00-5P 252309-02-7P
252309-03-8P 252309-04-9P 252309-05-0P
252309-06-1P 252309-07-2P 335243-50-0P
335243-53-3P 349668-18-4P 349668-19-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of phenylimidazolyl(indolyl)ethylamines as somatostatin receptor antagonists)
RN 252308-47-7 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-00-5 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-02-7 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-03-8 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-07-2 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HI

RN 335243-50-0 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 335243-53-3 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



● HI

RN 252309-04-9 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-05-0 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-06-1 CAPLUS

Absolute stereochemistry.



RN 349668-18-4 CAPLUS
CN Ethanimidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 349668-19-5 CAPLUS
CN Carbamic acid, [(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2005 ACS ON STN
ACCESSION NUMBER: 2001:101103 CAPLUS
DOCUMENT NUMBER: 134:163050
TITLE: Preparation of hydantoin, thiohydantoin, pyrimidinedione, and thioxopyrimidinone derivatives and their affinity for somatostatin receptors
INVENTOR(S): Poitout, Lydie; Thirieau, Christophe; Brault, Valerie
PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S., Fr.
SOURCE: PCT Int. Appl., 166 pp.

DOCUMENT TYPE: CODEN: PIXXD2
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: 1 French
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001009090	A2	20010208	WO 2000-FR2164	20000728
WO 2001009090	A3	20020808		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OL, OM, OS, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2796945	A1	20010202	FR 1999-9886	19990730
FR 2796945	B1	20020628		
CA 2380070	AA	20010208	CA 2000-2380070	20000728
AU 2000070091	A5	20010219	AU 2000-70091	20000728
BR 2000012852	A	20020430	BR 2000-12852	20000728
EP 1246807	A2	20021009	EP 2000-958634	20000728
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
NZ 516718	A	20030429	NZ 2000-516718	20000728
JP 2003518011	T2	20030603	JP 2001-514294	20000728
US 6759415	B1	20040706	US 2002-48144	20020123
NO 200200463	A	20020213	NO 2002-463	20020129
US 2004209908	A1	20041021	US 2004-813139	20040330
PRIORITY APPLN. INFO.:			FR 1999-9886	A 19990730
			WO 2000-FR2164	W 20000728
			US 2002-48144	A3 20020123


OTHER SOURCE(S): MARPAT 134:163050
GI



AB The title compds. I [R1 = carbocyclic or heterocyclic aryl radical optionally substituted with a nonarom. heterocyclic radical optionally substituted; R2 = H, alkyl, aryl; R3 = H, (CH2)pZ3, Z3 = alkyl, cycloalkyl, bisaryalkyl, diaryalkyl, Y1(CH2)p-phenyl-(X1)n, carbocyclic or heterocyclic aryl, nonarom. heterocyclic radical, X1 = H, Cl, F, Br, I, CF3, NO2, OH, NH2, CN, N3, OCF3, alkyl, alkoxy, S-alkyl, (CH2)pNH2, (CH2)pNH-alkyl, (CH2)pN-dialkyl; Y1 = O, S, NH, -; R4 = (CH2)pZ4, Z4 = amino, alkylamino, N,N-dialkylamino; R5 = H, alkyl; X = O, S; p 0-6; q = 1-5; n = 0, 1; provided that when n represents 0, m represents 1, 2 or 3, and when n represents 1, m represents 0 or 1, useful for treating pathol. conditions or diseases wherein somatostatin receptors are involved, were prepared E.g., benzyl (2S)-2-amino-3-(4-phenyl-1H-imidazol-2-yl)propanoate

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056729	A1	20000928	WO 2000-CA321	20000324
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, OL, OM, OS, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2368047	AA	20000928	CA 2000-2368047	20000324
EP 1163238	A1	20011219	EP 2000-913979	20000324
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000010655	A	20020213	BR 2000-10655	20000324
TR 200102799	T2	20020722	TR 2001-200102799	20000324
NZ 514709	A	20030328	NZ 2000-514709	20000324
JP 2003524620	T2	20030819	JP 2000-606590	20000324
US 6750348	B1	20040615	US 2000-535314	20000324
AU 775123	B2	20040715	AU 2000-35460	20000324
NO 2001004593	A	20011029	NO 2001-4593	20010921
US 2004235823	A1	20041125	US 2004-837467	20040430
PRIORITY APPLN. INFO.:			US 1999-125823P	P 19990324
			US 2000-535314	A3 20000324
			WO 2000-CA321	W 20000324


OTHER SOURCE(S): MARPAT 133:266589
GI



AB Title compds. [YW(X)(Z)(CR1R2)nArCR3R4N(R5)(CR6R7)qR8; W = N, Y is void; WY = CH; R1 to R7 may be the same or different and are independently selected from H, straight, branched or cyclic C1-6 alkyl; R8 = substituted heterocyclic group or a substituted aromatic group; Ar = aromatic or heteroarom. ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and q are independently = 0-2; X = O, Q1; A = optionally substituted, saturated or


was prepared
IT 325139-07-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of hydantoin, thiohydantoin, pyrimidinone, and thioxopyrimidinone derivs. and their affinity for somatostatin receptors)
RN 325139-07-9 CAPLUS
CN 1H-Imidazole-2-propanoic acid, β -[[[(1,1-dimethylethoxy)carbonyl]amino]-4-phenyl-, phenylmethyl ester, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 325139-12-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of hydantoin, thiohydantoin, pyrimidinone, and thioxopyrimidinone derivs. and their affinity for somatostatin receptors)
RN 325139-12-6 CAPLUS
CN 1H-Imidazole-2-propanoic acid, β -amino-4-phenyl-, phenylmethyl ester, dihydrochloride, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl


L12 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:688234 CAPLUS
DOCUMENT NUMBER: 133:266589
TITLE: Preparation of heterocyclic derivatives as chemokine receptor antagonists effective against HIV, tumor, and allergy
INVENTOR(S): Bridger, Gary; Skerlj, Renato; Kaller, Al; Harwig, Curtis; Bogucki, David; Wilson, Trevor R.; Crawford, Jason; McEachern, Ernest J.; Atsma, Ben; Nan, Sigiao; Zhou, Yuanxi; Scholz, Dominique
PATENT ASSIGNEE(S): Anormed Inc., Can.
SOURCE: PCT Int. Appl., 274 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

unsatd. 5 or 6-membered ring; P = optionally substituted carbon atom, optionally substituted nitrogen atom, sulfur or oxygen atom; B = optionally substituted 5 to 7-membered ring; Ring A and Ring B in the above formula can be connected to the group W from any position via the group V; V = bond, (CH2)m, CO; m = 0-2; Z = H, optionally substituted C1-6 alkyl group, C0-6 alkyl group substituted with an optionally substituted aromatic or heterocyclic group, optionally substituted C0-6 alkylamino, C3-7 cycloalkylamino group, optionally substituted carbonyl group or sulfonyl, pharmaceutically acceptable acid addition, salts, metal complexes, stereoisomers, isomer mixts., and pharmaceutical composition are prepared


Title compds. are having protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5 and inhibiting the subsequent binding of their natural ligands. Thus, the title compound I was prepared and tested for inhibition of HIV-1 NL4.3 or IIB replication in MT-4 cells and exhibited EC50's of less than 20µg/mL.

IT 297769-64-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic derivs. as chemokine receptor antagonists effective against HIV, tumor, and allergy)
RN 297769-64-3 CAPLUS
CN 1,4-Benzenedimethanamine, N-[(4-phenyl-1H-imidazol-2-yl)methyl]-N'-(2-pyridinylmethyl)-N-(5,6,7,8-tetrahydro-8-quinolinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:457071 CAPLUS

DOCUMENT NUMBER: 133:89553

TITLE: Preparation of imidazopyrazines, imidazobenzodiazepines, and related compounds as prenyl transferase inhibitors.
INVENTOR(S): Gordon, Thomas B.; Morgan, Barry A.
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques S.A., Fr.
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039130	A2	20000706	WO 1999-US31302	19991230
WO 2000039130	A3	20001102		
W:	AB, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KD, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2356756	AA	20000706	CA 1999-2356756	19991230
EP 1140942	A2	20011010	EP 1999-968984	19991230
EP 1140942	B1	20040310		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
EP 1382607	A2	20040121	EP 2003-78315	19991230
EP 1382607	A3	20040630		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY			
AT 261447	E	20040315	AT 1999-968984	19991230
ES 2215420	T3	20041001	ES 1999-968984	19991230
RU 2241712	C2	20041210	RU 2001-121317	19991230
NO 2001003281	A	20010829	NO 2001-3281	20010629
PRIORITY APPLN. INFO.:			US 1998-114301P	P 19981231
			US 1998-224428	A1 19981231
			EP 1999-968984	A3 19991230
			WO 1999-US31302	W 19991230

OTHER SOURCE(S): MARPAT 133:89553

GI



RN 280775-44-2 CAPLUS
CN 1H-imidazole-2-methanamine, 4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



L12 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:53629 CAPLUS

DOCUMENT NUMBER: 132:108300

TITLE: Preparation of disulfide cysteine-containing peptides for treating pathologies resulting from the formation of heterotrimeric G protein
INVENTOR(S): Prevost, Gregoire; Lonchampt, Marie-Odile; Gordon, Thomas
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (SCRAS), Fr.
SOURCE: PCT Int. Appl., 49 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 200002881	A2	20000120	WO 1999-FR1609	19990705
WO 200002881	A3	20000316		
W:	AB, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2780974	A1	20000114	FR 1998-8731	19980708
FR 2780974	B1	20010928		
CA 2336846	AA	20000120	CA 1999-2336846	19990705
AU 9946222	A1	20000201	AU 1999-46222	19990705
AU 756268	B2	20030109		
EP 1100801	A2	20010523	EP 1999-929394	19990705
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
JP 2002520327	T2	20020709	JP 2000-559111	19990705
NZ 509789	A	20040130	NZ 1999-509789	19990705
TW 561156	B	20031111	TW 1999-8811517	19990717
NO 2001000029	A	20010108	NO 2001-29	20010103
US 6544995	B1	20030408	US 2001-743208	20010104
ZA 2001001061	A	20021002	ZA 2001-1061	20010207
US 2003162786	A1	20030828	US 2003-356862	20030203

AB Title compds. [1; X = (CHR11)n3(CH2)n4Z(CH2)n5; n3 = 0, 1; n4, n5 = 0-3; Z = O, NR12, S, bond; Y = CO, CH2, CS, bond; R1 = (substituted) imidazolyl, triazolyl, tetrazolyl, benzimidazolyl, isoquinolinyl, pyridyl, etc.; R3 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R4, R5 = H, (substituted) alkyl, cycloalkyl, aryl, heterocyclyl; R6 = H, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; R7 = H, :O, :S, (substituted) alkyl, alkenyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, cycloalkenylalkyl, aryl, aralkyl, heterocyclyl, heterocyclylalkyl; W = null, C], were prepared as prenyl transferase inhibitors (no data). Thus, 1-(2-ethoxy-2-oxoethyl)-2-[(1S)-1-[(phenylmethoxy)carbonyl]amino]pentyl]-4-(2-methoxyphenyl)imidazole (preparation given) was hydrogenated in HOAc over Pd/C to give 8-butyl-6-oxo-2-(2-methoxyphenyl)imidazo[1,2-a]pyrazine. This was converted to 8-butyl-7-[3-(imidazol-5-yl)-1-oxopropyl]-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine in several steps.

IT 280775-81-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazopyrazines, imidazobenzodiazepines, and related compds. as prenyl transferase inhibitors)

RN 280775-81-7 CAPLUS

CN Carbamic acid, [(4-(2-methoxyphenyl)-1H-imidazol-2-yl)methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




IT 280775-35-1P 280775-43-1P 280775-44-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazopyrazines, imidazobenzodiazepines, and related compds. as prenyl transferase inhibitors)

RN 280775-35-1 CAPLUS

CN Carbamic acid, [(1S)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]pentyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 280775-43-1 CAPLUS



CN Carbamic acid, [(4-phenyl-1H-imidazol-2-yl)methyl](phenylmethyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

PRIORITY APPLN. INFO.:

FR 1998-8731 A 19980708
WO 1999-FR1609 W 19990705
US 2001-743208 A3 20010104

OTHER SOURCE(S): MARPAT 132:108300

GI



AB The invention concerns the use of cysteine deriva. I and II (X, Y are alkyl, C6 ring; R1 = H alkyl, alkylthio, R2, R3 = H, alkyl; R4 = H2, O; R5 = H, alkyl, alkenyl, alkynyl, aryl, aralkyl, heterocycle; R6, R7 = H, amino acid; R8, R9 = H, alkyl, aryl, arylalkyl, heterocycle) were prepared for treating diseases resulting from the formation of heterotrimeric G protein. Said diseases include in particular diseases related to biol. functions or the following disorders: smell, taste, light perception, neurotransmission, neurodegeneration, functioning of endocrine and exocrine glands, autocrine and paracrine regulation, blood pressure, embryogenesis, benign cell proliferation, oncogenesis, viral infection, immunol. functions, diabetes, obesity, benign and malignant proliferative diseases. Thus, bis-1,1'-7-(2-amino-1-oxo-3-thiopropyl)-8-(cyclohexylmethyl)-2-(2-methoxyphenyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazine disulfide and bis-1,1'-7-(2-amino-1-oxo-thiopropyl)-2-(1-naphthyl)-8-(2-methylpropyl)-5,6,7,8-tetrahydroimidazo[1,2a]pyrazin-7-yl disulfide were prepared and tested as proliferation inhibitor of human cells MCP7 (52-86 % at 30 µM).


IT 255827-25-9P 255827-32-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of disulfide cysteine containing peptides for treating pathologies resulting from the formation of heterotrimeric g protein)

RN 255827-25-9 CAPLUS

CN Carbamic acid, [(1S)-2-cyclohexyl-1-[4-(2-methylphenyl)-1H-imidazol-2-yl]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 255827-32-8 CAPLUS


CN 1H-imidazole-2-propanoic acid, 4-(2-methoxyphenyl)-8-[[[(phenylmethoxy)carbonyl]amino]-, phenylmethyl ester, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 1999:811276 CAPLUS
 DOCUMENT NUMBER: 132:50255
 TITLE: Preparation of cyclic somatostatin analogs
 INVENTOR(S): Gordon, Thomas D.
 PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques S.A., Fr.
 SOURCE: PCT Int. Appl., 73 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9965942	A1	19991223	WO 1999-US13304	19990611
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IL, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TO				
CA 2335184	AA	19991223	CA 1999-2335184	19990611
AU 9948223	A1	20000105	AU 1999-48223	19990611
AU 745493	B2	20020321		
EP 1086131	A1	20010328	EP 1999-931793	19990611
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002518409	T2	20020625	JP 2000-554767	19990611
RU 2242481	C2	20041220	RU 2001-101530	19990611
TW 527361	B	20030411	TW 1999-88110016	19990615
NO 2000006320	A	20010212	NO 2000-6320	20001212
US 6602849	B1	20030805	US 2001-719784	20010214
PRIORITY APPLN. INFO.: US 1998-89503P P 19980616				
US 1998-98181 A1 19980616				
WO 1999-US13304 W 19990611				
OTHER SOURCE(S): MARPAT 132:50255				
GI				




AB Imidazole-containing somatostatin cyclic deriva. I [Y, Z = D- or L-natural or unnatural α -amino acid; n = 0-50, provided that both n cannot be zero at the same time; m = 1-10; a = H or R1; b = OH, OR1, or (un)substituted amino or a and b form an amide bond; R1 = H, alkyl, arylalkyl; R2 = H or (un)substituted alkyl, Ph, phenylalkyl, or heterocyclyl alkyl; R3, R4 = H or (un)substituted alkyl, cycloalkyl, aryl, or arylalkyl or R3 and R4 together with carbons to which they are attached are (un)substituted aryl; R5 = H or (un)substituted alkyl or arylalkyl; R6 = H, alkyl, alkoxy, arylalkyl, or arylalkoxy] were prepared which selectively bind to somatostatin receptor subtypes. Thus, cyclo[Tyr-D-Trp-Lys-Val-Phe Ψ (4-(3-methoxyphenyl)imidazole)-Gly] was prepared by a multistep procedure starting with cyclocondensation of benzyloxycarbonyl-L-phenylalanine with 2-bromo-3'-methoxyacetophenone to form 2-[1-(S)-amino-2-phenylethyl]-4-(3-methoxyphenyl)imidazole, followed by protection, peptide coupling, and deprotection steps.
 IT 252753-48-3P 252753-50-7P 252753-75-6P
 252753-98-3P 252754-02-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of cyclic somatostatin analogs)
 RN 252753-48-3 CAPLUS
 CN 1H-Imidazole-2-methanamine, 4-(3-methoxyphenyl)- α -(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252753-50-7 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-2-phenylethyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252753-75-6 CAPLUS
 CN Carbamic acid, [(1S)-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-2-phenylethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 252753-98-3 CAPLUS
 CN L-Tyrosinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-tryptophyl-D-tryptophyl-N6-[(1,1-dimethylethoxy)carbonyl]-L-lysyl-N-[(1S)-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-2-phenylethyl]-O-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 252754-02-2 CAPLUS
 CN L-Valinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-O-(phenylmethyl)-L-tyrosyl-D-tryptophyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-N-[(1S)-1-[4-(3-methoxyphenyl)-1H-imidazol-2-yl]-2-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

PAGE 1-A





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:795813 CAPLUS

DOCUMENT NUMBER: 132:35702

TITLE: Preparation of imidazolyl- β -carbolines and related compounds as somatostatin receptor mediators and sodium channel blockers.

INVENTOR(S): Thureau, Christophe Alain; Poitout, Lydie Francine; Galcera, Marie-Odile; Moinet, Christophe Philippe; Gordon, Thomas D.; Morgan, Barry A.; Bigg, Dennis C. H.; Pommier, Jacques

PATENT ASSIGNEE(S): Societe De Conseil De Recherches Et D'applications Scientifiques S. A., Fr.

SOURCE: PCT Int. Appl., 107 pp.

DOCUMENT TYPE: CODEN: PIXXD2

LANGUAGE: Patent


FAMILY ACC. NUM. COUNT: English

PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964420	A1	19991216	WO 1999-US12874	19990608
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MM, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TO				
CA 2335339	AA	19991216	CA 1999-2335339	19990608
AU 9945536	A1	19991230	AU 1999-45536	19990608
AU 761020	B2	20030529		
EP 1086101	A1	20010328	EP 1999-928479	19990608
EP 1086101	B1	20021218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2002517500	T2	20020618	JP 2000-553429	19990608
AT 229954	E	20030115	AT 1999-928479	19990608
ES 2188184	T3	20030616	ES 1999-928479	19990608


RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252279-12-2 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252279-13-3 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-(4-methoxyphenyl)-1H-imidazol-2-yl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-14-4 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, (α S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252279-15-5 CAPLUS

NZ 508765 A 20031031 NZ 1999-508765 19990608
RU 2233841 C2 20040810 RU 2001-101433 19990608
NO 2000006268 A 20010129 NO 2000-6268 20001211
HK 1032049 A1 20030417 HK 2001-102432 20010404
US 6586445 B1 20030701 US 2001-719455 20010613
US 2004038970 A1 20040226 US 2003-383949 20030307
PRIORITY APPLN. INFO.: US 1998-89180P P 19980612
US 1998-97297 A1 19980612
WO 1999-US12874 W 19990608
US 2001-719455 A3 20010613

OTHER SOURCE(S): MARPAT 132:35702
GI



AB Title compds. [1; dotted lines = optional double bonds; X = N, NR4; R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, (CH2)mOZ1, etc.; Z1 = (substituted) alkyl, benzothienyl, Ph, naphthyl, benzofuryl, thienyl, indolyl, etc.; R2 = alkyl, ACOZ25, (substituted) Ph, etc.; Z5 = H, alkyl, aryl, aralkyl; R3 = H; R4 = CYNX1X2, COX2, X2; Y = O, S; X2 = (CH2)mY1X3; X3 = H, (substituted) alkyl, cycloalkyl, alkoxy, aryloxy, alkylamino, Ph, etc.; Y1 = O, S, NH, bond; R5 = alkyl, cycloalkyl, (substituted) Ph, furyl, thienyl, pyrrolyl, pyridinyl, etc.; R6 = H, PhSO2; R7 = H, alkyl, alkoxyalkyl, dialkylaminoalkyl; X1 = H, Cl, F, Br, iodo, NO2, OH, CF3, alkyl, etc.; m = 0-6; n = 1-5], were prepared as drugs (no data). Thus, 2-[1(5)-amino-2-(3-indolyl)ethyl]-4-phenyl-1H-imidazole in CHCl3 was treated with p-anisaldehyde and CF3CO2H followed by 2 days stirring to give a residue which was stirred overnight with aminomethylpolystyrene resin in THF to give 78% 1,2,3,4-tetrahydro-1(RS)-(4-methoxyphenyl)-3(S)-(4-phenyl-1H-imidazol-2-yl)-9H-pyrido[3,4-b]indole.


IT 252279-08-6 252279-09-7 252279-12-2
252279-13-3 252279-14-4 252279-15-5
252279-34-8

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazolyl- β -carbolines and related compds. as somatostatin receptor mediators and sodium channel blockers)

RN 252279-08-6 CAPLUS


CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN 1H-Indole-3-ethanamine, α -(4-(4-nitrophenyl)-1H-imidazol-2-yl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-34-8 CAPLUS
CN 1H-Imidazole-2-methanamine, α -(benzo[b]thien-3-ylmethyl)-4-phenyl-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252279-23-5P 252279-24-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazolyl- β -carbolines and related compds. as somatostatin receptor mediators and sodium channel blockers)

RN 252279-23-5 CAPLUS

CN 1H-Imidazole-2-methanamine, α -(benzo[b]thien-3-ylmethyl)-4-phenyl-, monohydrochloride, (α R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 252279-24-6 CAPLUS
CN Carbamic acid, [(1R)-2-benzo[b]thien-3-yl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:795794 CAPLUS
DOCUMENT NUMBER: 132:35701
TITLE: Preparation of imidazolyl derivatives as agonists or antagonists of somatostatin receptors
INVENTOR(S): Thureau, Christophe Alain; Poitout, Lydie Francine; Gálcerá, Marie-Odile; Gordon, Thomas D.; Morgan, Barry; Moinet, Christophe Philippe
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques, S.A., Fr.
SOURCE: PCT Int. Appl., 342 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9964401	A2	19991216	WO 1999-US12760	19990608
WO 9964401	A3	20030417		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KB, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2334945	AA	19991216	CA 1999-2334945	19990608
AU 9944257	A1	19991230	AU 1999-44257	19990608
AU 746963	B2	20020509		
EP 1086086	A1	20010328	EP 1999-927323	19990608
EP 1086086	B1	20041013		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2003523921	T2	20030812	JP 2000-553410	19990608
AT 279396	E	20041015	AT 1999-927323	19990608
NO 2000006267	A	20010207	NO 2000-6267	20001211
US 2004176379	A1	20040909	US 2004-771725	20040204
PRIORITY APPLN. INFO.: US 1998-89087P P 19980612				
US 1998-96431 A1 19980612				
WO 1999-US12760 W 19990608				
US 2001-719457 A3 20010613				

OTHER SOURCE(S): MARPAT 132:35701
GI

252302-29-7P 252302-31-1P 252302-32-2P
252302-35-5P 252302-37-7P 252302-39-9P
252302-41-3P 252302-43-5P 252302-44-6P
252302-46-8P 252302-47-9P 252302-48-0P
252302-49-1P 252302-50-4P 252302-51-5P
252302-52-6P 252302-53-7P 252302-54-8P
252302-55-9P 252302-56-0P 252302-58-2P
252302-60-6P 252302-61-7P 252302-63-9P
252302-65-1P 252302-67-3P 252302-69-5P
252302-71-9P 252302-74-2P 252302-77-5P
252302-79-7P 252302-80-0P 252302-81-1P
252302-82-2P 252302-83-3P 252302-84-4P
252302-85-5P 252302-86-6P 252302-88-8P
252302-89-9P 252302-90-2P 252302-91-3P
252302-92-4P 252302-93-5P 252302-95-7P
252302-96-8P 252302-97-9P 252302-98-0P
252302-99-1P 252303-00-7P 252303-02-9P
252303-03-0P 252303-04-1P 252303-05-2P
252303-06-3P 252303-07-4P 252303-08-5P
252303-09-6P 252303-10-9P 252303-12-1P
252303-13-2P 252303-14-3P 252303-15-4P
252303-16-5P 252303-17-6P 252303-18-7P
252303-19-8P 252303-21-2P 252303-22-3P
252303-25-6P 252303-26-7P 252303-27-8P
252303-28-9P 252303-29-0P 252303-30-3P
252303-32-5P 252303-33-6P 252303-34-7P
252303-35-8P 252303-36-9P 252303-38-1P
252303-39-2P 252303-40-5P 252303-41-6P
252303-42-7P 252303-44-9P 252303-46-1P
252303-47-2P 252303-50-7P 252303-53-0P
252303-54-1P 252303-57-4P 252304-37-3P
252304-38-4P 252304-39-5P 252304-40-8P
252304-42-0P 252304-43-1P 252304-45-3P
252304-46-4P 252304-47-5P 252304-48-6P
252304-49-7P 252304-50-0P 252304-51-1P
252304-52-2P 252304-53-3P 252304-58-8P
252304-60-2P 252304-62-4P 252304-64-6P
252304-66-8P 252304-70-4P 252304-72-6P
252304-75-9P 252304-76-0P 252304-77-1P
252304-79-3P 252304-80-6P 252304-81-7P
252304-82-8P 252304-83-9P 252304-85-1P
252304-87-3P 252304-88-4P 252304-90-8P
252304-93-1P 252304-94-2P 252304-99-7P
252305-49-0P 252305-50-3P 252305-51-4P
252305-52-5P 252305-53-6P 252305-54-7P
252305-55-8P 252305-56-9P 252305-57-0P
252305-58-1P 252305-59-2P 252305-60-5P
252305-61-6P 252305-63-8P 252305-64-9P
252305-65-0P 252305-66-1P 252305-67-2P
252305-68-3P 252305-69-4P 252305-70-7P
252305-71-8P 252305-72-9P 252305-73-0P
252305-74-1P 252305-75-2P 252305-76-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolyl derive. as agonists or antagonists of somatostatin receptors)
RN 252292-70-9 CAPLUS
CN 2-Furancarboxamide, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The title compds. [1; R1 = H, (CH2)mCO(CH2)mZ1, (CH2)mZ1, etc.; Z1 = (un)substituted benzo[b]thiophene, Ph, naphthyl, etc.; R2 = H, alkyl; R1 and R2 taken together with the nitrogen atoms to which they are attached form II-IV; R3 = (CH2)mS(CH2)mZ2; S = O, S, CO, etc.; Z2 = H, alkyl, NH2, etc.; R4 = H, (CH2)mA1; A1 = C(Y)NX1X2; C(Y)X2; C(NH)X2, X2; Y = O, S; X1 = H, alkyl, etc.; X2 = alkyl, etc.; R5 = alkyl, (un)substituted aryl, etc.; R6 = H, alkyl; R7 = alkyl, (CH2)mZ4; Z4 = (un)substituted Ph, naphthyl, indolyl, etc.; m = 0-6] which are useful as agonists or antagonists of somatostatin receptors (no data), and for inhibiting the proliferation of Helicobacter pylori, were prepared. Thus, activating 2-furancarboxylic acid with carbonyldiimidazole followed by addition of 2-[(1S)-1-amino-2-(indol-3-yl)ethyl]-4-phenyl-1H-imidazole afforded 94% the title compound V. Compds. I are effective at 0.01-10.0 mg/kg/day.

IT 252292-69-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of imidazolyl derive. as agonists or antagonists of somatostatin receptors)
RN 252292-69-6 CAPLUS
CN Carbamic acid, [(1S)-2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 252292-70-9P 252292-72-1P 252292-74-3P
252292-75-4P 252301-46-5P 252301-47-6P
252301-48-7P 252301-49-8P 252301-50-1P
252301-51-2P 252301-52-3P 252301-53-4P
252301-54-5P 252301-56-7P 252301-57-8P
252301-58-9P 252301-60-3P 252301-61-4P
252301-62-5P 252301-63-6P 252301-64-7P
252301-65-8P 252301-66-9P 252301-67-0P
252301-70-5P 252301-71-6P 252301-72-7P
252301-73-8P 252301-74-9P 252301-75-0P
252301-76-1P 252301-77-2P 252301-79-4P
252301-81-8P 252301-83-0P 252301-85-2P
252301-86-3P 252301-87-4P 252301-88-5P
252301-89-6P 252301-90-9P 252301-91-0P
252301-92-1P 252301-93-2P 252301-94-3P
252301-95-4P 252301-96-5P 252301-97-6P
252301-98-7P 252301-99-8P 252302-00-4P
252302-01-5P 252302-02-6P 252302-03-7P
252302-04-8P 252302-05-9P 252302-06-0P
252302-07-1P 252302-08-2P 252302-09-3P
252302-10-6P 252302-11-7P 252302-12-8P
252302-13-9P 252302-14-0P 252302-15-1P
252302-16-2P 252302-17-3P 252302-18-4P
252302-19-5P 252302-20-8P 252302-21-9P
252302-22-0P 252302-23-1P 252302-24-2P
252302-25-3P 252302-27-5P 252302-28-6P




RN 252292-72-1 CAPLUS
CN 2,5-Pyrrolidinedione, 1-[[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]oxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-74-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252292-75-4 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252301-46-5 CAPLUS
CN Carbamic acid, [5-[[[iminophenylmethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-47-6 CAPLUS
CN Carbamic acid, [5-[[[2-chlorophenyl]iminomethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-48-7 CAPLUS
CN Carbamic acid, [5-[[[4-chlorophenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-52-3 CAPLUS
CN Carbamic acid, [5-[[[2,4-difluorophenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-53-4 CAPLUS
CN Carbamic acid, [5-[[[4-(trifluoromethoxy)phenyl]methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-54-5 CAPLUS
CN Carbamic acid, [5-[[[2,6-dichlorophenyl]iminomethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-49-8 CAPLUS
CN Carbamic acid, [5-[[[imino(4-methoxyphenyl)methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-50-1 CAPLUS
CN Carbamic acid, [5-[[[imino[4-(trifluoromethyl)phenyl]methyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-51-2 CAPLUS
CN Carbamic acid, [5-[[[4-(1,1-dimethylethyl)phenyl]iminomethyl]amino]-5-(5-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-56-7 CAPLUS
CN Carbamic acid, [5-[[[2-[(1,1-dimethylethyl)sulfonyl]-1-iminoethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252301-57-8 CAPLUS
CN Carbamic acid, [5-[[[imino-2-thienylmethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252301-58-9 CAPLUS
CN Carbamic acid, [5-[[[1-iminoethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 252301-60-3 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-61-4 CAPLUS
CN Ethanimidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-62-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1S)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-63-6 CAPLUS
CN Ethanimidamide, N-[(1S)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-64-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252301-65-8 CAPLUS
CN Ethanimidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252301-66-9 CAPLUS
CN 2-Thiophenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252301-67-0 CAPLUS
CN Ethanimidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 252301-70-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-71-6 CAPLUS
CN Ethanimidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252301-72-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252301-73-8 CAPLUS
CN Ethanimidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI


RN 252301-74-9 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-((3-pyridinylmethyl)amino)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-75-0 CAPLUS
CN Carbamic acid, [5-(((2-chloro-3-quinolinyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-76-1 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-((2-quinolinylmethyl)amino)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-77-2 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-((4-pyridinylmethyl)amino)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-86-3 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-((phenylmethyl)amino)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252301-87-4 CAPLUS
CN Carbamic acid, [5-(((2-hydroxyphenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-88-5 CAPLUS
CN Carbamic acid, [5-(((4-hydroxyphenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-89-6 CAPLUS
CN Carbamic acid, [5-(((4-fluorophenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-79-4 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-((2-pyridinylmethyl)amino)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252301-81-8 CAPLUS
CN Carbamic acid, [5-(((1H-indol-3-yl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-83-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[[5-(((1,1-dimethylethoxy)carbonyl)amino)-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 252301-85-2 CAPLUS
CN Carbamic acid, [5-(((1-methyl-1H-indol-3-yl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252301-90-9 CAPLUS
CN Carbamic acid, [5-(((3-methoxyphenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-91-0 CAPLUS
CN Carbamic acid, [5-(((4-methoxyphenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-92-1 CAPLUS
CN Carbamic acid, [5-(((2-methoxyphenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-93-2 CAPLUS
CN Carbamic acid, [5-(((2-nitrophenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-94-3 CAPLUS
CN Carbamic acid, [5-(((4-nitrophenyl)methyl)amino)-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-95-4 CAPLUS
CN Carbamic acid, [5-[[[(3,4-dichlorophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-96-5 CAPLUS
CN Carbamic acid, [5-[[[(3-methoxy-2-nitrophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-97-6 CAPLUS
CN Carbamic acid, [5-[[[(4-bromophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-98-7 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[[2-thienylmethyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-03-7 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[[2-(trifluoromethyl)phenyl]methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252302-04-8 CAPLUS
CN Carbamic acid, [5-[[[(1,1'-biphenyl)-4-ylmethyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-05-9 CAPLUS
CN Carbamic acid, [5-[[[(2-bromophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-06-0 CAPLUS
CN Carbamic acid, [5-[[[(4-(dimethylamino)phenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252301-99-8 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[[[(3,4,5-trimethoxyphenyl)methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252302-00-4 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[[[(4-phenylmethoxy)phenyl]methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-01-5 CAPLUS
CN Carbamic acid, [5-[[[(2-fluorophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-02-6 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[[2-(phenylmethoxy)ethyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252302-07-1 CAPLUS
CN Carbamic acid, [5-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(trifluoromethoxy)phenyl]methyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-08-2 CAPLUS
CN Carbamic acid, [5-[[[4-(3-(dimethylamino)propoxy)phenyl]methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-09-3 CAPLUS
CN Carbamic acid, [5-[[[(3-fluoro-4-methoxyphenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-10-6 CAPLUS
CN Carbamic acid, [5-[[[(4-(1,1-dimethylethyl)phenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252302-11-7 CAPLUS
CN Carbamic acid, [5-[[[(3-bromophenyl)methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-12-8 CAPLUS
CN Carbamic acid, [5-[[[3-(4-methoxyphenoxy)phenyl]methyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252302-13-9 CAPLUS
CN 3-Quinolinemethanamine, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-14-0 CAPLUS
CN 2-Quinolinemethanamine, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-15-1 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-19-5 CAPLUS
CN 2-Quinolinemethanamine, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252302-20-8 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-21-9 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


pyridinylmethyl)-, (alphaR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-16-2 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-17-3 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252302-18-4 CAPLUS
CN 3-Quinolinemethanamine, 2-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252302-22-0 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-23-1 CAPLUS
CN 3-Quinolinemethanamine, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252302-24-2 CAPLUS
CN 2-Quinolinemethanamine, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)



RN 252302-25-3 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-27-5 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252302-28-6 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(3-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-35-5 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-37-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(3-pyridinylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-39-9 CAPLUS
CN 3-Quinolinemethanamine, 2-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-29-7 CAPLUS
CN 3-Quinolinemethanamine, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-31-1 CAPLUS
CN 2-Quinolinemethanamine, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-32-2 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(4-pyridinylmethyl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-41-3 CAPLUS
CN 2-Quinolinemethanamine, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-43-5 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(4-pyridinylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-44-6 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-pyridinylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-46-8 CAPLUS
CN 1H-Indole-3-ethanamine, N-((3-fluoro-4-methoxyphenyl)methyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-47-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-((3-bromophenyl)methyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-48-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-butyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-53-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-54-8 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-55-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-49-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-pentyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-50-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-[3-(methylthio)propyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-51-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-52-6 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[2-(phenylmethoxy)ethyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252302-56-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252302-58-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252302-60-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-butyl-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252302-61-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-pentyl- (9CI) (CA INDEX NAME)




RN 252302-63-9 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[3-(methylthio)propyl]- (9CI) (CA INDEX NAME)




RN 252302-65-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252302-67-3 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[2-(phenylmethoxy)ethyl]- (9CI) (CA INDEX NAME)




RN 252302-69-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 252302-71-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252302-74-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252302-77-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-79-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-80-0 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-pentyl-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-81-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-82-2 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[2-(phenylmethoxy)ethyl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-83-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-84-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-85-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-86-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-88-8 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-bromophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-89-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-butyl- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-90-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-91-3 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[2-(phenylmethoxy)ethyl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-92-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-93-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-(1,1-dimethylethyl)phenyl]methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-95-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-96-8 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-], (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-97-9 CAPLUS
CN Phenol, 2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-98-0 CAPLUS
CN Phenol, 4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252302-99-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-00-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-05-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-06-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-07-4 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(2-thienyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252303-02-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-03-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-04-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)


RN 252303-08-5 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-09-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-10-9 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(4-(trifluoromethoxy)phenyl)methyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252303-12-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-{3-(dimethylamino)propoxy}phenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-13-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-fluoro-4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-18-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-hexyl-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-19-8 CAPLUS
CN Carbamic acid, [(5S)-5-[(4-morpholinylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-21-2 CAPLUS
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-[(3-thiazolidinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 252303-14-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-(3,3-dimethylbutyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-15-4 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[2-(phenylmethoxy)ethyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-16-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-(cyclohexylmethyl)-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-17-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-{1,1-dimethylethyl}phenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-22-3 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(aminocarbonyl)-1-piperidinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-25-6 CAPLUS
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(phenyl-1-piperazinyl)carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-26-7 CAPLUS
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-[[[1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-27-8 CAPLUS
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(phenylmethyl)-1-piperazinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-28-9 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(4-fluorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-29-0 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(2-methoxyphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-34-7 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(4-chlorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-35-8 CAPLUS
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(2-pyridinyl)-1-piperazinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-36-9 CAPLUS
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(phenylmethyl)-1-piperidinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-30-3 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(3-chlorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-32-5 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(4-nitrophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-33-6 CAPLUS
CN Carbamic acid, [(5S)-5-[[[3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-38-1 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-39-2 CAPLUS
CN Carbamic acid, [(5S)-5-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-40-5 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-8-yl)carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-41-6 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(2-chlorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252303-42-7 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(4-hydroxyphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252303-44-9 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(2,4-dimethylphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252303-53-0 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(4-methoxyphenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-54-1 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(diphenylmethyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-57-4 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(2-fluorophenyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-46-1 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1S)-5-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-47-2 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-1-piperidinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252303-50-7 CAPLUS
CN Carbamic acid, [(5S)-5-[[[4-(2-furanylcarbonyl)-1-piperazinyl]carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 252304-37-3 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-38-4 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-chloro-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-39-5 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-chloro-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-40-8 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-42-0 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-43-1 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(1,1-dimethylethyl)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-45-3 CAPLUS




● HI

RN 252304-49-7 CAPLUS
CN 2-Thiophenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252304-50-0 CAPLUS
CN Ethanimidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-51-1 CAPLUS
CN 4-Morpholinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,4-difluoro-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-46-4 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 252304-47-5 CAPLUS
CN Benzenecarboximidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,6-dichloro-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252304-48-6 CAPLUS
CN Ethanimidamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-[(1,1-dimethylethyl)sulfonyl]-, monohydriodide (9CI) (CA INDEX NAME)


RN 252304-52-2 CAPLUS
CN 3-Thiazolidinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-53-3 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-58-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-60-2 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-62-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-64-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-66-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-70-4 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-77-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252304-79-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(1,3-benzodioxol-5-ylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-80-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-72-6 CAPLUS
CN 2(1H)-isoquinolinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4-dihydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252304-75-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-76-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 252304-81-7 CAPLUS
CN 1,3,8-TriazaSpiro[4.5]decane-8-carboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-82-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-83-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-85-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(2,4-dimethylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-87-3 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-((((1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl)amino)carbonyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-88-4 CAPLUS
CN 1-Piperidinecarboxamide, N-((((1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl)-4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-90-8 CAPLUS
CN 1-Piperazinecarboxamide, N-((((1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl)-4-(2-furanylcarbonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252305-49-0 CAPLUS
CN 1H-Indole-5-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-50-3 CAPLUS
CN 1H-Indole-3-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)



RN 252305-51-4 CAPLUS
CN 1H-Indole-4-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-52-5 CAPLUS
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252304-93-1 CAPLUS
CN 1-Piperazinecarboxamide, N-((((1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl)-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-94-2 CAPLUS
CN 1-Piperazinecarboxamide, N-((((1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl)-4-(diphenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252304-99-7 CAPLUS
CN 1-Piperazinecarboxamide, N-((((1S)-5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl)-4-(2-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252305-53-6 CAPLUS
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 252305-54-7 CAPLUS
CN 1H-Indole-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-55-8 CAPLUS
CN 1H-Indole-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 252305-56-9 CAPLUS
CN 1H-Indole-3-butanamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-57-0 CAPLUS
CN 1H-Indole-3-propanamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-58-1 CAPLUS
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-59-2 CAPLUS
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-5-bromo- (9CI) (CA INDEX NAME)




RN 252305-60-5 CAPLUS
CN 1H-Indole-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 252305-61-6 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-63-8 CAPLUS
CN Benzo[b]thiophene-3-acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-69-4 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 252305-70-7 CAPLUS
CN 2-Furancarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-71-8 CAPLUS
CN 2-Pyridinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-72-9 CAPLUS
CN Acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(phenylthio)- (9CI) (CA INDEX NAME)




RN 252305-73-0 CAPLUS
CN 1-Naphthalenecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-64-9 CAPLUS
CN 2-Benzofurancarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-65-0 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 252305-66-1 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252305-67-2 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252305-68-3 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 252305-74-1 CAPLUS
CN 2-Quinolinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)



RN 252305-75-2 CAPLUS
CN 8-Quinolinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)



RN 252305-76-3 CAPLUS
CN 3-Quinolinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




IT 252305-78-5P 252305-79-6P 252305-80-9P

252305-82-1P 252305-83-2P 252305-84-3P
 252305-85-4P 252305-86-5P 252305-87-6P
 252305-88-7P 252305-89-8P 252305-90-1P
 252305-91-2P 252305-92-3P 252305-93-4P
 252305-94-5P 252305-95-6P 252305-96-7P
 252305-97-8P 252305-99-0P 252306-00-6P
 252306-01-7P 252306-02-8P 252306-03-9P
 252306-05-1P 252306-06-2P 252306-07-3P
 252306-08-4P 252306-09-5P 252306-10-8P
 252306-11-9P 252306-12-0P 252306-13-1P
 252306-14-2P 252306-15-3P 252306-16-4P
 252306-17-5P 252306-19-7P 252306-20-0P
 252306-21-1P 252306-22-2P 252306-23-3P
 252306-24-4P 252306-25-5P 252306-26-6P
 252306-27-7P 252306-29-9P 252306-31-3P
 252306-32-4P 252306-34-6P 252306-35-7P
 252306-36-8P 252306-37-9P 252306-39-1P
 252306-40-4P 252306-41-5P 252306-42-6P
 252306-65-3P 252306-66-4P 252306-67-5P
 252306-68-6P 252306-69-7P 252306-70-0P
 252306-71-1P 252306-72-2P 252306-73-3P
 252306-74-4P 252306-84-6P 252306-85-7P
 252306-86-8P 252306-87-9P 252306-88-0P
 252306-89-1P 252306-90-4P 252306-91-5P
 252306-92-6P 252306-93-7P 252306-94-8P
 252306-95-9P 252306-96-0P 252306-97-1P
 252306-98-2P 252306-99-3P 252307-00-9P
 252307-01-0P 252307-02-1P 252307-04-3P
 252307-05-4P 252307-06-5P 252307-07-6P
 252307-09-8P 252307-10-1P 252307-11-2P
 252307-12-3P 252307-13-4P 252307-17-8P
 252307-19-0P 252307-21-4P 252307-22-5P
 252307-23-6P 252307-24-7P 252307-26-9P
 252307-27-0P 252307-28-1P 252307-29-2P
 252307-30-5P 252307-31-6P 252307-32-7P
 252307-33-8P 252307-34-9P 252307-36-1P
 252307-37-2P 252307-38-3P 252307-39-4P
 252307-40-7P 252307-41-8P 252307-42-9P
 252307-43-0P 252307-45-2P 252307-46-3P
 252307-47-4P 252307-48-5P 252307-49-6P
 252307-50-9P 252307-51-0P 252307-52-1P
 252307-53-2P 252307-54-3P 252307-55-4P
 252307-56-5P 252307-57-6P 252307-58-7P
 252307-59-8P 252307-60-1P 252307-61-2P
 252307-62-3P 252307-63-4P 252307-64-5P
 252307-65-6P 252307-67-8P 252307-68-9P
 252307-69-0P 252307-70-3P 252307-71-4P
 252307-72-5P 252307-73-6P 252307-75-8P
 252307-76-9P 252307-77-0P 252307-78-1P
 252307-79-2P 252307-80-5P 252307-81-6P
 252307-82-7P 252307-83-8P 252307-85-0P
 252307-86-1P 252307-88-3P 252307-89-4P
 252307-90-7P 252307-91-8P 252307-92-9P
 252307-93-0P 252307-94-1P 252307-95-2P
 252307-96-3P 252307-97-4P 252307-98-5P
 252307-99-6P 252308-01-3P 252308-02-4P
 252308-03-5P 252308-04-6P 252308-05-7P
 252308-06-8P 252308-07-9P 252308-08-0P
 252308-10-4P 252308-11-5P 252308-13-7P
 252308-14-8P 252308-15-9P 252308-16-0P
 252308-17-1P 252308-18-2P 252308-19-3P
 252308-21-7P 252308-22-8P 252308-23-9P
 252308-24-0P 252308-25-1P 252308-26-2P
 252308-27-3P 252308-28-4P 252308-30-8P
 252308-31-9P 252308-32-0P 252308-33-1P


252308-35-3P 252308-36-4P 252308-37-5P
 252308-38-6P 252308-39-7P 252308-41-1P
 252308-42-2P 252308-43-3P 252308-44-4P
 252308-45-5P 252308-46-6P 252308-47-7P
 252308-48-8P 252308-49-9P 252308-52-4P
 252308-53-5P 252308-54-6P 252308-55-7P
 252308-57-9P 252308-58-0P 252308-59-1P
 252308-60-4P 252308-62-6P 252308-63-7P
 252308-64-8P 252308-65-9P 252308-66-0P
 252308-67-1P 252308-79-5P 252308-81-9P
 252308-82-0P 252308-83-1P 252308-84-2P
 252308-85-3P 252308-86-4P 252308-87-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of imidazolyl derivs. as agonists or antagonists of somatostatin receptors)


RN 252305-79-6 CAPLUS
 CN 4-Quinolinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-79-6 CAPLUS
 CN 1-Isoquinolinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-80-9 CAPLUS
 CN Propanamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 252305-82-1 CAPLUS
 CN 2-Thiopheneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-83-2 CAPLUS
 CN Acetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(2-pyrimidinylthio)- (9CI) (CA INDEX NAME)




RN 252305-84-3 CAPLUS
 CN 3-Pyridinecarboxamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252305-85-4 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 252305-86-5 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 252305-87-6 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 252305-88-7 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-bromo- (9CI) (CA INDEX NAME)




RN 252305-89-8 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-bromo- (9CI) (CA INDEX NAME)




RN 252305-90-1 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-bromo- (9CI) (CA INDEX NAME)




RN 252305-91-2 CAPLUS
 CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252305-92-3 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 252305-93-4 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 252305-94-5 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252305-95-6 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252305-96-7 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252305-97-8 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252305-99-0 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252306-00-6 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252306-01-7 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252306-02-8 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252306-03-9 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252306-05-1 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]- (9CI) (CA INDEX NAME)




RN 252306-06-2 CAPLUS
CN Benzeneacetamide, N-[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 252306-07-3 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-08-4 CAPLUS
CN 1,5-Pentanediamine, N1-[(2-chloro-3-quinolinyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-09-5 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-quinolinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-10-8 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-11-9 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-12-0 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 252306-13-1 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-14-2 CAPLUS
CN Phenol, 2-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 252306-15-3 CAPLUS
CN Phenol, 4-[[[5-amino-1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 252306-16-4 CAPLUS
CN 1,5-Pentanediamine, N1-[(3-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-17-5 CAPLUS
CN 1,5-Pentanediamine, N1-[(3-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-19-7 CAPLUS
CN 1,5-Pentanediamine, N1-[(4-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-25-5 CAPLUS
CN 1,5-Pentanediamine, N1-[(4-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-26-6 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 252306-27-7 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252306-29-9 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[[4-(phenylmethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252306-31-3 CAPLUS
CN 1,5-Pentanediamine, N1-[(2-fluorophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-20-0 CAPLUS
CN 1,5-Pentanediamine, N1-[(2-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-21-1 CAPLUS
CN 1,5-Pentanediamine, N1-[(2-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-22-2 CAPLUS
CN 1,5-Pentanediamine, N1-[(4-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-23-3 CAPLUS
CN 1,5-Pentanediamine, N1-[(3,4-dichlorophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-24-4 CAPLUS
CN 1,5-Pentanediamine, N1-[(3-methoxy-2-nitrophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-32-4 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[(2-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252306-34-6 CAPLUS
CN 1,5-Pentanediamine, N1-[(1,1'-biphenyl)-4-ylmethyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-35-7 CAPLUS
CN 1,5-Pentanediamine, N1-[(2-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-36-8 CAPLUS
CN 1,5-Pentanediamine, 1-(4-phenyl-1H-imidazol-2-yl)-N1-[[4-(trifluoromethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252306-37-9 CAPLUS
CN 1,5-Pentanediamine, N1-[[4-{3-(dimethylamino)propoxy}phenyl]methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-39-1 CAPLUS
CN 1,5-Pentanediamine, N1-[(3-fluoro-4-methoxyphenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-40-4 CAPLUS
CN 1,5-Pentanediamine, N1-[(4-(1,1-dimethylethyl)phenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 252306-41-5 CAPLUS
CN 1,5-Pentanediamine, N1-[(3-bromophenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)



RN 252306-42-6 CAPLUS
CN 1,5-Pentanediamine, N1-[(3-(4-methoxyphenoxy)phenyl)methyl]-1-(4-phenyl-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252306-65-3 CAPLUS
CN Propanamide, 3-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


(methylamino)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-70-0 CAPLUS
CN Benzamide, 4-(aminomethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-71-1 CAPLUS
CN Propanamide, 2-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-72-2 CAPLUS
CN Pentanamide, 5-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-66-4 CAPLUS
CN Acetamide, 2-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-67-5 CAPLUS
CN Butanamide, 4-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-68-6 CAPLUS
CN Hexanamide, 6-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-69-7 CAPLUS
CN Acetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2- (9CI) (CA INDEX NAME)




RN 252306-73-3 CAPLUS
CN Benzamide, 4-(aminomethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-74-4 CAPLUS
CN Benzeneacetamide, 4-amino-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-84-6 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-(4-methoxyphenyl)-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-85-7 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-86-8 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-87-9 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-88-0 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-89-1 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-90-4 CAPLUS
CN Benzeneacetamide, 2-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-91-5 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-92-6 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-93-7 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-94-8 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-95-9 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-96-0 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-97-1 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-98-2 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252306-99-3 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-04-3 CAPLUS
CN Benzeneacetamide, 4-(dimethylamino)-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-05-4 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-06-5 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-00-9 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-01-0 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-02-1 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-07-6 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-09-8 CAPLUS
CN Benzeneacetamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-10-1 CAPLUS
CN Benzeneacetamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-11-2 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-12-3 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-13-4 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-17-8 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-19-0 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-21-4 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-22-5 CAPLUS
CN Benzeneacetamide, 2-fluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-23-6 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-24-7 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-26-9 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-27-0 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-28-1 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-29-2 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-30-5 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252307-31-6 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-36-1 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CH 1


CRN 252307-35-0
CMF C28 H26 N4 O2

Absolute stereochemistry.




CH 2

CRN 76-05-1
CMF C2 H F3 O2




RN 252307-37-2 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-32-7 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-33-8 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-34-9 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-38-3 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4-dichloro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-39-4 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-40-7 CAPLUS
CN Benzeneacetamide, N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-41-8 CAPLUS
CN Benzeneacetamide, 4-hydroxy-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252307-42-9 CAPLUS
CN Benzeneacetamide, 2,4-difluoro-N-[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252307-43-0 CAPLUS
CN Carbamic acid, [5-[(1H-indol-5-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-49-6 CAPLUS
CN Carbamic acid, [5-[(5-methoxy-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252307-50-9 CAPLUS
CN Carbamic acid, [5-[(5-hydroxy-1H-indol-2-yl)carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-51-0 CAPLUS
CN Carbamic acid, [5-[(5-methoxy-1H-indol-2-yl)carbonyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-52-1 CAPLUS
CN Carbamic acid, [5-[[4-(1H-indol-3-yl)-1-oxobutyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-45-2 CAPLUS
CN Carbamic acid, [5-[(1H-indol-3-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-46-3 CAPLUS
CN Carbamic acid, [5-[(1H-indol-4-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-47-4 CAPLUS
CN Carbamic acid, [5-[(1H-indol-2-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-48-5 CAPLUS
CN Carbamic acid, [5-[(1H-indol-3-ylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252307-53-2 CAPLUS
CN Carbamic acid, [5-[[3-(1H-indol-3-yl)-1-oxopropyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-54-3 CAPLUS
CN Carbamic acid, [5-[[5-(5-hydroxy-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-55-4 CAPLUS
CN Carbamic acid, [5-[[5-(5-bromo-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-56-5 CAPLUS
CN Carbamic acid, [5-[[2-methyl-1H-indol-3-yl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-57-6 CAPLUS
CN Carbamic acid, [5-[(benzo[b]thien-2-ylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-58-7 CAPLUS
CN Carbamic acid, [5-[(benzo[b]thien-3-ylacetyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-59-8 CAPLUS
CN Carbamic acid, [5-[(2-benzofuranylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-60-1 CAPLUS
CN Carbamic acid, [5-[(3,4-dichlorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-61-2 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3,4,5-trimethoxyphenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-67-8 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-pyridinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-68-9 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(phenylthio)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-69-0 CAPLUS
CN Carbamic acid, [5-[(1-naphthalenylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-70-3 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-62-3 CAPLUS
CN Carbamic acid, [5-[(4-methylphenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-63-4 CAPLUS
CN Carbamic acid, [5-[(4-hydroxyphenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-64-5 CAPLUS
CN Carbamic acid, [5-[(2,4-difluorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-65-6 CAPLUS
CN Carbamic acid, [5-[(2-furanylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


INDEX NAME)




RN 252307-71-4 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(8-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-72-5 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(3-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-73-6 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-quinolinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-75-8 CAPLUS
CN Carbamic acid, [5-[(1-isoquinolinylcarbonyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-76-9 CAPLUS
CN Carbamic acid, [5-[(1-oxo-3-(phenylsulfonyl)propyl)amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-77-0 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-thienylacetyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-82-7 CAPLUS
CN Carbamic acid, [5-[(2-chlorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 252307-83-8 CAPLUS
CN Carbamic acid, [5-[(2-bromophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-85-0 CAPLUS
CN Carbamic acid, [5-[(3-bromophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-86-1 CAPLUS
CN Carbamic acid, [5-[(4-bromophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-78-1 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-pyrimidinylthio)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 252307-79-2 CAPLUS
CN Carbamic acid, [5-[(4-phenyl-1H-imidazol-2-yl)-5-[(2-pyridinylcarbonyl)amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-80-5 CAPLUS
CN Carbamic acid, [5-[(2-chlorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-81-6 CAPLUS
CN Carbamic acid, [5-[(3-chlorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


RN 252307-88-3 CAPLUS
CN Carbamic acid, [5-[(2-fluorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-89-4 CAPLUS
CN Carbamic acid, [5-[(3-fluorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-90-7 CAPLUS
CN Carbamic acid, [5-[(4-fluorophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-91-8 CAPLUS
CN Carbamic acid, [5-[(2-nitrophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-92-9 CAPLUS
CN Carbamic acid, [5-[(3-nitrophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-93-0 CAPLUS
CN Carbamic acid, [5-[[[4-(4-nitrophenyl)acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-94-1 CAPLUS
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[2-(trifluoromethyl)phenyl]acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-95-2 CAPLUS
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[3-(trifluoromethyl)phenyl]acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-96-3 CAPLUS
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(trifluoromethyl)phenyl]acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-97-4 CAPLUS
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[2-(4-methoxyphenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-98-5 CAPLUS
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[3-(4-methoxyphenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252307-99-6 CAPLUS
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(4-methoxyphenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-01-3 CAPLUS
CN Carbamic acid, [5-[[[4-(4-phenyl-1H-imidazol-2-yl)-5-[[[4-(4-methoxyphenyl)acetyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-02-4 CAPLUS
CN Carbamic acid, [5-[[[4-(4-dimethylamino)phenyl]acetyl]amino]-5-(4-phenyl-1H-imidazol-2-yl)pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 252308-03-5 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-04-6 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-05-7 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 252308-06-8 CAPLUS
CN Benzeneacetamide, 4-hydroxy-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-07-9 CAPLUS
CN Benzeneacetamide, 2,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-08-0 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4-dichloro- (9CI) (CA INDEX NAME)


yl)ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 252308-10-4 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-14-8 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 252308-11-5 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 252308-15-9 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-13-7 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 252308-16-0 CAPLUS

CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-17-1 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-methyl- (9CI) (CA INDEX NAME)


RN 252308-19-3 CAPLUS
CN Benzeneacetamide, 2,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)





RN 252308-21-7 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252308-18-2 CAPLUS
CN Benzeneacetamide, 4-hydroxy-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252308-22-8 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-(diethylamino)phenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)




RN 252308-23-9 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 252308-24-0 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 252308-25-1 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-30-8 CAPLUS
CN Benzeneacetamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-31-9 CAPLUS
CN Benzeneacetamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-32-0 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252308-26-2 CAPLUS
CN Benzeneacetamide, 3,4-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-27-3 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3,4,5-trimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-28-4 CAPLUS

Absolute stereochemistry.




RN 252308-33-1 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-35-3 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-36-4 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-37-5 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-38-6 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-39-7 CAPLUS
CN Benzeneacetamide, 2-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-41-1 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-42-2 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-43-3 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-44-4 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-45-5 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-46-6 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-47-7 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-48-8 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-49-9 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-52-4 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-53-5 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-54-6 CAPLUS
CN Benzeneacetamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-59-1 CAPLUS
CN Carbamic acid, [4-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-4-oxobutyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-60-4 CAPLUS
CN Carbamic acid, [6-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-6-oxohexyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-62-6 CAPLUS
CN Carbamic acid, [2-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-55-7 CAPLUS
CN Benzeneacetamide, 4-(dimethylamino)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-57-9 CAPLUS
CN Carbamic acid, [3-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-3-oxopropyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-58-0 CAPLUS
CN Carbamic acid, [2-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-63-7 CAPLUS
CN Carbamic acid, [4-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-64-8 CAPLUS
CN Carbamic acid, [2-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-1,1-dimethyl-2-oxoethyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-65-9 CAPLUS
CN Carbamic acid, [5-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-5-oxopentyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-66-0 CAPLUS
CN Carbamic acid, [[4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252308-67-1 CAPLUS
CN Carbamic acid, [4-[2-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]-2-oxoethyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252308-79-5 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-84-2 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-85-3 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-86-4 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-81-9 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-82-0 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-83-1 CAPLUS
CN Benzenecarboximidamide, 4-methoxy-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-87-5 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HI


IT 252308-88-6P 252308-89-7P 252308-90-0P
252308-91-1P 252308-92-2P 252308-93-3P
252308-94-4P 252308-95-5P 252308-96-6P
252308-97-7P 252308-98-8P 252308-99-9P
252309-00-5P 252309-01-6P 252309-02-7P
252309-03-8P 252309-04-9P 252309-05-0P
252309-06-1P 252309-07-2P 252309-08-3P
252309-09-4P 252309-10-7P 252309-11-8P
252309-12-9P 252309-13-0P 252309-14-1P
252309-15-2P 252309-16-3P 252309-18-5P
252309-19-6P 252309-20-9P 252309-21-0P
252309-22-1P 252309-23-2P 252309-24-3P
252309-25-4P 252309-26-5P 252309-27-6P
252309-28-7P 252309-29-8P 252309-30-1P
252309-42-5P 252309-43-6P 252309-44-7P
252309-45-8P 252309-46-9P 252309-47-0P
252309-48-1P 252309-49-2P 252309-50-5P
252309-51-6P 252309-53-8P 252309-54-9P
252309-55-0P 252309-56-1P 252309-57-2P
252309-58-3P 252309-59-4P 252309-61-8P
252309-63-0P 252309-64-1P 252309-65-2P
252309-66-3P 252309-67-4P 252309-68-5P
252309-69-6P 252309-70-9P 252309-71-0P
252309-73-2P 252309-74-3P 252309-75-4P
252309-76-5P 252309-77-6P 252309-79-8P
252309-80-1P 252309-81-2P 252309-82-3P
252309-84-5P 252309-85-6P 252309-86-7P
252309-87-8P 252309-88-9P 252309-89-0P
252309-90-3P 252309-91-4P 252309-92-5P

252309-93-6P 252309-95-8P 252309-96-9P
252309-97-0P 252310-00-2P 252310-01-3P
252310-02-4P 252310-03-5P 252310-04-6P
252310-05-7P 252310-06-8P 252310-08-0P
252310-09-1P 252310-10-4P 252310-11-5P
252310-12-6P 252310-13-7P 252310-14-8P
252310-15-9P 252310-16-0P 252310-17-1P
252310-18-2P 252310-19-3P 252310-21-7P
252310-22-8P 252310-23-9P 252310-24-0P
252310-25-1P 252310-26-2P 252310-27-3P
252310-28-4P 252310-29-5P 252310-31-9P
252310-32-0P 252310-33-1P 252310-34-2P
252310-35-3P 252310-36-4P 252310-38-6P
252310-39-7P 252310-40-0P 252310-41-1P
252310-43-3P 252310-44-4P 252310-45-5P
252310-46-6P 252310-47-7P 252310-48-8P
252310-49-9P 252310-50-2P 252310-51-3P
252310-52-4P 252310-53-5P 252310-55-7P
252310-56-8P 252310-58-0P 252310-59-1P
252310-60-4P 252310-62-6P 252310-63-7P
252310-64-8P 252310-65-9P 252310-66-0P
252310-68-2P 252310-71-7P 252310-72-8P
252310-73-9P 252310-74-0P 252310-75-1P
252310-76-2P 252310-77-3P 252310-80-8P
252310-81-9P 252310-82-0P 252310-83-1P
252310-84-2P 252310-85-3P 252310-86-4P
252310-87-5P 252310-88-6P 252310-89-7P
252310-93-3P 252310-94-4P 252310-97-7P
252310-98-8P 252313-17-0P 252313-18-1P
252313-19-2P 252313-20-5P 252313-22-7P
252313-23-8P 252313-24-9P 252313-25-0P
252313-26-1P 252313-27-2P 252313-28-3P
252313-29-4P 252313-30-7P 252313-31-8P
252313-33-0P 252313-34-1P 252313-35-2P
252313-36-3P 252313-37-4P 252313-38-5P
252313-39-6P 252313-40-9P 252313-41-0P
252313-42-1P 252313-43-2P 252313-45-4P
252313-46-5P 252313-47-6P 252313-48-7P
252313-50-1P 252313-51-2P 252313-52-3P
252313-53-4P 252313-54-5P 252313-55-6P
252313-57-8P 252313-58-9P 252313-59-0P
252313-60-3P 252313-61-4P 252313-62-5P
252313-63-6P 252313-64-7P 252313-65-8P
252313-66-9P 252313-67-0P 252313-68-1P
252313-69-2P 252313-70-5P 252313-71-6P
252313-72-7P 252313-73-8P 252313-74-9P
252313-75-0P 252313-77-2P 252313-78-3P
252313-79-4P 252313-80-7P 252313-81-8P
252313-82-9P 252313-83-0P 252313-84-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolyl derive. as agonists or antagonists of somatostatin receptors)

RN 252308-88-6 CAPLUS
CN Benzenesethanimidamide, 2,6-dichloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-89-7 CAPLUS
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-(phenylmethoxy)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-90-0 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-91-1 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-92-2 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-93-3 CAPLUS
CN Benzenecarboximidamide, 4-methoxy-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-94-4 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-95-5 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-96-6 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-97-7 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252308-98-8 CAPLUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252308-99-9 CAPLUS

RN 252309-02-7 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-03-8 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-04-9 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(4-methoxyphenyl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-00-5 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HI

RN 252309-01-6 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI



● HI

RN 252309-05-0 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-06-1 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-07-2 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-08-3 CAPLUS

CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-09-4 CAPLUS

CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-12-9 CAPLUS

CN Benzenecarboximidamide, 4-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-13-0 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-10-7 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-11-8 CAPLUS

CN Benzenecarboximidamide, 2-chloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-14-1 CAPLUS

CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-15-2 CAPLUS

CN Benzenecarboximidamide, 4-[(1,1-dimethylethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-16-3 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-18-5 CAPLUS
CN Benzenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-19-6 CAPLUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-20-9 CAPLUS
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-21-0 CAPLUS
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-22-1 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-23-2 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-24-3 CAPLUS
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-25-4 CAPLUS
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-26-5 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-27-6 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-28-7 CAPLUS
CN Benzenecarboximidamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)




● HI

RN 252309-29-8 CAPLUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI


RN 252309-30-1 CAPLUS
CN Ethanimidamide, 2-[(1,1-dimethylethyl)sulfonyl]-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI

RN 252309-42-5 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HI

RN 252309-43-6 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)

[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-44-7 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-45-8 CAPLUS
CN Benzenecarboximidamide, 4-methoxy-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-46-9 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-47-0 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-48-1 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-49-2 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-50-5 CAPLUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1S)-1-(4-phenyl-1H-imidazol-2-yl)-2-[1-(phenylmethyl)-1H-imidazol-4-yl]ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-51-6 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-53-8 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-54-9 CAPLUS
CN Benzenecarboximidamide, 2-chloro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-55-0 CAPLUS
CN Benzenecarboximidamide, 4-chloro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-56-1 CAPLUS
CN Benzenecarboximidamide, 4-methoxy-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-57-2 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethyl)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-58-3 CAPLUS
CN Benzenecarboximidamide, 4-(1,1-dimethylethyl)-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-59-4 CAPLUS
CN Benzenecarboximidamide, 2,4-difluoro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-61-8 CAPLUS
CN Benzenecarboximidamide, N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(trifluoromethoxy)-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-63-0 CAPLUS
CN Benzenecarboximidamide, 2,6-dichloro-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI

RN 252309-64-1 CAPLUS
CN Ethanimidamide, 2-[[[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]sulfonyl]-N-[(1S)-2-phenyl-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HI


RN 252309-65-2 CAPLUS
CN 1H-Indole-3-ethanamine, alpha-(4-phenyl-1H-imidazol-2-yl)-N-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-66-3 CAPLUS
CN Phenol, 2-[[[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-67-4 CAPLUS
CN Phenol, 4-[[[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-68-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-(4-fluorophenyl)methyl]-alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-69-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxyphenyl)methyl]-alpha-(4-phenyl-1H-imidazol-2-yl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-70-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-71-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-methoxyphenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252309-73-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-77-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-79-8 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-(2-thienylmethyl)-, (αS)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)


CM 1

CRN 252309-78-7
CMF C24 H22 N4 S

Absolute stereochemistry.




Absolute stereochemistry.




RN 252309-74-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252309-75-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252309-76-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 252309-80-1 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(3,4,5-trimethoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-81-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-82-3 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(2-trifluoromethylphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-84-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-85-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-(dimethylamino)phenyl)methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252309-86-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-phenyl-1H-imidazol-2-yl)-N-[(4-(trifluoromethoxy)phenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252309-90-3 CAPLUS
CN Phenol, 4-[[[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 252309-91-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)- (9CI) (CA INDEX NAME)




RN 252309-92-5 CAPLUS
CN 1H-Indole-3-ethanamine, α-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)-N-[(3-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252309-87-8 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]-α-(4-phenyl-1H-imidazol-2-yl)-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252309-88-9 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 252309-89-0 CAPLUS
CN Phenol, 2-[[[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 252309-93-6 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[[4-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252309-95-8 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[[2-methoxyphenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252309-96-9 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[[2-nitrophenyl]methyl]- (9CI) (CA INDEX NAME)




RN 252309-97-0 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-nitrophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-00-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-01-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-02-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-03-5 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-thienylmethyl)- (9CI) (CA INDEX NAME)




RN 252310-04-6 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-05-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-06-8 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-(trifluoromethyl)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-08-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-09-1 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-(dimethylamino)phenyl]methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)



RN 252310-10-4 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-(trifluoromethoxy)phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 252310-11-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]- α -[4-(2-methoxyphenyl)-1H-imidazol-2-yl]- (9CI) (CA INDEX NAME)




RN 252310-12-6 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-13-7 CAPLUS
CN Phenol, 2-[[[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-14-8 CAPLUS
CN Phenol, 4-[[[(1R)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252310-18-2 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-methoxyphenyl)methyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-19-3 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-nitrophenyl)methyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-21-7 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-nitrophenyl)methyl]-, (α R)- (9CI) (CA INDEX NAME)




RN 252310-15-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-16-0 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-methoxyphenyl)methyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-17-1 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(4-methoxyphenyl)methyl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-22-8 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-23-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-24-0 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-25-1 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-thienylmethyl)-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-26-2 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-27-3 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-28-4 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-(trifluoromethyl)phenyl)methyl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-29-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-31-9 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-(dimethylamino)phenyl]methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-32-0 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[[4-(trifluoromethoxy)phenyl]methyl]-, (aR)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-33-1 CAPLUS


CN 1H-Indole-3-ethanamine, N-[[4-[3-(dimethylamino)propoxy]phenyl]methyl]- α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-34-2 CAPLUS
CN 1H-Indole-3-ethanamine, α -[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(phenylmethyl)-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-35-3 CAPLUS
CN Phenol, 4-[[[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-36-4 CAPLUS
CN Phenol, 4-[[[(1S)-2-(1H-indol-3-yl)-1-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]ethyl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-38-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-fluorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-39-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3-methoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-40-0 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-methoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)


[(4-nitrophenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-45-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3,4-dichlorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-46-6 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(3-methoxy-2-nitrophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


[(4-methoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-41-1 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-methoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-43-3 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-nitrophenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-44-4 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(2-nitrophenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)




RN 252310-47-7 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(4-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-48-8 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-(2-thienylmethyl)-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-49-9 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[(3,4,5-trimethoxyphenyl)methyl]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-50-2 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-fluorophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-51-3 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[[2-(trifluoromethyl)phenyl]methyl]-, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-52-4 CAPLUS
CN 1H-Indole-3-ethanamine, N-[(2-bromophenyl)methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)


CN 4-Morpholinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-58-0 CAPLUS
CN 3-Thiazolidinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252310-59-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 252310-60-4 CAPLUS
CN 1,4-Piperidinedicarboxamide, N1-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 252310-53-5 CAPLUS
CN 1H-Indole-3-ethanamine, N-[[4-(dimethylamino)phenyl]methyl]-α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-55-7 CAPLUS
CN 1H-Indole-3-ethanamine, α-[4-(4-methoxyphenyl)-1H-imidazol-2-yl]-N-[[4-(trifluoromethoxy)phenyl]methyl]-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-56-8 CAPLUS




RN 252310-62-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-63-7 CAPLUS
CN 2H-Pyrido[3,4-b]indole-2-carboxamide, 1,3,4,9-tetrahydro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-64-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-65-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-fluorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-66-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-68-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-(3-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-74-0 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-75-1 CAPLUS
CN 1-Piperidinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-76-2 CAPLUS
CN 1,4-Dioxo-8-azaaspiro[4.5]decane-8-carboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-71-7 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-72-8 CAPLUS
CN 2(1H)-Isoquinolinecarboxamide, 3,4-dihydro-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-6,7-dimethoxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-73-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-77-3 CAPLUS
CN 1-Piperidinecarboxamide, 4-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-80-8 CAPLUS
CN 1-Piperazinecarboxamide, 4-(1,3-benzodioxol-5-ylmethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-81-9 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-82-0 CAPLUS
CN 1,3,8-Triazaspiro[4.5]decane-8-carboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-oxo-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-83-1 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-chlorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-84-2 CAPLUS
CN 1-Piperazinecarboxamide, 4-(4-hydroxyphenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-88-6 CAPLUS
CN 1-Piperidinecarboxamide, 4-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-89-7 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-furanylcarbonyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-93-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-85-3 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2,4-dimethylphenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-86-4 CAPLUS
CN 1-Pyrrolidinecarboxamide, 3-hydroxy-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-87-5 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-94-4 CAPLUS
CN 1-Piperazinecarboxamide, 4-(diphenylmethyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-97-7 CAPLUS
CN 1-Piperazinecarboxamide, 4-(2-fluorophenyl)-N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252310-98-8 CAPLUS
CN 1-Piperazinecarboxamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-4-[2-(methylthio)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252313-17-0 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-18-1 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-19-2 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-24-9 CAPLUS
CN Benzeneacetamide, 2-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-25-0 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-26-1 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-20-5 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-22-7 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-23-8 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-27-2 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-28-3 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-29-4 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-30-7 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-34-1 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-31-8 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-35-2 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-33-0 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-36-3 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-37-4 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-40-9 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 252313-38-5 CAPLUS
CN Benzeneacetamide, 4-(dimethylamino)-N-[2-(1H-indol-3-yl)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-41-0 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 252313-39-6 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 252313-42-1 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-43-2 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-47-6 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 252313-45-4 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-48-7 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 252313-46-5 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252313-50-1 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-51-2 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-54-5 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-52-3 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-55-6 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-53-4 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-57-8 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-58-9 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-59-0 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-60-3 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-64-7 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-65-8 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-66-9 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-61-4 CAPLUS
CN Benzeneacetamide, N-[1-[4-(4-bromophenyl)-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 252313-62-5 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-63-6 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-67-0 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-68-1 CAPLUS
CN Benzeneacetamide, 2-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-69-2 CAPLUS
CN Benzeneacetamide, 3-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-70-5 CAPLUS
CN Benzeneacetamide, 4-fluoro-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-73-8 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-71-6 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-74-9 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-72-7 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-75-0 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-77-2 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252313-80-7 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252313-78-3 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-81-8 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-79-4 CAPLUS
CN Benzeneacetamide, N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252313-82-9 CAPLUS
CN Benzeneacetamide, 4-(dimethylamino)-N-[2-(1H-indol-3-yl)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]ethyl]- (9CI) (CA INDEX NAME)




RN 252313-83-0 CAPLUS
CN Benzeneacetamide, 2-chloro-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-84-1 CAPLUS
CN Benzeneacetamide, 3-chloro-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




IT 252313-86-3P 252313-87-4P 252313-89-6P
252313-90-9P 252313-91-0P 252313-92-1P
252313-93-2P 252313-94-3P 252313-96-5P
252313-97-6P 252313-99-8P 252314-00-4P
252314-01-5P 252314-02-6P 252314-03-7P
252314-04-8P 252314-05-9P 252314-96-8P



RN 252313-90-9 CAPLUS
CN Benzeneacetamide, 4-bromo-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)



RN 252313-91-0 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 252313-92-1 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-fluoro- (9CI) (CA INDEX NAME)


252314-97-9P 252314-98-0P 252314-99-1P
252315-01-8P 252315-03-0P 252315-05-2P
252315-07-4P 252315-09-6P 252315-11-0P
252315-33-6P 252315-35-8P 252315-37-0P
252315-40-5P 252315-42-7P 252315-44-9P
252315-47-2P 252315-49-4P 252315-96-1P
252315-97-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazolyl derivs. as as agonists or antagonists of somatostatin receptors)


RN 252313-86-3 CAPLUS
CN Benzeneacetamide, 4-chloro-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-87-4 CAPLUS
CN Benzeneacetamide, 2-bromo-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-89-6 CAPLUS
CN Benzeneacetamide, 3-bromo-N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252313-93-2 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-nitro- (9CI) (CA INDEX NAME)




RN 252313-94-3 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 252313-96-5 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 252313-97-6 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252314-01-5 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 252313-99-8 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 252314-02-6 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 252314-00-4 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 252314-03-7 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 252314-04-8 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]- (9CI) (CA INDEX NAME)




RN 252314-97-9 CAPLUS
CN Benzamide, N-[[[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-98-0 CAPLUS
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-1-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-99-1 CAPLUS
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252314-05-9 CAPLUS
CN Benzeneacetamide, N-[1-[4-[4-(diethylamino)phenyl]-1H-imidazol-2-yl]-2-(1H-indol-3-yl)ethyl]-4-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 252314-96-8 CAPLUS
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-01-8 CAPLUS
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(4-(phenylmethoxy)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-03-0 CAPLUS
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(2-(1-methylethyl)phenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-05-2 CAPLUS
CN Thiourea, N-(3-chlorophenyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-33-6 CAPLUS
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 252315-35-8 CAPLUS
CN Benzamide, N-[[[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]amino]thioxomethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-37-0 CAPLUS
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-07-4 CAPLUS
CN Thiourea, N-hexyl-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252315-09-6 CAPLUS
CN Thiourea, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-11-0 CAPLUS
CN Thiourea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 252315-40-5 CAPLUS


CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-1-naphthalenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-42-7 CAPLUS
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-44-9 CAPLUS
CN Thiourea, N-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-N'-[2-(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-47-2 CAPLUS
CN Thiourea, N-(3-chlorophenyl)-N'-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-49-4 CAPLUS
CN Thiourea, N-(1,3-benzodioxol-5-ylmethyl)-N'-[(1S)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 252315-96-1 CAPLUS
CN Thiophenecarboximidamide, N-[(1R)-2-(1H-indol-3-yl)-1-(4-phenyl-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)



● HI




RN 252315-92-7 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)-1,5-pentanedyl]bis-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



L12 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:27832 CAPLUS
DOCUMENT NUMBER: 130:81398
TITLE: Novel 2-(iminomethyl)aminophenyl derivatives as NO synthase inhibitors and traps for radical oxygen species
INVENTOR(S): Auvin, Serge; Harnett, Jeremiah; Bigg, Dennis; Chabrier De Lassauniere, Pierre-Stienne
PATENT ASSIGNEE(S): Societe De Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S, Fr.
SOURCES: PCT Int. Appl., 134 pp.
CODEN: PIXD2
DOCUMENT TYPE: Patent
LANGUAGES: French
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9858934	A1	19981230	WO 1998-FR1250	19980615
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
FR 2764889	A1	19981224	FR 1997-7701	19970620
FR 2764889	B1	20000901		
TW 422842	B	20010221	TW 1998-87109245	19980610
AU 9882189	A1	19990104	AU 1998-82189	19980615
AU 737964	B2	20010906		
EP 991654	A1	20000412	EP 1998-932205	19980615
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO			
TR 9903175	T2	20000421	TR 1999-9903175	19980615
BR 9810197	A	20000808	BR 1998-10197	19980615

RN 252315-97-2 CAPLUS
CN Thiophenecarboximidamide, N-[2-(1H-indol-3-yl)-1-(4-(2-methoxyphenyl)-1H-imidazol-2-yl)ethyl]-, monohydriodide (9CI) (CA INDEX NAME)




● HI

IT 252279-08-6 252279-09-7 252315-91-6
252315-92-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of imidazolyl derivs. as as agonists or antagonists of somatostatin receptors)


RN 252279-08-6 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, (α S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 252279-09-7 CAPLUS
CN 1H-Indole-3-ethanamine, α -(4-phenyl-1H-imidazol-2-yl)-, (α R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 252315-91-6 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)-1,5-pentanedyl]bis-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


NZ	501656	A	20011221	NZ	1998-501656	19980615
JP	2002507965	T2	20020312	JP	1999-503871	19980615
RU	2202543	C2	20030420	RU	2000-101328	19980615
ZA	9805392	A	19990120	ZA	1998-5392	19980615
NO	9906208	A	20000215	NO	1999-6208	19991215
MX	9911971	A	20000430	MX	1999-11971	19991217
US	2002007062	A1	20020117	US	2001-882264	20010615
US	6630461	B2	20031007			
US	2002045753	A1	20020418	US	2001-945782	20010904
US	6599903	B2	20030729			
US	2002042511	A1	20020411	US	2001-953682	20010917
US	6586454	B2	20030701			
US	2003078420	A1	20030424	US	2002-191950	20020709
US	6809088	B2	20041026			

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 130:81398
GI




AB Amidines AXHtCYC6H4N:CBNH2 [A = H, (un)substituted HOC6H4, 6-hydroxy-2,5,7,8-tetramethylchroman-2-yl; B = (un)substituted alkyl, Ph, pyridyl, thienyl, furyl, pyrrolyl, thiazolyl; X = (un)substituted CONHX1, NHCOX1, CH2, CO, bond; X1 = (CH2)n; n = 0-6; Y = Y1, CONHY1, NHCOY1, COY1, Y1CO, (un)substituted NHY1, Y1NH, Y1CH2NHCO, OY1, SY1, Y1S, Y1OY1, Y1NHY1; Y1 = (CH2)n; Het = (un)substituted heterocyclic] were prepared for use as NO synthetase inhibitors and reactive oxygen species traps. Thus, 4-FC6H4NO2 was treated with imidazole and the 1-p-nitrophenylimidazole reduced to the amine and treated with the thiophene fragment to give the amidine I. I had an NO synthetase-inhibiting IC50 < 3.5 μ M.
IT 218944-36-6P 218944-40-2P 218944-41-3P
218944-66-2P 218944-68-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel 2-(iminomethyl)aminophenyl derivs. as NO synthetase inhibitors and traps for radical oxygen species)
RN 218944-36-6 CAPLUS
CN Carbamic acid, [[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl]methyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 218944-40-2 CAPLUS
CN Benzamide, N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-


2-yl)methyl]-N-methyl-4-nitro- (9CI) (CA INDEX NAME)




RN 218944-41-3 CAPLUS
CN Benzamide, 4-amino-N-[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 218944-66-2 CAPLUS
CN Phenol, 2,6-bis(1,1-dimethylethyl)-4-[2-[[methyl(4-nitrophenyl)amino]methyl]-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 218944-68-4 CAPLUS
CN Phenol, 4-[2-[[[4-(aminophenyl)methylamino]methyl]-1H-imidazol-4-yl]-2,6-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)



IT 218944-42-4P 218944-69-5P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 2-(iminomethyl)aminophenyl derivs. as NO synthase inhibitors and traps for radical oxygen species)
RN 218944-42-4 CAPLUS
CN Benzamide, N-[[[5-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-

AU 9749680 A1 19980715 AU 1997-49680 19971120
EP 946587 A2 19991006 EP 1997-912529 19971120
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI
JP 2001505585 T2 20010424 JP 1998-527528 19971120
ZA 9710603 A 19980625 ZA 1997-10603 19971125
AU 1996-4219 A 19961216
AU 1997-5929 A 19970401
AU 1997-9030 A 19970909
WO 1997-JP4243 W 19971120
PRIORITY APPLN. INFO.:
OTHER SOURCE(S): MARPAT 129:95714
GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I (X = S, NR9; Y = CHR3, (un)substituted phenylene; R1 = (un)substituted indolyl, (un)substituted benzofuranyl; R2 = H, phenyl-lower alkyl; R3 = H, (CH2)nR6; R4 = H, (un)substituted Ph, (un)substituted pyridyl; R5 = H, imidazolyl, Ph, nitrophenyl, phenyl-lower alkyl, optionally esterified carboxy, CONR7R8; R4R5 = CH:CHCH:CH; R6 = optionally protected OH, acyl, carboxy, acylamino, lower alkoxy, phenyl-lower alkoxy, lower alkylthio, (un)substituted Ph; R7, R8 = independently H, Ph, phenyl-lower alkyl, lower alkoxy; R9 = H, lower alkyl, lower cycloalkyl, (un)substituted benzyl; m = 0, 1; n = 0-3] and pharmaceutically acceptable salts thereof are described as strong inhibitors of the production of nitric oxide. Compds. I are useful for prevention and treatment of nitric oxide-mediated diseases such as adult respiratory distress syndrome, cardiovascular ischemia, myocarditis, heart failure, synovitis, shock, diabetes, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, glomerulonephritis, peptic ulcer, inflammatory bowel disease, cerebral infarction, cerebral ischemia, cerebral hemorrhage, migraine, rheumatoid arthritis, gout, neuritis, post-herpetic neuralgia, osteoarthritis, osteoporosis, systemic lupus erythematosus, rejection by organ transplantation, asthma, metastasis, Alzheimer's disease, arthritis, CNS disorders, dermatitis, hepatitis, liver cirrhosis, multiple sclerosis, pancreatitis, atherosclerosis, and the like in humans and animals. Thus, 2-step cyclocondensation of amino ketone II (preparation given) with protected 3-(2-pyridyl)-L-alanine and methylamine gave protected imidazole III (Boc = Me3CO2C). Deprotection of III followed by acylation with indole-2-carboxylic acid gave desired compound IV. IV inhibited nitric oxide production 100% in murine macrophage cell line RAW264.7 at 10-5 M.

IT 209525-11-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of new heterocyclic amides as nitric oxide production inhibitors)
RN 209525-11-1 CAPLUS
CN 1H-Indole-2-carboxamide, N-[[[1S]-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

2-yl)methyl]-4-[[[imino-2-thienylmethyl]amino]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 218944-69-5 CAPLUS
CN 2-Thiophenecarboximidamide, N-[4-[[[4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-1H-imidazol-2-yl)methyl]methylamino]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

REFERENCES COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L12 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:424263 CAPLUS
DOCUMENT NUMBER: 129:95714
TITLE: Preparation of new heterocyclic amides as nitric oxide production inhibitors
INVENTOR(S): Yatabe, Takumi; Inoue, Takayuki; Hamashima, Hitoshi; Shima, Ichiro; Ohne, Kazuhiko; Yoshihara, Kousei; Oku, Teruo
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan; Itoh, Yoshikuni
SOURCE: PCT Int. Appl., 533 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827108	A2	19980625	WO 1997-JP4243	19971120
WO 9827108	A3	19980730		
W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IS, IT, LU, MC, NL, PT, SE				




IT 209528-41-6P 209528-42-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of new heterocyclic amides as nitric oxide production inhibitors)
RN 209528-41-6 CAPLUS
CN Carbamic acid, [(1S)-1-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-2-(2-pyridinyl)ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209528-42-7 CAPLUS
CN 2-Pyridineethanamine, α-[4-(4-nitrophenyl)-1H-imidazol-2-yl]-, trihydrobromide, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●3 HBr


L12 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:424117 CAPLUS
DOCUMENT NUMBER: 129:113523
TITLE: Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
INVENTOR(S): Bocan, Thomas Michael Andrew; Boxer, Peter Alan; Peterson, Joseph Thomas, Jr.; Schrier, Denis; White, Andrew David
PATENT ASSIGNEE(S): Warner-Lambert Co., USA; Bocan, Thomas Michael Andrew;

Boxer, Peter Alan; Peterson, Joseph Thomas, Jr.;
Schriner, Denis; White, Andrew David
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9826773	A1	19980625	WO 1997-US21532	19971121
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, ID, IL, IS, JP, KR, LC, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2264692	AA	19980625	CA 1997-2264692	19971121
AU 9877353	A1	19980715	AU 1998-77353	19971121
AU 737117	B2	20010809		
EP 946166	A1	19991006	EP 1997-949584	19971121
EP 946166	B1	20040218		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9714142	A	20000229	BR 1997-14142	19971121
JP 2001507342	T2	20010605	JP 1998-527715	19971121
NZ 334925	A	20010629	NZ 1997-334925	19971121
EP 1366765	A1	20031203	EP 2003-18081	19971121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, AL				
AT 259640	E	20040315	AT 1997-949584	19971121
PT 946166	T	20040630	PT 1997-949584	19971121
ES 2212142	T3	20040716	ES 1997-949584	19971121
ZA 9711279	A	19980623	ZA 1997-11279	19971215
US 6340709	B1	20020122	US 1999-269123	19990319
PRIORITY APPLN. INFO.: US 1996-32753P P 19961217				
EP 1997-949584 A3 19971121				
WO 1997-US21532 W 19971121				


OTHER SOURCE(S): MARPAT 129:113523
AB Matrix metalloproteinase inhibitors 4-RC6H4SO2NHCHR1COR2 [R = (un)substituted Ph; R1 = alkyl, phenylalkyl, phenyl; R2 = OH, alkoxy, NHCH] and 4-RC6H4C(=NR3)CR4R5CR6R7COR8 [R3 = (un)substituted OH, NH2; R4-R7 = H, F, (un)substituted alkyl; R8 = OH, SH] are useful for preventing and treating neurol. disorders, especially Alzheimer's, Huntington's, and Parkinson's disease and amyotrophic lateral sclerosis, and in promoting wound healing. IC50 for matrix metalloproteinase inhibition are reported for a number of compds. Formulations containing (R)-4-(4-NCC6H4)C6H4SO2NHCH(CO2H)CH2Ph, (S)-4-(4-H2NC6H4)C6H4SO2NHCH(CO2H)CH2C6H4OEt-3, and 4-(4-BrC6H4)C6H4SO2NHCH(CO2H)CHMe2 are reported.
IT 181361-72-8 209199-38-2
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of matrix metalloproteinase inhibitors for treating neurol. disorders and promoting wound healing)
RN 181361-72-8 CAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 209199-38-2 CAPLUS
CN Cyclohexanecarboxamide, N-hydroxy-1-[[[(1S)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1998:207292 CAPLUS
DOCUMENT NUMBER: 128:270871
TITLE: Preparation of azolyl dipeptide analogs as retroviral protease inhibitors
INVENTOR(S): Carr, Thomas Joseph; Demareh, Peter Lawrence; Dreyer, Geoffrey Bainbridge; Fenwick, Ashley Edward
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: U.S., 42 pp., Cont. of U.S. Ser. No. 193.026, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5733882	A	19980331	US 1995-396356	19950228
PRIORITY APPLN. INFO.: US 1994-193026				B1 19940117
OTHER SOURCE(S): MARPAT 128:270871				
GI				




1/7/03



AB The present invention provides compds., more particularly dipeptide analogs I [R1, R3 = independently (un)substituted O, O-C1-6 alkyl, O-C2-6 alkenyl, O-C2-6 alkynyl, C1-6 alkyl substituted by 1-5 F atoms; O = H, C3-6 cycloalkyl, C5-6 cycloalkenyl, aryl, heterocyclyl; R2 = H, OH; R4 = R6NR11, CONR11CHR6R7; R5 = R6NR11, R10NR11; X = NR11, O, S; R7 = O, O-C1-6 alkyl, O-C2-6 alkenyl; R8, R9 = independently H, OH, halo, NO2, acyl, CF3, aryl, etc.; R8R9 = fused C2-4 alkylene, aryl, heterocyclyl; R10 = A-(B)n; R11 = H, C1-4 alkyl; B = amino acid; A = H, (un)substituted aryl, heterocyclyl, aryl-W, heterocyclyl-W, phthaloyl, etc.; W = CO, O2C, NR11CO, SCO, NR11CS, SO2, NR11SO2, P(O)(OR22); R22 = H, C1-6 alkyl, Ph, phenyl-C1-4 alkyl; with proviso), or a pharmaceutically acceptable salt thereof, which bind to retroviral proteases. These compds. are inhibitors of retroviral proteases and are useful for treating diseases related to infection by retroviruses. Thus, cyclocondensation of protected valinal Z-Val-H (Z = PhCH2O2C) with ammonia and glyoxal gave imidazole II. Deprotection of II, followed by coupling with dipeptide isostere III, and final desilylation gave desired title compound IV as its HCl salt. The prepared compds., including IV, showed inhibition of HIV-1 protease with Ki = 1 nM to 5 µM, and inhibited infection of cells with the HIV virus with IC50 = 0.1 to 10 µM.


IT 149379-11-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azolyl dipeptide analogs as retroviral protease inhibitors)
RN 149379-11-3 CAPLUS
CN Carbamic acid, [2-hydroxy-5-[[[2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R*,2R*,4S*,5(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 149356-97-8P 149379-10-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of azolyl dipeptide analogs as retroviral protease inhibitors)
RN 149356-97-8 CAPLUS
CN Carbamic acid, [2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149379-10-2 CAPLUS
CN Carbamic acid, [2-[[[1,1-dimethylethyl]dimethylsilyl]oxy]-5-[[[2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R*,2R*,4S*,5(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1997:568118 CAPLUS
DOCUMENT NUMBER: 127:248417
TITLE: Preparation of amino acid heterobicyclic amide

INVENTOR(S): derivatives as farnesyl transferase inhibitors
Gordon, Thomas D.; Morgan, Barry A.
PATENT ASSIGNEE(S): Biomeasure Incorporated, USA
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730053	A1	19970821	WO 1997-US2651	19970214
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 2002013319	A1	20020131	US 1996-752546	19961120
US 6673927	B2	20040106		
CA 2245823	AA	19970821	CA 1997-2245823	19970214
AU 9719645	A1	19970902	AU 1997-19645	19970214
AU 716636	B2	20000302		
ZA 9701254	A	19980714	ZA 1997-1254	19970214
EP 904274	A1	19990331	EP 1997-907717	19970214
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
CN 1216545	A	19990512	CN 1997-193864	19970214
JP 2001500838	T2	20010123	JP 1997-529596	19970214
TW 432066	B	20010501	TW 1997-86101769	19970214
RU 2201931	C2	20030410	RU 1998-117378	19970214
US 2003119864	A1	20030626	US 2002-273735	20021018
PRIORITY APPLN. INFO.:			US 1996-49997P	P 19960216
			US 1996-602438	A 19960216
			US 1996-752546	A 19961120
			WO 1997-US2651	W 19970214


OTHER SOURCE(S): MARPAT 127:248417
GI




AB Title compds. I and II [R1 = H, lower alkyl, lower alkythio; R1R2 = CH2, CO, CMe2; R2, R3 = independently H, lower alkyl, cycloalkyl; R4 = H2, O; R5 = H, (un)substituted lower alkyl, lower alkenyl, lower alkynyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower

CN Propanamide, 3,3'-dithio[2-amino-N-[(1S)-1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]pentyl]-N-methyl-, (2R,2'R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-A




PAGE 1-B

IT 195450-28-3P 195450-42-1P 195450-43-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of amino acid bicyclic amide derivs. as farnesyl transferase inhibitors)


RN 195450-28-3 CAPLUS
CN Carbamic acid, [1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 195450-42-1 CAPLUS
CN 1H-imidazole-2-methanamine, alpha-butyl-N-methyl-4-phenyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 195450-43-2 CAPLUS

alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R6, R7 = independently H, CONHCHR13CO2R14, (un)substituted lower alkyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R6R7 = fused aryl or heterocyclyl; R8, R9 = independently H, (un)substituted lower alkyl, cycloalkyl, cycloalkyl lower alkyl, cycloalkenyl, cycloalkenyl lower alkyl, aryl, aryl lower alkyl, heterocyclyl, heterocyclyl lower alkyl; R8, R9 = fused aryl or heterocyclyl; X = NR9, S, O; R13 = (un)substituted lower alkyl; R14 = H, lower alkyl, and pharmaceutically acceptable salts thereof are capable of inhibiting the activity of farnesyl transferase. Thus, tetrahydroimidazo[1,2-a]pyrazine III, prepared in 6 steps from Cbz-L-Nle-OH (Cbz = PhCH2O2C), BrCH2COC6H4OMe-2, BrCH2CO2Et, and Boc-L-Cys(CPh3)-OH (Boc = Me3CO2C), displayed antiproliferative activities of 6.25-12.5 µM, 12.5 µM, 10-30 µM, and 12.5-25 µM against A-427 lung carcinomas, HT-29 colon adenocarcinomas, Calu-1 lung carcinomas, and MIA PaCa pancreatic cancer cells, resp.

IT 195449-70-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid bicyclic amide derivs. as farnesyl transferase inhibitors)

RN 195449-70-8 CAPLUS
CN Propanamide, 2-amino-3-mercapto-N-[1-[4-(2-methoxyphenyl)-1H-imidazol-2-yl]pentyl]-N-methyl-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 195449-56-0P 195449-72-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid bicyclic amide derivs. as farnesyl transferase inhibitors)

RN 195449-56-0 CAPLUS
CN Propanamide, 2-amino-3-mercapto-N-methyl-N-[1-(4-phenyl-1H-imidazol-2-yl)pentyl]-, [S-(R*,S*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 195449-72-0 CAPLUS

CN Carbamic acid, [2-[methyl[1-(4-phenyl-1H-imidazol-2-yl)pentyl]amino]-2-oxo-1-[[[triphenylmethyl]thio]methyl]ethyl]-, 1,1-dimethylethyl ester, [S-(R*,S*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L12 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1996:467020 CAPLUS
DOCUMENT NUMBER: 125:114630
TITLE: Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands

INVENTOR(S): Thurkauf, Andrew; Horvath, Raymond F.; Yuan, Jun; Peterson, John M.


PATENT ASSIGNEE(S): Neurogen Corporation, USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616040	A1	19960530	WO 1995-US15262	19951122
W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT			
RW:	KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
US 5681956	A	19971028	US 1995-401201	19950309
US 5633377	A	19970527	US 1995-462833	19950605
US 5646281	A	19970708	US 1995-461135	19950605
US 5656762	A	19970812	US 1995-461858	19950605
US 5712392	A	19980127	US 1995-464548	19950605
AU 9643689	A1	19960617	AU 1996-43689	19951122
ZA 9509910	A	19970822	ZA 1995-9910	19951122
ZA 9509911	A	19970822	ZA 1995-9911	19951122
EP 793653	A1	19970910	EP 1995-942473	19951122
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
ZA 9707500	A	19980223	ZA 1997-7500	19951122
JP 10502670	T2	19980310	JP 1995-517074	19951122
JP 2941950	B2	19990830		
BR 9509760	A	19980630	BR 1995-9760	19951122
US 6069251	A	20000530	US 1997-859861	19970521
US 6358955	B1	20020319	US 2000-497988	20000204
US 2002143044	A1	20021003	US 2002-100691	20020318
US 6797824	B2	20040928		
PRIORITY APPLN. INFO.:			US 1994-344154	A2 19941123
			US 1994-344552	A2 19941123

US 1995-401201 A2 19950309
US 1990-635256 A2 19901228
US 1993-81317 A2 19931108
US 1994-313435 A2 19940927
US 1995-462833 A1 19950605
WO 1995-US15262 W 19951122
US 1997-859861 A1 19970521
US 2000-497988 A1 20000204


OTHER SOURCE(S): MARPAT 125:114630
GI



AB Disclosed are compds. (I), wherein R1 represents optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl groups; X, Z, and Y are optionally substituted nitrogen or carbon atoms; R3 and R4 are organic or inorg. substituents which may together form ring structures; m is zero, one or two; and R5 and R6 are organic or inorg. substituents; and the pharmaceutically acceptable addition salts thereof, which compds. are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism. Specifically, 2-phenyl-4(5)-[(4-(2-pyrimidinyl)piperazin-1-yl)methyl]imidazole dihydrochloride was prepared and was shown to bind to the dopamine D4 receptor site (Ki = 1033, 8200, 2.7 for D2, D3, D4 binding sites, resp.).


IT 179332-49-1P 179333-51-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole derivs. as dopamine receptor partial agonists or antagonists for memory enhancement and treatment of schizophrenia and depression and Parkinsonism)

RN 179332-49-1 CAPLUS
CN 1H-Imidazole-2-methanamine, N-methyl-4-phenyl-N-(phenylmethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 179333-51-8 CAPLUS
CN 1H-Imidazole-2-methanamine, N-methyl-4-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 181361-76-2 CAPLUS
CN Butanediamide, 2-cyclohexyl-N4-hydroxy-N1-[3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, [S-(R*,R*)] (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 167983-28-0DP, deriva.
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, activity, and structure of matrix metalloproteinase inhibitors containing a heterocyclic P2'-P3' amide bond isostere)

RN 167983-28-0 CAPLUS
CN Carbamic acid, [3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:239751 CAPLUS

DOCUMENT NUMBER: 124:289584
TITLE: Preparation of 7-[(benzimidazolymethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists

INVENTOR(S): Ali, Padi; Bondinell, William; Huffman, William Francis; Lego, M. Amparo; Keenan, Richard McCulloch; Kwon, Chet; Miller, William Henry; Nguyen, Thomas; Takata, Dennis T.

PATENT ASSIGNEE(S): SmithKline Beecham Corp., USA
SOURCE: PCT Int. Appl., 193 pp.



L12 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1996:466542 CAPLUS

DOCUMENT NUMBER: 125:221708
TITLE: Design, synthesis, activity, and structure of a novel class of matrix metalloproteinase inhibitors containing a heterocyclic P2'-P3' amide bond isostere

AUTHOR(S): Chen, Jian Jeffrey; Zhang, Yiping; Hammond, Scott; Dewdney, Nolan; Ho, Teresa; Lin, Xiaohong; Browner, Michel F.; Castelano, Arlindo L.

CORPORATE SOURCE: Roche Bioscience, Inflammatory Disease Business Unit, Palo Alto, CA, 94304, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(13), 1601-1606
CODEN: BMCLE8; ISSN: 0960-894X


PUBLISHER: Elsevier
DOCUMENT TYPE: Journal

LANGUAGE: English
AB A novel series of hydroxamate-based inhibitors of matrix metalloproteinases containing benzimidazole and imidazole heterocycles as amide bond isosteres have been prepared. Potent inhibition (in the low nanomolar range) and selectivity (> 100-fold) can be attained with inhibitors containing only one amide bond. X-ray crystal structures of matrix metalloproteinase-7 (MMP-7) with two different inhibitors bound confirm that imidazole is an excellent amide bond isostere.

IT 167983-80-4DP, deriva.
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 167983-80-4 CAPLUS
CN 1H-Imidazole-2-methanamine, alpha-(2-methylpropyl)-4-phenyl-, (aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 181361-72-8P 181361-76-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, activity, and structure of matrix metalloproteinase inhibitors containing a heterocyclic P2'-P3' amide bond isostere)


RN 181361-72-8 CAPLUS
CN Butanediamide, N4-hydroxy-N1-[(1S)-3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-2-(2-methylpropyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9600730	A1	19960111	WO 1995-US8306	19950629
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, DE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SG, SI, SK, TJ, TT, UA, US, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9530010	A1	19960125	AU 1995-30010	19950629
AU 702661	B2	19990225		
EP 767792	A1	19970416	EP 1995-926152	19950629
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
CN 1156995	A	19970813	CN 1995-194853	19950629
HU 76344	A2	19970828	HU 1996-3525	19950629
BR 9508178	A	19971118	BR 1995-8178	19950629
JP 10504808	T2	19980512	JP 1995-503462	19950629
US 5977101	A	19991102	US 1996-505171	19961220
NO 9605608	A	19970227	NO 1996-5608	19961227
NZ 329656	A	20000128	NZ 1998-329656	19980128
NZ 329822	A	20000228	NZ 1998-329822	19980223
PRIORITY APPLN. INFO.:			US 1994-267695	A 19940629
			US 1995-428933	A 19950425
			WO 1995-US8306	W 19950629

OTHER SOURCE(S): MARPAT 124:289584
GI



AB Title compds. [e.g., I; A = fibrinogen receptor antagonist template (sic); G = Nh, O, S, etc.; R2,R3 = H, halo, alkyl, etc.; R2R3 = atoms to form a ring; W = CHR1UCHR1V, VZ; R1 = H, (un)substituted alkyl; U,V = bond, CO, O, CH:CH, etc.; Z = N-attached pyrrolidine- or piperidine-di-yl] were prepared. Thus, Me 7-carboxy-4-methyl-3-oxo-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2-acetate was amidated by 2-aminomethylbenzimidazole to give, after saponification, title compound II. Title compds. inhibit vitronectin

binding to SK&F 107260 in the concentration range of about 0.001 to 50µM (sic).


IT 175529-80-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of)

7-[(benzimidazolymethyl)aminocarbonyl]-1,4-benzodiazepine-2-acetates and analogs as vitronectin receptor antagonists)


RN 175529-80-3 CAPLUS

CN 1H-1,4-Benzodiazepine-2-acetic acid, 2,3,4,5-tetrahydro-4-methyl-3-oxo-7-[[[(4-phenyl-1H-imidazol-2-yl)methyl]amino]carbonyl]- (9CI) (CA INDEX NAME)


NAME)




IT 175531-38-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of
7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-
acetates and analogs as vitronectin receptor antagonists)
RN 175531-38-1 CAPLUS
CN 1H-imidazole-2-methanamine, 4-phenyl- (9CI) (CA INDEX NAME)



IT 175531-07-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of
7-[(benzimidazolylmethyl)aminocarbonyl]-1,4-benzodiazepine-2-
acetates and analogs as vitronectin receptor antagonists)
RN 175531-07-4 CAPLUS
CN 1H-1,4-Benzodiazepine-2-acetic acid, 2,3,4,5-tetrahydro-4-methyl-3-oxo-7-
[[[4-phenyl-1H-imidazol-2-yl)methyl]amino]carbonyl]-, methyl ester (9CI)
(CA INDEX NAME)




L12 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1995:804314 CAPLUS
DOCUMENT NUMBER: 133:228900
TITLE: Preparation of azole-fused peptides as substance P
antagonists and analgesics.
INVENTOR(S): Morgan, Barry A.; Gordon, Thomas D.; Hansen, Philip
E.; Singh, Jasbir
PATENT ASSIGNEE(S): Sterling Winthrop Inc., USA
SOURCE: U.S., 34 pp. Cont. of U.S. Ser. No. 131,706,
abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent




RN 168110-21-2 CAPLUS
CN D-Tryptophanamide, L-prolyl-D-tryptophyl-L-phenylalanyl-N-[3-methyl-1-(4-
phenyl-1H-imidazol-2-yl)butyl]-, (S)-, trimethanesulfonate (9CI) (CA
INDEX NAME)
CH 1
CRN 167982-33-4
CMF C50 H55 N9 O4

Absolute stereochemistry.



CH 2

CRN 75-75-2
CMF C H4 O3 S




IT 167983-28-0P 167983-29-1P 167983-30-4P
167983-80-4P

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5378803	A	19950103	US 1992-912949	19920710
PRIORITY APPLN. INFO.:			US 1992-912949	B1 19920710
			US 1987-131706	19871211

OTHER SOURCE(S): MARPAT 123:228900
GI



AB Title compds. [I; Q1 = Pro, bond; Q2 = Pro, D-Trp, bond; Q3 = Pro, D-Trp, Phe, (R)-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2-yl)-3-carbonyl, bond; Q4 = Pro, D-Trp, Phe, bond; Q5 = D-Trp, Phe, bond; Q6 = Leu, Met, bond; Q7 = Phe, N-MePhe, Met, bond; R1 = H, Z, BOC; R2 = H; R3 = Me2CH, Me2CHCH2, H2N(CH2)4, PhCH2, 4-HOCSH4CH2, pyridylmethyl, (1H-indol-3-yl)methyl; R2R3 = atoms to form 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-2,3-diyl; R5 = H, OH or alkali metal salt thereof, MeO, EtO, amino, etc.; X = oxa thia, imido; Y = oxo, H2; n = 0,1; starred center is L or D; with a proviso], were prepared. Thus, title compound (II; starred center has D-configuration), prepared via thionation of 2-D-Trp-NH2 with P2S5 and cyclocondensation of the product with Et 3-chloro-2-oxo-3-phenylpropionate, antagonized substance P in the guinea pig ileum test with pA2 = 7.3, and in the mouse acetylcholine-induced writhing test showed intrathecal ED50 = 0.78 µg/mouse.


IT 167982-33-4P 168110-21-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of azole-fused peptides as substance P antagonists and analgesics)
RN 167982-33-4 CAPLUS
CN D-Tryptophanamide, L-prolyl-D-tryptophyl-L-phenylalanyl-N-[3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of azole-fused peptides as substance P antagonists and
analgesics)


RN 167983-28-0 CAPLUS
CN Carbamic acid, [3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167983-29-1 CAPLUS
CN 1H-imidazole-2-methanamine, α-(2-methylpropyl)-4-phenyl-, dihydrochloride, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl


RN 167983-30-4 CAPLUS
CN D-Tryptophanamide, 1-[(1,1-dimethylethoxy)carbonyl]-L-prolyl-D-tryptophyl-L-phenylalanyl-N-[3-methyl-1-(4-phenyl-1H-imidazol-2-yl)butyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167983-80-4 CAPLUS
CN 1H-imidazole-2-methanamine, α -(2-methylpropyl)-4-phenyl-,
(aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1993:517245 CAPLUS
DOCUMENT NUMBER: 119:117245
TITLE: Preparation of N-imidazolylalkyl-5-amino-4-hydroxyhexanamides and analogs as retroviral protease inhibitors
INVENTOR(S): Carr, Thomas Joseph; DeMarsh, Peter Lawrence; Penwick, Ashley Edward
PATENT ASSIGNEE(S): Smithkline Beecham Corp., USA
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9302057	A1	19930204	WO 1992-US6047	19920717
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KR, LU, NL, NO, PL, RO, RU, SE, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9224129	A1	19930223	AU 1992-24129	19920717
CN 1071434	A	19930428	CN 1992-109761	19920717
ZA 9205360	A	19930614	ZA 1992-5360	19920717
EP 602069	A1	19940622	EP 1992-917238	19920717
R: BE, CH, DE, FR, GB, IT, LI, NL				
JP 07500577	T2	19950119	JP 1992-503016	19920717
ES 2068739	B1	19951101	ES 1993-107	19930121
ES 2068739	A1	19950416		
PRIORITY APPLN. INFO.:				
		US 1991-731563	A	19910717
		US 1992-870975	A	19920420
		WO 1992-US6047	A	19920717

OTHER SOURCE(S): MARPAT 119:117245
AB R5CHR1CH(OH)CHR2CHR3R4 [I; R1, R3 = fluoroalkyl, cycloalk(en)yl(alkyl), aryl(alkyl), heterocyclyl(alkyl), etc.; R2 = H, OH; R4 = azolylamino, N-(azolylalkyl)carbamoyl; R5 = substituted amino] were prepared. Thus, Me2CHCHR1NH2 (R = imidazol-2-yl) (preparation given) was condensed with (2R, 4S, 5S)-PhCH2CH(NHCO2CMe3)CH(OR6)CH2CH(CH2Ph)COR7 (II; R6 = SiMe2CMe3, R7 = OH) to give, after deprotection, II (R6 = H, R7 = NHCHRCHMe2, R = imidazol-2-yl). I had Ki of 1 nM to 5 μ M for inhibition of HIV-1 protease.
IT 149356-97-8P 149379-10-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of retroviral protease inhibitors)
RN 149356-97-8 CAPLUS
CN Carbamic acid, [2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]-, phenylmethyl ester, (S)- (9CI) (CA INDEX NAME)


4-phenylimidazoles
Morgenstern, R.; Bechmann, K.
Inst. Pharmakol. Toxikol., Humboldt-Univ., Berlin, Ger. Dem. Rep.
Pharmazie (1975), 30(2), 103-5
CODEN: PHARAT; ISSN: 0031-7144
Journal
German
GI For diagram(s), see printed CA Issue.
AB All 40 4-phenylimidazoles (I) tested for antihistaminic activity on guinea pig ileum were effective and inhibited histamine-induced contractions competitively and noncompetitively dependent on the dose. Some compts. at concns. below antagonistic values induced contractions themselves. The influence of substituents at C-4, C-2, N-1, or C-5 on antihistaminic activity was discussed.
IT 48167-31-3 54887-81-9 54887-82-0
RL: BIOL (Biological study)
(antihistaminic)
RN 48167-31-3 CAPLUS
CN 1H-imidazole-2-methanamine, N,N-diethyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 54887-81-9 CAPLUS
CN 1H-imidazole-2-methanamine, N,N-dimethyl-4-phenyl- (9CI) (CA INDEX NAME)



RN 54887-82-0 CAPLUS
CN 1H-imidazole-2-methanamine, 4-(4-methoxyphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




L12 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1973:136289 CAPLUS
DOCUMENT NUMBER: 78:136289
TITLE: Imidazole derivatives
INVENTOR(S): Bornowski, Heinz; Herzig, Oenter
SOURCE: Fr. Demande, 14 pp.
CODEN: PRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Absolute stereochemistry.




RN 149379-10-2 CAPLUS
CN Carbamic acid, [2-(((1,1-dimethylethyl)dimethylsilyl)oxy)-5-[[2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R*,2R*,4S*,5(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 149379-11-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as retroviral protease inhibitor)
RN 149379-11-3 CAPLUS
CN Carbamic acid, [2-hydroxy-5-[[2-methyl-1-(4-phenyl-1H-imidazol-2-yl)propyl]amino]-5-oxo-1,4-bis(phenylmethyl)pentyl]-, 1,1-dimethylethyl ester, [1S-[1R*,2R*,4S*,5(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L12 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1975:557696 CAPLUS
DOCUMENT NUMBER: 83:157696
TITLE: Antihistaminic activities of certain

FR 2132632 A1 19721124 FR 1972-4864 19720214
FR 2132632 B1 19770415
CH 572041 A 19760130 CH 1972-4956 19720405
SU 450805 T 19741125 SU 1972-1768897 19720406
PRIORITY APPLN. INFO.: DD 1971-154266 A1 19710407
AB The imidazoles I (R = morpholino, piperidino, Me2N, Et2N; R1 = H, 3,4-(MeO)2, p-MeO, p-HO, m-NO2, p-Br; R2 = H, Me, Pr; R3 = H, Me) and their acid salts were prepared by Mannich reaction of the corresponding phenylimidazoles. Thus, 4-(3,4-dimethoxyphenyl)-5-propylimidazole was heated at 100° with HCHO and morpholine in HOAc to give 69% I (R = morpholino, R1 = 3,4-(MeO)2, R2 = Pr, R3 = H), isolated as the di-HCl salt.
IT 41053-81-0P 41053-82-1P 41053-83-2P
41053-93-4P 54887-82-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 41053-81-0 CAPLUS
CN 1H-imidazole-2-methanamine, N,N-dimethyl-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 41053-82-1 CAPLUS
CN 1H-imidazole-2-methanamine, N,N-diethyl-4-phenyl-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 41053-83-2 CAPLUS
CN 1H-imidazole-2-methanamine, N,N-diethyl-4-phenyl-, compd. with 2,4,6-trinitrophenol (1:2) (9CI) (CA INDEX NAME)

CM 1


CRN 48167-31-3
CMP C14 H19 N3



CM 2

Oc1cc([N+](=O)[O-])cc([N+](=O)[O-])cc1[N+](=O)[O-]CN(C)CC1=NC=C(C2=CC=CC=C2C)N1

RN 54887-82-0 CAPLUS
CN 1H-Imidazole-2-methanamine, 4-(4-methoxyphenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)



STN INTERNATIONAL LOGOFF AT 13:20:34 ON 06 JAN 2005